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Patients undergoing oesophagectomy are at risk of developing Acute 
Respiratory Distress Syndrome (ARDS), an immune mediated form of severe 
respiratory failure. The immunomodulatory properties of Vitamin D are 
increasingly recognised. We hypothesised that preoperative Vitamin D 
supplementation would reduce levels of perioperative alveolar oedema in 
patients undergoing oesophagectomy. 
Vitamin D deficiency is common in patients with and at risk of ARDS. High 
dose supplementation with cholecalciferol is a safe and effective method of 
increasing Vitamin D levels. Supplementation reduces perioperative 
increases in inflammatory alveolar oedema. 
Circulating plasma concentrations of the active form of Vitamin D relate to 
long term post-operative mortality. Patients who survive at least 2 years 
post-op have higher preoperative circulating numbers of Natural Killer cells . 
We did not find any evidence of an effect of Vitamin D on Natural Killer Cells .  
In conclusion, preoperative Vitamin D status relates to perioperative changes 
in inflammatory alveolar oedema and high dose Vitamin D supplementation 
is a safe and effective method of improving preoperative Vitamin D status. 
Preoperative cholecalciferol administration should be considered in patients 
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UK  United Kingdom 
USA  United States of America 
UVB  Shortwave Ultraviolet Radiation 
VDBP  Vitamin D Binding Protein 
VDR  Vitamin D receptor 
VLDL  Very Low Density Lipoprotein 
WCC  White Cell Count 
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1.1 Acute Respiratory Distress Syndrome 
1.1.1 Definition 
Acute Respiratory Distress Syndrome (ARDS) is a form of rapid onset severe 
respiratory failure which causes significant mortality and morbidity in critically ill 
patients. It was first described by Ashburgh and colleagues in 1967 with a case 
series of 12 previously healthy patients who developed respiratory failure, 
infiltrates on the chest radiograph and decreased lung compliance in response to 
a variety of both direct and indirect pulmonary insults (1). Subsequently, ARDS 
was acknowledged to be an important cause of morbidity and mortality in 
critically ill patients, but the lack of a precise definition hampered subsequent 
studies. In 1994 the American European Consensus Committee (AECC) attempted 
to address this issue by defining ARDS using the following criteria: 
1) Acute onset of hypoxemia with PaO2/FiO2 (P/F) ratio less than or equal to 300 
mm Hg,  
2) Bilateral infiltrates on chest radiograph (CXR), 
3) No evidence of left atrial hypertension. 
In acknowledgment that severity of the syndrome is variable, patients who met 
all three of the above criteria were diagnosed with Acute Lung Injury (ALI) if the 
P/F ratio was between 200mmHg and 300mmHg (26.7-40.0kPa) and Acute 
Respiratory Distress Syndrome (ARDS) if the P/F ratio was less than 200mmHg 
(26.7kPa) (2). 
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While the AECC definition of ARDS improved clarity of diagnosis with criteria 
which are generally easily available at the ITU bedside, its reproducibility is 
limited due to the highly subjective nature of two elements of the definition 
(chest radiograph infiltrates and evidence of left atrial hypertension). In addition, 
ARDS can occur in the presence of left atrial hypertension and these patients 
were excluded by this definition (3). In 2012 a consensus group suggested the 
Berlin definition - a new criteria for diagnosis along with a new severity 
classification. The purpose of this was to simplify the diagnostic process and 
better prognosticate outcomes (4). It defines three levels of severity (mild, 
moderate and severe) according to severity of hypoxaemia. The Berlin definition 
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Table 1.1 Berlin Definition of Acute Respiratory Distress Syndrome. Adapted 
from (4). 
 Acute Respiratory Distress Syndrome 
Timing 
Within 1 week of a known clinical insult or new 
or worsening respiratory symptoms 
Chest Imaging  
(X Ray or CT Scan) 
Bilateral opacities not fully explained by 
effusions, lobar/lung collapse or nodules 
Origin of Oedema 
Respiratory failure not fully explained by cardiac 
failure or fluid overload. If no risk factor 
present, objective assessment such as 




200mmHg (26.6kPa) < PaO2/FiO2 ≤ 300mmHg 
(40kPa) with PEEP or CPAP ≥ 5cmH2O 
Moderate 
100mmHg (13.3kPa) < PaO2/FiO2 ≤ 200mmHg 
(26.6kPa) with PEEP≥5cmH2O 
Severe 
PaO2/FiO2 ≤ 100mmHg (13.3kPa) with PEEP ≥ 
5cmH2O 
 
While the Berlin definition addresses concerns regarding the didactic nature of 
the AECC guidelines in relation to radiograph appearances and left atrial 
hypertension, the requirement for patients to be receiving some form of 
ventilatory support (PEEP or CPAP ≥ 5cmH2O) excludes ward based patients 
including patients with an early form of the disease who can be managed with 
high concentrations of inspired oxygen alone and patients who are not 
considered suitable for ventilation. A 2007 study found that only 45% of patients 
meeting the AECC criteria for ALI were admitted to the intensive care unit, with 
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no significant difference in mortality between ALI patients treated on the ward 
or on ICU (5). This has implications for both clinical practice and research as early 
identification and supportive care of patients with ARDS may impact on clinical 
outcomes. 
1.1.2 Epidemiology 
In 2005, the incidence of ARDS in the USA was estimated to be around 190 600 
patients annually. The disease was also estimated to result in 3.6 million hospital 
days in the USA (6). It is likely that this figure underestimates the true incidence 
as it does not consider incidence of ARDS in children nor allow for increased 
mortality from ARDS in non-Caucasian populations (7). A 2007 study in three 
Spanish hospitals found that 5.1% of hospital admissions over a 4 month period 
had at least one risk factor for the development of ARDS and 6.5% of these 
patients developed the condition. This is equivalent to an incidence of 27.7 per 
100,000 head of population per year (5).   
1.1.3 Aetiology 
The majority of patients with ARDS develop the disease in the presence of severe 
sepsis secondary to pneumonia (44%) or a non-pulmonary infection (33%) (6).  
Other causes include aspiration of gastric contents, haemorrhage, major trauma, 
pancreatitis and drug reactions. However, not all patients with these diseases 
develop ARDS, and factors such as smoking and presence of comorbidities may 
influence the risk of development of ARDS (8, 9). 
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1.1.4 Pathophysiology 
Whether the cause of ARDS is a direct or indirect pulmonary insult, the alveolar 
inflammation which results represents a final common pathway, mediated by 
circulating pro-inflammatory chemokines and cytokines and characterised by 
neutrophil accumulation in the alveoli. Factors generated by micro-organisms, 
neutrophils and platelet-leukocyte interactions such as lipopolysaccharide (LPS), 
TNF-α and interleukins (e.g. IL-1β, IL-6, and IL-8) destabilize and disrupt alveolar 
capillary barrier function (10). Disrupted alveolar capillary barrier function results 
in increased permeability to water, proteins and immune cells; this is a hallmark 
of the exudative phase of early ARDS (11). Type 1 alveolar epithelial cells, which 
make up 90% of the cells in the epithelium, become necrotic resulting in the 
formation of hyaline membranes on the denuded basement membrane (12). 
Neutrophils typically dominate the cellular population in the alveoli in the early 
stages of the disease (13) although ARDS can develop in neutropenic patients 
suggesting that the presence of neutrophils is not critical for the development of 
the disorder (12).  
As the disease starts to resolve, alveolar oedema is resorbed and repair of the 
alveolar capillary barrier occurs with clearance of inflammatory cells and exudate 
from the airspaces predominantly by macrophages (12). Type II alveolar 
epithelial cells differentiate into type 1 cells as the alveolar epithelium repairs. In 
some cases ARDS resolves after the initial phase with no radiological evidence of 
ongoing disease. However, most patients who survive ARDS will have persistently 
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lower than expected carbon monoxide diffusion capacity (14) and a subset of 
patients will develop clinically significant fibrotic lung disease post ARDS as a 
result of proliferation of fibroblasts and myofibroblasts (12).  
1.1.5 ARDS Phenotypes 
ARDS is a heterogenous disease with patients meeting the criteria for diagnosis 
having a variety of causes of the disease, timing of onset in relation to that risk 
factor and severity of illness. Heterogeneity of the illness has been postulated as 
a reason for the failure of multiple clinical trials into potential treatments of 
ARDS which showed promise in pre-clinical trials but which did not improve 
outcomes when applied to a general ARDS population (15). 
While the Berlin criteria definition stratifies patients according to severity of 
hypoxaemia, some researchers have suggested dividing ARDS into phenotypes 
relating to factors such as direct vs indirect causes of ARDS (16) or timing of 
development of ARDS in relation to the precipitating illness/event (17). One 
group have suggested dividing ARDS into two subphenotypes – a 
hyperinflammatory group and a hypoinflammatory group, based on a 
combination of biological and clinical markers identified by latent class analysis, 
and have shown that stratification based on these criteria can identify a group 
with more severe inflammation and worse clinical outcomes (18). However, 
currently there is no consensus on any approach to reduce ARDS heterogenicity. 
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1.1.6 Treatment of ARDS  
Supportive care is the mainstay of treatment in ARDS as no pharmacological 
treatment has been shown to be effective in reducing morbidity or mortality. The 
only therapy which has been shown to be effective in reducing mortality in a 
non-stratified ARDS population in low tidal volume ventilation, which aims to 
reduce barotrauma in the alveoli which can occur if the lungs are hyperventilated 
(19). Early application of prone positioning has been shown to reduce mortality 
at 30 and 90 days when used in patients with severe ARDS (20), but other studies 
which enrolled patients without severe hypoxaemia failed to show any survival 
benefit (21). Patients with severe ARDS may also benefit from muscle paralysis, 
with a 48 hour administration of cisatracurium being associated with a decrease 
in mortality for the most severe hypoxemic patients (22), but other studies have 
shown that spontaneous modes of ventilation are more advantageous for 
patients with less severe disease (23). 
1.1.7 ARDS prognosis 
In 2005 in-hospital mortality from ARDS was estimated at 39%. (6) Advances in 
ventilation strategies have reduced in-hospital mortality, with a more recent 
study finding that 24% of patients diagnosed with ARDS died prior to hospital 
discharge (24). Cause of death in patients who do not survive an episode of ARDS 
is variable. Estimates of the proportion of patients who die as a result of 
refractory hypoxaemia vary and are likely to depend on facilities available at the 
treating institution.  In addition, multi-organ failure and refractory shock are 
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commonly cited causes of death in patients with ARDS and these are likely to be 
connected to the underlying aetiology (25, 26). 
Long term mortality in patients who survive an admission in ARDS is also high, 
with 22% of patients who survived to hospital discharge having died within 1 
year. The most common causes of death in these patients were infection and 
malignancy with age and presence of comorbidities independent risk factors 
(24).  
In patients who do survive, the majority will require ventilation for 1-2 weeks, 
although 10% require mechanical ventilation for 30 days or more (27).  Survivors 
can expect a prolonged recovery from the disease, with persistent functional 
disability common one year after discharge from the intensive care unit and 51% 
of survivors unable to return to work within 12 months (14). 
1.1.8 Models of ARDS 
Models of ARDS are useful in order to try to gain further understanding about 
the pathogenesis of the disease and the effects of potential treatments. 
However, the heterogeneity seen in ARDS makes modelling the disease difficult 
and no model replicates the condition perfectly.  
1.1.8.1 In-Vitro Models  
In-vitro models of lung injury are useful for primary investigations into the 
effects of substrates of interest on the alveolar epithelium; they use single layers 
of cultured alveolar epithelial cells to model the epithelial surface of the alveoli. 
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Models typically focus on alveolar type 2 cells and can use primary type 2 cells 
isolated from human resected lung specimens or A549 cells, a cultured cell line 
similar to type 2 cells derived from lung adenocarcinoma. The wound repair 
model uses a pipette tip to wound the single cell layer, and then looks at the 
effect of culture with or without the substrate of interest on speed of wound 
repair. In addition, cell proliferation and viability following culture with or 
without the substrate can be assessed using Bromodeoxyuridine (BRDU) and Cell 
titre assays (28). 
1.1.8.2 Animal Models 
Animal models of ARDS generally attempt to replicate either direct lung injury 
(e.g using intratracheal administration of LPS or acid to the lungs) or indirect lung 
injury (e.g. using models of intra-abdominal sepsis such as caecal ligation and 
puncture or using intravenous administration of LPS to mimic systemic sepsis). 
The majority of these models involve rodents. While the use of such models has 
generated useful knowledge with regards to the mechanisms of lung injury, no 
one model has so far been able to replicate the complex pathophysiology seen in 
patients with ARDS (29). 
1.1.8.3 Human Models 
1.1.8.3.1 Ex Vivo Lungs 
Ex-vivo human lung models have been used in pre-clinical trial experiments, for 
example to investigate the effect of mesenchymal stem cells on development of 
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ARDS (30). The model utilises donor human lungs that are unsuitable for 
transplantation. Similar models using lungs from small-medium sized animals 
have been widely used to research respiratory disease in the past (31). They offer 
a more complex model of lung structure than the single layers of cultured type 2 
cells described above, and allow the effects of lung architecture and type 1 cells, 
which are notoriously difficult to culture, to be studied (27). 
The human ex-vivo lung models allow researchers to study the effects of injury to 
the lung through application of stimuli such as live bacteria or LPS, a component 
of the outer membrane of gram negative bacteria. Introduction of potential 
treatments to the system can allow investigation of the possible benefits of the 
treatment, before proceeding to live human trials. Human lungs have been 
maintained for up to 12 hours using the EVLP method with no lung injury or loss 
of function. (27) 
1.1.8.3.2 Inhaled LPS 
This model uses LPS to induce a local inflammatory response in the lungs of 
healthy volunteers. 6 hours post inhalation a subclinical inflammatory response 
can be seen with neutrophil infiltration and local cytokine and chemokine 
release. In addition, mild systemic inflammatory changes are generated by this 
model (32, 33). This model has been used to investigate potential treatments for 
ARDS although, while this model has generated preliminary data for trials of 
multiple potential therapies including beta-agonists and statins, this has not 
translated into a positive clinical trial (34, 35). 
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1.1.8.3.3 Surgical Models 
Multiple surgical models have in used to investigate potentially modifiable risk 
factors for the development of ARDS including cardiac bypass surgery, abdominal 
aortic aneurysm (AAA) repair and oesophagectomy. Patients undergoing elective 
surgery are an attractive model as patients can be recruited in advance of a 
timed uniform insult, thus reducing some of the heterogeneity seen in many 
ARDS studies. The risk of ARDS is highest in patients undergoing 
oesophagectomy with one study identifying that 23% of patients develop ARDS 
post-op (36). Risk of ARDS post cardiac bypass surgery is relatively low (2%) and 
complicated by the high risk of cardiac dysfunction. Open AAA repair has now 
been largely superseded by endovascular methods which do not lead to the 
same levels of inflammation and therefore this model has not been used for 
clinical trials in recent years.  
1.1.8.3.4 Oesophagectomy  
Oesophagectomy is a long, complicated procedure with a high risk of post-
operative morbidity and mortality. It is typically a two stage operation – first, the 
abdominal stage to mobilise the stomach, then the thoracic stage to remove a 
portion of the oesophagus and anastomose the upper part of the oesophagus to 
a gastric conduit (figure 1.1).  
 
 














Figure 1.1 Diagram showing before (A) and after (B) a total oesophagectomy 
 
Typically a straightforward operation without complications will take 5-6 hours. 
The majority of patients undergoing the operation have oesophageal cancer, 
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through the diaphragm 
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In order to access the oesophagus during the thoracic stage one of the lungs 
must be collapsed so that all ventilation will occur via one lung (One Lung 
Ventilation or OLV). OLV causes different stresses to both lungs (see figure 1.2) 
which combined with a lengthy operation and the inflammatory effects of the 
abdominal component of the operation and handling of the gut results in high 
post-operative systemic and local inflammation, resulting in high risk of post-
operative ARDS. 
 
Figure 1.2 Pulmonary insults resulting from one lung ventilation 
Unpublished diagram created for the UKALI research group 
1.1.9 Quantification of alveolar oedema using PICCO monitoring 
Radiological evidence of alveolar oedema is part of the definition of ARDS, but 
the severity of alveolar oedema and whether the source of the oedema is cardiac 
or inflammatory can be difficult to determine at the bedside. Estimation of 
extravascular lung water (EVLW) by transpulmonary thermodilution can assist 
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with quantification of alveolar oedema (37), while the ratio of EVLW to 
pulmonary blood volume (Pulmonary Vascular Permeability Index or PVPI) can 
help differentiate between hydrostatic and inflammatory causes of oedema (38).  
The PICCO2 monitor uses transpulmonary thermodilution to calculate EVLW and 
PVPI. A thermistor is placed in a peripheral artery (femoral, brachial or radial) 
and a bolus of cold saline injected into the superior vena cava. The cold bolus 
travels through the heart and lungs into the systemic arteries, where it is 
detected by the thermistor. The monitor detects the time of transit, changes in 
temperature of the injected bolus and exponential downslope time of the 
transpulmonary thermodilution curve (39).  
These measurements can be used to measure cardiac output using the Stewart-
Hamilton algorithm: 
CO=[(Tb-Ti) x Vi x K]/[∫ΔTb x dt] 
CO= cardiac output (L/min) 
Tb=blood temperature before the injection of cold bolus (oC) 
Ti=temperature of the injectate solution (oC) 
Vi= injectate volume (mL) 
∫ΔTb x dt=area under the thermodilution curve 
K=correction constants 
 
Intrathoracic thermal volume (total volume of intrathoracic blood and 
extravascular fluid, ITTV) is the product of cardiac output and mean transit time. 
Pulmonary thermal volume (total intravascular and extravascular fluid in the 
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lungs, PTV) is the exponential downslope time of the thermodilution curve 
multiplied by cardiac output. The Global End-Diastolic Volume (GEDV) is the 
difference between ITTV and PTV (39). 
The total amount of blood in the thorax (ITBV) has been shown to have a linear 
relationship with GEDV and is calculated by multiplying GEDV by 1.25, and the 
difference between intrathoracic thermal volume and intrathoracic blood 
volume is the extravascular lung water (37). PICCO measurement of EVLW has 
been shown to correlate closely with gravimetric measurement of pulmonary 
oedema in dogs (40). 
The difference between the pulmonary thermal volume and EVLW is the 
pulmonary blood volume (PBV) and, finally, the ratio of EVLW and PBV is the 
pulmonary vascular permeability index (PVPI). A high PVPI indicates greater 
levels of EVLW compared to PBV and is therefore consistent with alveolar 
oedema due to an active inflammatory process, whereas hydrostatic alveolar 
oedema is associated with a low PVPI. Use of the PICCO method to calculate PVPI 
has been shown to be useful in helping differentiate patients with hydrostatic 
alveolar oedema from patients with ARDS (38). 
PICCO measurement of EVLW has been shown to be pharmaceutically 
manipulatable in the BALTI studies of the effect of beta agonists on prevention 
and treatment of ARDS (41, 42). Multiple studies have shown that Extra Vascular 
Lung Water, indexed according to predicted body weight (EVLWI), is an 
independent predictor of mortality in ARDS (43-45). Early reductions in EVLWI 
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may be associated with a survival benefit (46). PVPI has also shown to be a 
predictor of survival in ARDS patients and to be independent of EVLWI (44, 47). 
1.2 Vitamin D Biology 
The important role of Vitamin D in bone health has long been recognised; 
Vitamin D is essential for facilitating absorption of calcium from the gut and 
without it children will develop rickets and adults the painful bone condition 
osteomalacia. However, many other cells and tissues in the human body express 
the Vitamin D receptor and the importance of Vitamin D in many other 
physiological processes is increasingly recognised (48). 
1.2.1 Sources of Vitamin D 
Humans are able to obtain vitamin D via the skin or the gut. Sunlight is the 
greatest source of Vitamin D in humans; in the form of UVB radiation (290-
315nm) it acts on 7-dehydrocholesterol in the skin to produce Vitamin D3 (48). 
Two different isoforms of Vitamin D can be obtained via the gut, Vitamin D2 is 
typically obtained from mushrooms (where it is created via exposure to sunlight 
in a similar manner to photosynthesis of Vitamin D3 in humans) and Vitamin D3 is 
obtained from animal sources such as egg yolk and oily fish (49). Supplements 
can comprise of either isoform, with Vitamin D2 being commonly used in the USA 
and Vitamin D3 being more available in the UK. Table 1.2 summarises the vitamin 
D content of different sources of Vitamin D. 
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Table 1.2. Vitamin D content of different sources of Vitamin D.  
Adapted from (49) 
Source Vitamin D Content 
Salmon 
Fresh – Wild (3.5oz) 600-1000IU D3 
Fresh – Farmed (3.5oz) 100-250IU D3 or D2 
Canned (3.5oz) 300-600IU D3 
Sardines Canned (3.5oz) 300IU D3 
Mackerel Canned (3.5oz) 250IU D3 
Tuna Canned (3.6oz) 230IU D3 
Shiitake Mushrooms 
Fresh (3.5oz) 100IU D2 
Sun Dried (3.5oz) 1600IU D2 
Egg Yolk   20IU D3 or D2 
Cod Liver Oil (1tsp)  400-1000IU D3 
Multivitamin   400IU D2 or D3 
Sunlight, UVB  
0.5 minimal erythemal 
dose* 
3000IU D3 
*About 0.5 minimal erythemal dose of uvb radiation would be absorbed after 
exposure of the arms and legs to sunlight for 5-10 minutes on average (time of 
exposure required for a specific dose varies with time of day, season, latitude, 
skin sensitivity) 
1.2.2 Vitamin D Metabolism 
Whether sourced from the skin or gut, Vitamin D enters the circulation and is 
hydroxylated in the liver to form 25-OH Vitamin D, the main circulating form. 25-
OH Vitamin D predominantly circulates bound to Vitamin D Binding Protein 
(VDBP), although it is also able to circulate bound to albumin or unbound. 1,25-
(OH)2 Vitamin D, the physiologically active form, is typically formed in the kidney, 
although many other cells express 1α-hydroxylase and are capable of converting 
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25-OH Vitamin D to 1,25-(OH)2 Vitamin D to form higher local concentrations 








Figure 1.3 Human Vitamin D synthesis and metabolism 
While the classical Vitamin D pathway is well described, not all the vitamin D 
produced by the action of sunlight is converted immediately to the 
physiologically active form. Studies have shown that excess Vitamin D is stored in 
fat (ready for use in winter when sunlight levels are lower), but the factors that 
influence whether Vitamin D is converted to the physiologically active form or 
not are not well known. One study in post-menopausal women found a 
correlation between 25-OH and 1,25-(OH)2 Vitamin D plasma concentrations, 
that was strongest in deficient subjects (i.e. women who had low plasma 
concentrations of 25-OH vitamin D were also likely to have low plasma 
concentrations of 1,25-(OH)2 Vitamin D) (50), but this study was cross sectional, 
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and did not look at the longitudinal effects of changes in vitamin D status. 
Another study found that 1,25-(OH)2 Vitamin D status is linked to Vitamin D 
binding protein plasma concentrations and that women with different Vitamin D 
Binding Protein phenotypes have different relationships between 25-OH and 
1,25-(OH)2 vitamin D (51). Other studies have suggested that circulating 1,25-
(OH)2 vitamin D plasma concentrations are not solely reliant on 25-OH vitamin D 
status. For example, a study looking at the effects of sun exposure for 30mins 
daily over 4 weeks in the spring in elderly residential home residents found that 
while 25-OH vitamin D plasma concentrations increased significantly, there was 
no significant change in 1,25-(OH)2 Vitamin D plasma concentrations (52). 
Another study comparing 12 months treatment with Hormone Replacement 
Therapy (HRT) with Vitamin D3 supplementation in post-menopausal women 
found that despite the groups which received Vitamin D3 seeing a significant rise 
in serum 25-OH vitamin D, patients in the group which received HRT only had a 
greater rise in 1,25-(OH)2 Vitamin D plasma concentrations than patients in the 
groups that received Vitamin D3 either on its own on in combination with HRT 
(53). 
1.2.3 Effects of Vitamin D on immune functions 
1,25-(OH)2 Vitamin D acts by binding to and activating the Vitamin D receptor 
(VDR), a nuclear receptor. This complex then forms a heterodimer with the 
retinoid receptor (RVR) which induces the expression of Vitamin D responsive 
genes (54). VDR is expressed by numerous cells of the immune system including 
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neutrophils, macrophages and T and B lymphocytes (55, 56). The effects of 
vitamin D on human immunity are wide-ranging, acting across various aspects of 
both the innate and adaptive immune systems in endocrine, paracrine and 
intracrine manners. 
 
Figure 1.4: Impact of Vitamin D on cells of the immune system 
Adapted from figures in (57, 58) Solid lines indicate positive feedback, dashed 
lines indicate negative feedback. 
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As illustrated in figure 1.4, monocytes/macrophages and dendritic cells express 
CYP27B which converts 25-OH Vitamin D to 1,25-(OH)2 Vitamin D, leading to 
locally increased plasma concentrations of 1,25-(OH)2 Vitamin D compared to 
circulating plasma concentrations. This process is upregulated when the cell is 
stimulated with interferon-γ (IFN-γ) (59) or when Toll like receptors (TLRs) sense 
the pathogen associated molecular pattern (PAMP) (60). This process also 
downregulates CYP24A which is responsible for inactivating 1,25-dOH Vitamin D 
by conversion to 24,25-(OH)2 Vitamin D (54). 
In monocytes and macrophages, 25-OH vitamin D is converted to 1,25-(OH)2 
Vitamin D which interacts with the VDR to induce the intracrine release of 
antimicrobial peptides such as cathelicidins via binding to Vitamin D responsive 
elements (VDRE) in the promotor regions of cathelicidin antimicrobial peptide 
(CAMP) genes. CAMP is expressed by neutrophils, monocytes, dendritic cells, 
lymphocytes, natural killer (NK) cells and epithelial cells of the skin, respiratory 
tract and gastrointestinal tract. Cathelicidins not only have broad antimicrobial 
activity, acting against bacteria, fungi and viruses, they are also capable of 
inducing wound healing, angiogenesis and modulating apoptosis (61). 
As the most numerous circulating immune cell, neutrophils are likely to be the 
greatest source of cathelicidins. Neutrophils express VDR but not a functional 
CYP27B enzyme, suggesting that neutrophil release of cathelicidin may be more 
dependent on the endocrine effect of circulating plasma concentrations of 1,25-
(OH)2 Vitamin D formed in the kidney. A study in patients with chronic renal 
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disease found an association between serum plasma concentrations of the 
cathelicidin LL37 and circulating 1,25-(OH)2 Vitamin D plasma concentrations, but 
not plasma concentrations of 25-OH Vitamin D (62). However, a study in patients 
with sepsis (who would be expected to have high neutrophil numbers) found a 
correlation between circulating LL37 and 25-OH vitamin D (63). 
As antigen presenting cells, dendritic cells link the innate and adaptive immune 
systems. Multiple studies have demonstrated that 1,25-(OH)2 Vitamin D 
suppresses dendritic cell maturation, leading to reduced secretion of IL-12 and 
increased secretion of IL10 as a result of decreased expression of costimulatory 
molecules such as CD-40, CD-80 and CD86 and MHC class II. This results in 
reduced activation of naïve T cells. As dendritic cells express CYP27B in a similar 
manner to monocytes and macrophages it is likely that a local high concentration 
of 1,25-(OH)2 Vitamin D is necessary for these effects (64-66). 
Studies investigating the effect of Vitamin D on T cells have established that 
sunlight exposure or 1,25-(OH)2 Vitamin D supplementation increases circulating 
CD3+ lymphocytes and CD8+ T cells (67, 68). In vitro, 1,25-(OH)2 vitamin D 
suppresses the effects of Th1 cells, which secrete cytokines such as IFNγ and 
Tumour Necrosis Factor-α (TNFα) (69). There is also some evidence that 1,25-
(OH)2 Vitamin D increases Th2 mediated secretion of IL4, a cytokine involved in 
immune regulation (70). In addition, Vitamin D has been shown to increase 
numbers of Regulatory T cells (Treg) both in vivo (71) and in vitro (72).  
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The effect of Vitamin D on Natural Killer (NK) cells is less well defined and the 
few studies available mainly focus on the effects of Vitamin D on NK cell 
function, not circulating numbers. While some studies have suggested that 1,25-
(OH)2 Vitamin D increases NK cell cytotoxicity (73), others have suggested a 
reduction in cytotoxicity with Vitamin D (74). One study of vitamin D 
supplementation which found an increase in circulating numbers of Treg found 
no effect on circulating NK cell numbers (71). 
1.2.4 Role of Vitamin D deficiency in autoimmune disease 
Vitamin D deficiency has been implicated as a causative factor in multiple 
autoimmune diseases including multiple sclerosis (MS), inflammatory bowel 
disease (IBD), type 1 diabetes and rheumatoid arthritis (75). Such diseases are 
more common in people living in northern latitudes such as Canada and 
Northern Europe where exposure to sunlight is lower than further south (76). 
Exacerbations of MS are more likely to occur in the spring, when Vitamin D 
plasma concentrations are at their lowest, than in other seasons (77, 78). Studies 
in mice have shown that 1,25-(OH)2 Vitamin D treatment results in reversal of 
paralysis associated with experimental autoimmune encephalomyelitis (EAE, a 
mouse model of MS). This was accompanied by a reduction in IL17A secreting 
CD4+ T cells (79). However, studies have shown that EAE is less severe and onset 
is delayed in VDR knockout mice, suggesting that VDR plays a role in 
development of the disease (80). In IBD, VDR knockout mice show more severe 
symptoms of experimentally induced colitis than wild type mice with high colonic 
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expression of TNF-α, IL-1α, IL-1β, IL-12, IFN-γ, IL-10, MIP-1α and KC. Treatment 
with oral or rectal 1,25-(OH)2 Vitamin D reduced inflammation in the wild type 
mice (81). 
Studies in mice have also demonstrated that low plasma concentrations of 1,25-
(OH)2 Vitamin D  results in hypertension as a result of negative regulation of the 
renin-angiotensin system by VDR (82). However, in humans, a rare autosomal 
recessive loss of Vitamin D receptor function results in hereditary vitamin D-
resistant rickets (HVDRR). A group of 17 patients with HVDRR aged 6-36 years 
were studied to investigate the role of VDR in the renin-angiotensin system in 
humans. The patients were found to have elevated 1,25-(OH)2 Vitamin D plasma 
concentrations but normal renin and angiotensin converting enzyme (ACE) 
activity, non-significant mild elevation of angiotensin II, normal aldosterone 
plasma concentrations and no hypertension (83). No trend towards increases in 
autoimmune conditions or other extra skeletal effects of Vitamin D deficiency 
has been detected in patients with HVDRR (84).  
A study in middle aged men showed that circulating 1,25-(OH)2 Vitamin D plasma 
concentrations inversely correlate with hypertension and VLDL triglycerides with 
25-OH Vitamin D plasma concentrations correlate with fasting insulin and insulin 
sensitivity (85). A meta-analysis of studies of Vitamin D in patients with type 2 
diabetes concluded that Vitamin D and calcium insufficiency may negatively 
influence blood glucose plasma concentrations and supplementation with both 
nutrients may be helpful in optimizing glucose metabolism (86). In MS, lower 25-
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OH Vitamin D plasma concentrations are associated with a higher risk of relapse 
(87, 88) but a systematic review of trials of Vitamin D therapy in patients with MS 
was inconclusive (89). 
1.2.5 Effects of Vitamin D on pulmonary inflammation and infection 
Increased knowledge of the effects of Vitamin D on innate and adaptive 
immunity naturally lead to consideration of the effects of Vitamin D on 
pulmonary disease. Bronchial epithelial and resident immune cells convert 
circulating 25-OH Vitamin D to 1,25-(OH)2 Vitamin D which boosts innate 
immunity to pathogens and regulates adaptive immune responses. (90) High 
vitamin D levels are associated with improved responses to glucocorticosteroids, 
a mainstay of treatment in many diseases affecting the lungs (91). Additionally, 
Vitamin D binding protein has been linked with a role in the pathogenesis in 
COPD, with high levels associated with lower FEV1 and higher macrophage 
activation (92), 
A number of studies have investigated a role for Vitamin D deficiency in acute 
and chronic lung disease. The third national health and nutrition examination 
survey demonstrated an association between serum 25-hydroxyvitamin d and 
pulmonary function which persisted after adjustment for age, gender, height, 
body mass index, ethnicity, and smoking history (93). Epidemiological and 
observational studies have demonstrated a link between Vitamin D deficiency 
and risk of developing respiratory diseases including including viral respiratory 
infections, COPD, asthma, and TB. (94-98) Exposure to the sun and UV light was 
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utilised as a treatment for TB in the early 20th Century, with patients admitted to 
heliotherapy wards and moved outside in order to maximise sunlight exposure 
prior to the development of antibiotic therapy. (99) Trials of Vitamin D 
supplementation in patients with tuberculosis have not demonstrated a 
significant overall benefit in recovery (100, 101), although a meta-analysis of 6 
studies of Vitamin D supplementation in patients with TB demonstrated a non-
significant reduction of TB infections patients supplemented with vitamin D (99). 
Trials of Vitamin D supplementation to prevent other respiratory tract infections 
have also been undertaken, and while the results of individual trials have been 
inconclusive, a meta-analysis in 2013 demonstrated a protective effect of 
supplementation (102). In asthma, a meta-analysis of nine trials reported that in 
people with predominantly mild to moderate disease, vitamin D 
supplementation is likely to reduce both the risk of severe asthma exacerbation 
and healthcare use (103), which may again point to an effect on the risk of 
developing respiratory tract infections.  
1.2.6 Vitamin D and ARDS 
The known effects of Vitamin D on human immunity point to potential 
pathogenic links between vitamin D deficiency and ARDS. The effect of 
cathelicidins, released by resident alveolar macrophages, on wound healing, 
angiogenesis and modulating apoptosis is highly relevant to ARDS pathogenesis, 
in addition to the broad antimicrobial peptide which may play a role in reducing 
infection and therefore preventing lung Injury from occurring. Effects on the 
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adaptive immune system, promoting towards regulatory (Treg) cells and away 
from inflammatory Th17 cells may promote the resolution of Lung Injury.  
There have been a few studies of the role of Vitamin D in animal models of Lung 
Injury. A study using the LPS inhalation model in hamsters demonstrated that 
1,25-(OH)2 Vitamin D  inhibited neutrophil recruitment in the lung by 
approximately 40% without increasing plasma calcium concentration. There 
were no effects on monocyte recruitment (104). A study investigating effects of 
Vitamin D on lung injury induced by reperfusion of femoral vessels in rats found 
that pre-treatment with cholecalciferol ameliorated Lung injury and systemic IL6 
levels (105). However, a study using the LPS challenge model in mice found no 
relationship between serum vitamin D concentration and degree of lung injury, 
nor an effect on resolution of lung injury (106).  
Several studies have reported high prevalence of Vitamin D deficiency in patients 
admitted to critical care, with one study reporting that 17% of patients had 
undetectable levels (107). In 2009 Jeng et al published a study showing that 
critically ill patients have lower plasma concentrations of 25-OH vitamin D than 
healthy controls and that this correlates with plasma concentrations of 
cathelicidin (63). Vitamin D deficiency prior to hospital admission has been found 
to be a predictor for short and long term all-cause mortality and for blood 
culture positivity in critically ill patients (108). A 2014 meta-analysis found that 
vitamin D deficiency significantly increases susceptibility for severe infections 
and mortality in critically ill patients (109).  
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1.2.7 Optimal Vitamin D Plasma concentrations 
Vitamin D status is generally defined by circulating plasma concentrations of 25-
OH Vitamin D. There is no consensus as to what plasma concentration is optimal. 
The Institute of Medicine in 2010 recommended that plasma concentrations less 
than 30nmol/L carry an increased risk of osteomalacia and should be considered 
deficient and plasma concentrations less than 50nmol/L carry an increased risk 
of secondary hyperparathyroidism and should be considered inadequate (110). 
Most recommendations on supplementation aim to achieve plasma 
concentrations greater than 50nmol/L. However, a number of clinical trials of 
Vitamin D supplementation have shown health benefits in increasing circulating 
25-OH Vitamin D plasma concentrations higher than 50nmol/L including 
improvements in bone density, pain, well-being and mood and new cancer 
diagnoses (111). The 2011 Endocrine Society Guidelines recommend that 25-OH 
Vitamin D plasma concentrations less than 50nmol/L should be considered 
deficient and plasma concentrations between 50 and 75nmol/L should be 
considered insufficient (112). There is even less consensus on upper limits for 
Vitamin D. Rarely, prolonged ingestion of high doses of Vitamin D can result in 
hypercalcaemia although no plasma concentration of 25-OH Vitamin D which 
inevitably results in hypercalcaemia has been identified  (113). A study in people 
living a traditional lifestyle in Tanzania found that mean plasma concentrations 
were 115nmol/L and plasma concentrations ranged from 58 to 171nmol/L in 
healthy individuals (114). A number of studies have found that patients with high 
25-OH Vitamin D plasma concentrations have increased mortality, with the odds 
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of death increasing at plasma concentrations greater than 98nmol/L, 140nmol/L 
and 150nmol/L. However, all these studies were observational (115-117). 
The normal range for circulating plasma concentrations of 1,25-(OH)2 Vitamin D 
has recently been evaluated in 96 healthy volunteers using  liquid 
chromatography tandem mass spectrometry and was found to be 59-159pmol/L 
This new method of measuring 1,25-(OH)2 Vitamin D was compared with results 
of the vitamin D External Quality Assessment Scheme (DEQAS) as well as 
radioimmunoassays which is the more common method of analysis (118). 
Reference ranges for radioimmunoassays often vary according to the laboratory 
carrying out the measurements, but are normally in the region of 50-150pmol/L 
(119). Plasma concentrations of 1,25-(OH)2 Vitamin D may vary diurnally; a study 
in post-menopausal women found plasma concentrations were lower in the 
morning than later in the day (120) but studies in younger people did not find 
any evidence of variation (121, 122). 
1.2.8 Vitamin D Supplementation 
Recommendations on dosing strategies to increase Vitamin D plasma 
concentrations in deficient patients vary from 800IU/day to intermittent 
intramuscular mega doses (300,000 or 600,000IU) in patients with malabsorption 
or who are unable to take oral therapy. (123, 124) The most common dose used 
in clinical practice is 800IU orally per day, often in conjunction with oral calcium. 
(125)  
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Trials of Vitamin D supplementation have used a wide range of doses, mainly 
consisting of daily doses over a period of weeks or months. A trial of 4000IU/day 
for 6 months in insulin resistant Asian women found that median 25-OH Vitamin 
D plasma concentrations increased from 21nmol/L to 80nmol/L in the treatment 
arm compared with an increase from 19nmol/L to 29nmol/L in the placebo arm 
(likely secondary to increasing sun exposure) (126). Another trial of 5000IU/day 
in nursing home residents resulted in mean 25-OH Vitamin D plasma 
concentrations increasing from 29nmol/L to 126nmol/L after 12 months. Plasma 
concentrations exceeded 74nmol/L in 92% of the patients at the end of this trial 
(127). Other trials have using intermittent higher doses. A trial of fortnightly 
doses of 120,000IU cholecalciferol over 6 weeks resulted in mean increase in 25-
OH Vitamin D plasma concentrations of 35nmol/L (128). A trial in patients with 
asthma of 6 2-monthly doses of 120,000IU cholecalciferol resulted in significant 
increases in 25-OH Vitamin D plasma concentrations after 2 and 12 months 
(129). A trial of annual oral doses of 500,000IU cholecalciferol in older women at 
risk of falls showed that patients in the treatment arm had 25-OH Vitamin D 
plasma concentrations in excess of 120nmol/L on average compared to average 
plasma concentrations less than 50nmol/L in the placebo arm. However, it is of 
note that patients in the treatment arm of this trial were more at risk of falls 
than patients recruited to the placebo arm (130). 
 
 
Page | 32  
 
1.3 Conclusion 
ARDS is an immune mediated form of acute respiratory failure characterised by 
neutrophilic alveolar inflammation, breakdown of the alveolar capillary barrier 
and inflammatory alveolar oedema. Vitamin D has been shown to play a key role 
in regulation of human immunity with wide ranging effects on cells of the 
immune system. Vitamin D deficiency has been implicated as a causative factor 
in a number of autoimmune diseases. Overall, the immunomodulatory effects of 
Vitamin D are complex and yet to be fully defined. While Vitamin D 
supplementation has been suggested as a possible treatment for multiple 
autoimmune diseases, the potential for both positive and negative effects on 
immune function mean that randomised placebo controlled trials are essential to 
establish whether supplementation can be of benefit.  
Page | 33  
 
CHAPTER 2 
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2.1 Aims 
The aims of this thesis are to: 
1. Determine the prevalence of Vitamin D deficiency in patients at risk of 
ARDS due to undergoing oesophagectomy. How do Vitamin D plasma 
concentrations relate to clinical and biological markers of ARDS post 
oesophagectomy? 
 
2. Investigate the short term efficacy of a one-off high dose supplement of 




3. Examine the effects of a one off high dose supplement of cholecalciferol 
on biomarkers of alveolar oedema and systemic inflammation. 
 
2.2 Hypothesis 
Patients with Vitamin D deficiency are at greater risk of developing ARDS post 
oesophagectomy. Preoperative supplementation with cholecalciferol reduces 
post-operative alveolar oedema and systemic inflammation.  
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3.1 Historical Cohorts 
3.1.1 BALTI-prevention 
The preliminary work in this thesis was carried out on stored samples from 
patients recruited to the translational sub study of the BALTI-prevention trial 
(EudraCT 2007-004096-19, ISRCTN 47481946). This was a trial of long acting 
beta-2 agonist (salmeterol) vs placebo for prevention of ARDS in patients 
undergoing transthoracic oesophagectomy. 55 stored plasma samples taken 
immediately prior to the operation were available for Vitamin D analysis and 
results were entered into a database of clinical and biochemical data. Plasma 
samples and data were collected and archived by Dr Daniel Park. The 
translational study was approved alongside the main trial by the South 
Birmingham Local Research Ethics Committee. (REC reference 07/H1207/233.). 
Recruitment to the study took place between March 2008 and September 2009. 
Samples were stored in aliquots of 0.5 millilitres at -80oC until analysis was 
performed. 
3.1.2 BALTI and BALTI2 
Vitamin D analysis was also carried out on 52 stored plasma samples taken on 
the day of enrolment from patients recruited to the BALTI (35 samples) and 
BALTI2 (17 samples) trials which were trials of beta-2 agonists in patients 
diagnosed with ARDS. The trials were both double blind placebo controlled trials 
of intravenous salbutamol in the treatment of ARDS. Samples from the BALTI trial 
were collected and archived by Prof Gavin Perkins. The trial was approved by 
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East Birmingham Local Research Ethics Committee. 40 patients were recruited to 
the BALTI trial between January 2001 and December 2003 at Birmingham 
Heartlands hospital. Samples were stored in aliquots of 0.5 millilitres at -80oC 
until analysis was performed. There was insufficient plasma for analysis from 5 
patients. Samples from the BALTI-2 trial (EudraCT Number: 2006-002647-86, 
ISRCTN38366450) were collected and archived by Dr Christopher Bassford. The 
trial was approved by the Oxfordshire Local Research Ethics Committee (REC 
reference 06/Q1604/123). The 17 samples used in this work were recruited to a 
bronchoscopic substudy of the trial. Samples were stored in aliquots of 0.5 
millilitres at -80oC until analysis was performed. The overall trial was suspended 
on safety grounds by the trial steering committee on 26th March 2010. 326 
patients had been recruited at this point, and an interim analysis was 
undertaken. This showed an increased mortality rate in those patients given the 
active drug compared to those treated with placebo. 
3.2 Patient recruitment 
3.2.1 Open label dosing study 
18 patients were recruited to an open label dosing study of cholecalciferol to 
help determine what dose of cholecalciferol to use in the placebo controlled trial 
(EudraCT 2011-004199-12, ISRCTN 66719785). Patients were recruited between 
April and September 2012. Patients were eligible for inclusion in the trial if they 
met the criteria detailed in table 3.1. 
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Table 3.1 Inclusion and exclusion criteria for open label dosing study and 
Vindaloo trial 
Inclusion Criteria Exclusion Criteria 
Planned transthoracic 
oesophagectomy at a participating 
centre 
known intolerance of vitamin D 
aged over 18 years on day of first 
dose of IMP 
known sarcoidosis, hyperparathyroidism, 
or nephrolithiasis 
Ability to give written informed 
consent to participate in the study 
taking more than 1000iu/day vitamin D 
supplementation in the month preceding 
enrolment 
 known baseline serum corrected calcium 
>2.65 mmol/L 
 undergoing haemodialysis 
 Pregnant or breastfeeding 
 Taking cardiac glycoside, carbamazepine, 
phenobarbital, phenytoin, primidone or 
long-term immunosuppressant therapy 
 Taking oral preparation containing > 10 
micrograms vitamin D/day up to 2 months 
before first dose of IMP 
 Diagnosis of COPD with an FEV1 less than 
50% predicted or resting oxygen 
saturations of less 92% 
 
3 doses of cholecalciferol were trialled sequentially – patients 1-6 received 
100,000IU cholecalciferol, patients 7-12 received 200,000IU cholecalciferol and 
patients 13-18 received 300,000IU. These doses were chosen because a review 
of the available literature at the time showed that a single oral dose of 100,000IU 
of Vitamin D2 had been shown to increase serum total 25(OH)D levels by 110 
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nmol/l in TB patients with all volunteers achieving serum levels above 75 nmol/l 
at one week post dose, with no patient developing hypercalcaemia (131). Higher 
single oral doses had been successfully used in elderly patients with 300,000 IU 
of Vitamin D3 achieving greater serum levels than regular oral dosing without 
major toxicity (132). Patients were administered the dose of cholecalciferol after 
consenting to inclusion in the trial at the pre-operative assessment clinic 
appointment which was 3-14 days prior to the planned date of the operation. 
Plasma concentrations of 25-OH Vitamin D peak at 7 days post oral dosing and 
decrease linearly thereafter, returning to baseline around day 84 on average 
(133). This window was therefore pragmatically chosen in order for the 
operation to coincide with peak plasma 25-OH Vitamin D concentrations while 
maximising recruitment of patients. The drug used was Vigantol® 812 oil (Merck 
Darmstadt Germany), an oily solution containing 20,000IU/ml cholecalciferol. 
Patients unable to swallow due to the severity of their oesophageal disease are 
routinely given a nasogastric or percutaneous endoscopic gastrostomy feeding 
tube and the drug was administered via that if required.  
The primary outcome for the trial was 25-OH Vitamin D3 plasma concentration 
on the day of oesophagectomy. 
The trial was approved by the South Birmingham local research ethics committee 
(REC reference number: 11/WM/0330)  
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3.2.2 VINDALOO Trial 
79 patients were recruited to the Vindaloo (VItamiN D to prevent Acute Lung 
injury following OesOphagectomy), a placebo controlled, double blind, 
randomised controlled trial between September 2012 and March 2015 (EudraCT 
2012-000332-25, ISRCTN 27673620). The trial was approved by the South 
Birmingham local Research Ethics Committee (REC reference 12/WM/0092). The 
inclusion and exclusion criteria were the same as for the open label study 
described in table 3.1.  
Following analysis of the results of the open label study (see chapter 5) patients 
were allocated to 15ml (containing 300,000IU cholecalciferol) Vigantol® oil or 
15ml placebo Miglyol 812 oil using sequential patient study number as 
predetermined randomisation by the supplier, Nova Labs. Neither investigators 
nor patients were aware of the subject’s allocation while they were participating 
in the trial.  
The primary endpoint for the Vindaloo trial was extravascular lung water at the 
end of the operation and the trial was powered to detect a change of 20% in 
EVLWI with a power of 80% (p=0.05). This study was conceived as a phase 2, 
proof of efficacy study and therefore the endpoint chosen was not intended to 
be clinically meaningful. As a group, patients undergoing oesophagectomy have a 
mean post-operative EVLWI of 10.1ml/kg and standard deviation of 3.0ml/kg and 
the power calculation estimated 34 patients were required in each arm to reach 
the primary endpoint. In order to allow for dropouts such as open/close cases, 
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changes to operative plans and other difficulties with data collection, it was 
intended to recruit 40 patients in each arm of the study. 
3.3 Transpulmonary Thermodilution Analysis (PICCO2) 
Picco2 measurements were collected at the beginning of the operation (after 
induction of anaesthesia but before the operation commenced), at the end of 
the operation and on the first morning after the operation. The theory and 
calculations behind PICCO2 measurements is explained in detail in section 1.1.9.  
All patients undergoing oesophagectomy have a central venous catheter inserted 
as a routine part of clinical care. Patients agreed to femoral artery catheter 
insertion as part of the trial consent process. The PICCO2 catheter was inserted 
into the right femoral artery by a member of the trial team under aseptic 
conditions using ultrasound guidance where required – ultrasound guidance was 
required in order to site the line one case, and in one further case the line could 
not be sited despite ultrasound guidance. Central Venous Pressure (CVP) was 
measured using the central venous catheter and manually entered into the 
PICCO2 machine prior to obtaining PICCO2 measurements. 
PICCO2 readings were obtained by connecting an injectate sensor to the central 
venous catheter and the PICCO2 machine. At least 15ml of cold saline was 
injected into the superior vena cava via the central venous catheter and the 
PICCO2 machine calculated measures of haemodynamics and transpulmonary 
volumes by analysing the thermodilution curve. Three injections were carried out 
and the PiCCO2 measures for these studies were calculated from the mean of the 
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three readings. Where the individual PiCCO2 measures of cardiac output varied 
by more than 20%, a fourth injection was performed and the deviant 
measurement was discarded, as per the guidance in the supplied manual. Studies 
have shown that using 3 injections results in a %CV <10% for Cardiac Index (CI), 
Global End Diastolic Volume Index (GEDI) and Extravascular Lung Water Index 
(EVLWI) (134, 135). 
3.4 Blood Collection and Processing 
Blood samples were collected on the day of drug administration (baseline), on 
the morning of the day of the operation (preop), at the end of the operation 
(post op), on the morning of the first day after the operation (day 1) and on the 
morning of the third day after the operation (day 3). Where possible, blood was 
collected from pre-sited arterial or central lines, or alongside clinical samples, to 
avoid subjecting the patients to extra venepuncture. All baseline blood samples 
were venous and all pre- and post op samples were arterial, subsequently 
samples were collected from arterial lines were available or from the venous 
circulation if arterial lines had been removed. Blood was collected into 7ml 
Lithium Heparin and 4.5ml Ethylenediaminetetraacetic acid (EDTA) Vacutainer® 
tubes (Becton Dickinson Ltd, Oxford, UK).  
In the laboratory, blood in vacutainer tubes was placed in a centrifuge and spun 
at 560g for 10 minutes. The supernatant (plasma) was aspirated immediately and 
divided into 0.5ml aliquots, then stored at -80C in cryovials for future analysis. 
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For analysis of peripheral blood mononuclear cells, after plasma was removed 
the blood cells were diluted 4:1 with Phosphate Buffered Saline (PBS). 15mL of 
this cell solution was over-layered on 10mL of lymphoprepTM (Axis-Shield, 
Dundee, UK) and spun in a centrifuge at 800g for 20 minutes with minimal 
acceleration and no brake to avoid disruption of the layers. After centrifugation 
an interphase buffy layer was visible (figure 3.1) which was aspirated using a 
Pasteur pipette and washed using PBS. 
 
Figure 3.1 Collection of PBMCs from blood samples using LymphoprepTM 
Cell count and viability was then assessed using a haemocytometer and the 
trypan blue exclusion test: 10µl of cell solution was mixed with 10µl of filtered 
0.4% trypan blue solution, and left to incubate for 5 minutes. 10µl of this mixture 
was then placed on a haemocytometer with an improved Neubaur grid. Non-
viable cells take up the trypan blue dye and therefore appear blue in colour, 
while viable cells exclude the dye and are paler than the non-viable cells. The 
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total number of viable cells was calculated by doubling the number of viable cells 
on the haemocytometer grid to account for trypan blue solution dilution, and 
then multiplying by 104 to give the number of cells per ml in the cell suspension. 
Viability was greater than 95% in all cases (Mean=98.9 SD=0.57, n=117). Purity 
was assessed using by fixing and staining the cells and visual inspection under the 
microscope. 50μL of the re-suspended cell pellet was placed in the cytospin 
apparatus and spun at 450g for 3 minutes in a Shandon Mk II cytocentrifuge 
(Thermo electron corporation Basingstoke, UK). The slides were air dried quickly 
and then stained with Diff-Quick (Baxter Incorp., UK). The differential cell count 
was performed by counting numbers of different cells until a total of greater 
than 100 cells had been seen. The percentage of each cell type seen was then 
calculated. Mean purity was 95.1% (n=117, SD 3.04). 
3.5 Analysis of Plasma 
3.5.1 Enzyme Linked Immunosorbent Assay (ELISA) 
Enzyme Linked Immunosorbent Assays (ELISAs) use a sandwich technique to 
determine concentration of analytes in samples. It uses a 96 well plate with 
capture antibody coated to the walls of the wells. When a solution containing the 
analyte of interest is added to the wells it binds to the capture antibody. Any 
unbound substance is then washed off and a detection antibody added which 
binds to the combined capture antibody and analyte. Unbound detection 
antibody is then washed off and a solution containing hydrogen peroxide and 
tetramethylbenzidine (TMB) added which turns the solution a blue colour as a 
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result of interaction with the detection antibody. The intensity of the blue colour 
is proportional to the amount of analyte bound in the conjugate. The reaction is 
stopped by addition of sulphuric acid which turns the solution yellow and allows 
results to be read using a plate reader. Comparison of the optical density in the 
investigation wells with optical density from wells with a known concentration of 
the analyte allows concentration of analyte in the investigation sample to be 
calculated. 
3.5.1.1 Vitamin D Binding Protein 
Vitamin D Binding Protein (VDBP) concentrations were measured using a 
commercially available kit (Immundiagnostik, Bensheim, Germany). The kit 
contains a 96-well plate precoated with polyclonal anti-VDBP antibodies. This 
plate was washed with the supplied wash buffer, then 100μL standard, control or 
prediluted sample was added. The standard range of concentrations was 
supplied in the kit and comprised 60ng/ml, 20ng/ml, 6.6 ng/ml, 2.2ng/ml and 
0ng/ml. Two quality controls were provided in the kit and a biological control 
was also included to assess inter-plate variation. Plasma samples from blood 
collected in lithium heparin vacutainer tubes were diluted 1:40,000 prior to use. 
Duplicates of each standard, control and sample were used. The plate was 
covered with a self-adhesive plastic film and placed on a horizontal mixer for 1 
hour at room temperature. The contents of the plate were discarded and the 
plate washed using the provided wash buffer. 100μL conjugate was added to the 
wells and the plate incubated for 1 hour on a horizontal mixer at room 
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temperature. The contents of the wells were again discarded and the plate 
washed with wash buffer. 100μL TMB substrate was added to the wells and the 
plate incubated for 10-20 minutes at room temperature (the time of incubation 
was determined by visual inspection of the colour change as recommended by 
the manufacturer). When good differentiation of the colour was observed 100μL 
Stop solution was added to the wells and mixed well. Absorption was 
immediately determined using a Synergy-2 microplate spectrophotometer 
(Biotek, Winooski, Vermont, USA) reading at 450nm against 620nm as a 
reference. Mean absorbance of the 0ng/ml standard was subtracted from the 
absorbance of standards, controls and standards. Regression analysis of the 
standard absorbance curve allowed calculation of the VDBP concentration in 
each sample.  
3.5.1.1.1 Quality Control of the VDBP Assay 
The test was carried out using 11 separate kits. R2 of the standard curve was 
greater than 0.95 in all cases (minimum R2=0.997). An example of the standard 
curve is shown in figure 3.2.  
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Figure 3.2 Sample Standard Curve for Vitamin D Binding Protein (VDBP) 
Spiking experiments were undertaken in which pooled healthy control plasma 
was measured with and without supplementation with a known concentration of 
VDBP. Expected values were calculated using the mean value obtained from 
pooled unspiked replicates and the concentration of the spike added. Mean 
percentage recovery was 104.7% expected, with a coefficient of variance (CV) of 
2.4%. These are comparable with the expected variance provided by the 
manufacturer. A biological control sample was included in each plate to 
determine interpolate variation. The CV was 28.9% which is below the range of 
acceptable variation of 30%. The range of values assessed varied quite 
significantly with some values at the limit of the assay. Inevitable human errors 
and the large dilution factor involved compound these issues to produce a 
broader cv.  The manufacturer provided two quality controls consisting of 
predetermined concentrations of VDBP. All values for the controls were within 
the acceptable range set by the manufacturer with the exception of the higher 
control on one plate. This control exceeded the upper limit of the acceptable 
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range by 2.5ng/ml. As this variation was small, and the biological sample from 
the plate was within 1 standard deviation of the mean concentration, results 
from this plate were included in the analysis. The limit of detection was 6.09 
ng/ml. 
3.5.1.2 LL-37 
Total LL-37 plasma concentrations were measured by Dr Aaron Scott using 
indirect ELISA as described by Chakraborty et al (136), with minor modifications. 
This method has previously been validated by Dr Scott (137). The standard range 
of concentrations comprised 125ng/ml, 62.5ng/ml, 31.25ng/ml, 15.63ng/ml, 
7.81ng/ml and 0ng/ml. LL-37 standards and samples were made up to 50 µl in 
serum free media and incubated in Greiner high binding plates (Sigma-Aldrich, St 
Louis, MO, USA) overnight at 37°C in an unsealed plate to allow adherence. 
Plates were washed three times with phosphate buffered saline with 0.05% 
Tween 20 (PBST) and blocked using PBST containing 1% Bovine Serum Albumin 
(BSA) for 1 hour at room temperature with gentle agitation. Polyclonal rabbit 
anti-human antibody directed against aa 134-170 of hCAP18 (Innovagen, Lund, 
Sweden) was diluted 1:10000 in PBST and 100 µl added to each well. Following 
incubation for 2 hours at room temperature, plates were again washed three 
times with PBST and 100 µl of goat anti-rabbit horseradish peroxidase (HRP) 
antibody (1:1000) added per well. Plates were incubated for 1 hour at room 
temperature then washed with PBST. HRP activity was measured by the addition 
of 100 μl TMB per well, followed by 15min incubation in the dark at room 
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temperature. The reaction was stopped by addition of 100μl 1M Hydrochloric 
Acid followed by reading at 450 nm. A standard curve was generated for each 
assay by plotting optical density from the standards versus standard 
concentrations. Regression analysis of the standard absorbance curve allowed 
calculation of the LL37 concentration in each sample. R2 of the standard curve 
was greater than 0.95 in all cases. An example of the standard curve is 
demonstrated in figure 3.3. The Limit of Detection was 62.52pg/ml, All values 
stated were in ng/ml, well within the detection limit. CV recovery with 
recombinant LL-37 spike was <10%. 




















Figure 3.3 Sample Standard Curve for LL37 
3.5.2 Luminex 
Two different commercially available Luminex multiplex kits were used to 
measure the inflammatory cytokines, IL-6, IL-8, IL-10, TNFa, IL2, IL1ra, Il1β and 
IL17 (R&D Systems Ltd, Abingdon, UK) and the soluble cytokine receptors TNFRI, 
TNFRII and sRAGE (Millipore, Billerica, Massachusetts). These analytes were 
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chosen because they were identified during analysis of the BALTI-prevention trial 
as significantly changing over the course of oesophagectomy, or because they 
have previously been shown to be affected by Vitamin D. Luminex uses colour 
coded magnetic microbeads which are precoated with antibodies which 
specifically bind to the analytes of interest. A biotinylated antibody is then added 
followed by streptavidin-phycoerythin (Strep-PE) conjugate, which binds to the 
biotinylated antibody. The microbeads are then suspended in buffer and 
analysed using a Luminex 200. Two lasers are used – one identifies the analyte 
that is being detected and one determines the magnitude of the Strep-PE signal 
which is in proportion to the amount of analyte bound to the bead.  
The procedure was similar for both kits. Seven doubling solutions of the supplied 
standard were used. The standard contained a known concentration of all of the 
analytes being investigated. The microbead solution was resuspended by 
vortexing and 50μL of microbead solution added to each well of a 96 well 
microplate.  50μL of standard, diluted plasma sample or control was added to 
each well and the plate was sealed and incubated for 3 hours at room 
temperature on a horizontal plate shaker. The plate was washed by applying a 
magnetic holder to the bottom of the plate to hold the magnetic beads in place, 
removing the liquid, then applying wash buffer 3 times. Next, 50μL biotin 
antibody cocktail was added to the wells and the plate sealed and left to 
incubate for 1 hour at room temperature. The plate was washed as previously, 
and 50μL Strep-PE added to each well. The plate was covered and incubated for 
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30 minutes at room temperature and then the plate was washed again. The 
microbeads were resuspended in buffer and read using the luminex instrument.  
3.5.2.1 Quality Control of Luminex Assay 
The standard curves were generated by the luminex software which uses a 5PL 
logistic regression to calculate analyte concentrations. The inter assay and intra 
assay %CVs for the different analytes are shown in table 3.2, along with the limits 
of detection. None of the analytes measured were below the lower limit of 
detection. The sensitivity of the Magplex kits was sufficiently to accurately 
measure all analytes at the dilutions used. These panels have been by the 
manufacturers against quantikine/high sensitivity ELISA kits. Data from theme 
Magplex panels correlates with the ELISA results.  Whilst the acceptable 
variability with the Millipore kits was especially high, we are happy the values 
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Table 3.2 Assay characteristics for Luminex Analytes 
Analyte Inter assay %CV Intra assay %CV Limit of 
Detection 
IL6 13.1 5.7 1.7 
IL8 13.8 6.7 1.8 
IL10 24.1 5.9 1.6 
TNF-a 20.9 4.0 1.2 
s-RAGE 33.7 9.2 7.2 
s-TNF-RI 34.3 16.0 41 
s-TNF-RII 36.3 15.9 0.4 
IL2 18.2 4.5 1.8 
IL1ra 20.9 8.9 18 
IL1β 28.2 6.7 0.8 
IL17 14.6 2.6 1.8 
 
3.5.3 Measurement of plasma 25-OH and 1,25-(OH)2 Vitamin D 
Plasma 25-OH Vitamin D2 25-OH Vitamin D3 and total 1,25-(OH)2 Vitamin D 
plasma concentrations were measured by the bioanalytical facility at the 
University of East Anglia, Norwich. The professionals at this laboratory are 
trained to meet the standards of good laboratory practice (GLP) and the facility 
participates in the vitamin D External Quality Assessment Scheme (DEQAS). 25-
OH Vitamin D plasma concentrations were measured by Liquid chromatography-
tandem mass spectrometry (LC-MS/MS) and 1,25-(OH)2 Vitamin D plasma 
concentrations were measured by enzyme immunoassay (EIA). The lower limit of 
detection for 25-OH Vitamin D (either isoform) were 2.5nmol/L and for 1,25-
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(OH)2 Vitamin D was 20pmol/L. The normal range for 1,25-(OH)2 Vitamin D using 
this technique is 43-144pmol/L. The assay characteristics for both isoforms of 25-
OH Vitamin D and 1,25-(OH)2 Vitamin D are shown in table 3.3. For the 25-OH 
Vitamin D measurements the intra-assay %CV was marginally higher than the 
inter-assay %CV, but the results obtained were validated by the facility in 
Norwich and we are satisfied the values measured lie within acceptable limits. 
Table 3.3 Assay characteristics for 25-OH Vitamin D and 1,25-(OH)2 Vitamin D 
 Inter assay %CV Intra assay %CV % Recovery 
25-OH Vitamin D2 10.0 10.8 95.8 
25-OH Vitamin D3 9.2 9.8 96.1 
1,25-(OH)2 Vitamin D 16.9 13.2 n/a 
 
3.6 Analysis of PBMCs 
PBMCs were analysed for numbers of natural killer cells using flow cytometry. 
After extraction from blood collected with lithium heparin (section 3.4), PBMCs 
were pelleted by centrifugation then resuspended in RPMI media at a 
concentration of 1 million/ml. 100μL of cell solution per well was transferred into 
Serocluster™ 96 well flexible plate (Costar, Corning, Amsterdam, The 
Netherlands) and stained for the cell surface antibodies CD3, CD56 and CD16. 
Cells were stained using 1μL each of Monoclonal Mouse anti-human CD3-APC 
(Clone BW264/56), Monoclonal mouse anti-human CD56-PE (clone  AF12-7H3) 
and monoclonal mouse anti-human CD16-FITC (clone VEP13) obtained from 
Miltenyi Biotec (Gladback, Germany). One well did not have any antibody added, 
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three contained single colour controls and one contained all three antibodies to 
allow cell identification. A further well was stained using CD3-APC, CD56-PEand 
IgG1-FitC to help gate set-up and to reduce false positives as a result of non-
specific staining of the CD16 antibody. Isotype controls were not used for CD3 or 
CD56 as the differentiation between positive and negative cells for these 
markers was bimodal, and therefore the use of isotype controls to correct for 
non-specific binding of the antibody was not felt to offer a more accurate result 
than using the internal control of unstained cells. The plate was covered using 
aluminium foil and incubated at 4C for 20 minutes before being washed using 
phosphate buffered solution (PBS).  
Cells were then analysed using flow cytometry using a Dako CyAn ADP™ flow 
cytometer and ‘Summit’ version 4.3 (Dako, Fort Collins, CO, USA). The same 
machine was used to assess all samples in this study to minimise experimental 
variables. The machine was cleaned prior to use to minimise the risk of 
contamination. Cell solutions were briefly vortexed before being loaded into the 
analyser to ensure a uniform distribution of cells. The cell solution with no 
antibody staining was loaded into the analyser first.  At least 10,000 events were 
recorded. Lymphocytes were gated using a forward scatter vs side scatter plot. 
This allowed identification of cells based on size and granularity (Figure 3.4A). 
Next, single cells were selected by excluding events with a larger than expected 
forward scatter area. This removes any clusters of cells or particles from the 
analysis (Figure 3.4B). The population of unstained single cells was examined to 
ensure there was no auto-fluorescence to complicate analysis of antibody 
Page | 55  
 
stained cells. Next, the single colour controls were analysed to ensure that there 
any overlap between emission wavelengths of different fluorochromes was 
minimised. Next the cell solution that had been stained with CD3, CD56 and 
CD16 was analysed. Cells which were CD3 negative were selected (Figure 3.4C) 











Figure 3.4 Gating strategy for identification of NK cells 
R1 indicates cells within identified as lymphocytes, R2 identifies the single cell 
population, R3 identifies CD3- cells, R4 identifies CD56dim, CD16+NK cells and R5 
identifies CD56bright CD16- NK cells. Data shown in graphs C, D and E represents 
log mean fluorescence, which has been compensated using single stained 
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3.7 In Vitro Assays 
3.7.1 Natural Killer Cell Cytotoxicity Assay 
The effect of Vitamin D on the cytotoxic capacity of Natural Killer cells was 
investigated using a cytotoxicity assay. The method used was similar to that 
described by Gilman Sachs et al (138). The human erythromyelocytic leukemia 
cell line K562 (ATTC, Manassas, VA, USA) was used as the target cell population 
as it is known to be sensitive to NK cell cytotoxicity (138). K562 cells were 
suspended in RPMI media supplemented with 10%FCS, and CellTracker™ Green 
added to the suspension at a concentration of 1nM (Molecular Probes, Life-
Technologies, Paisley, UK). Cells were incubated for 45 minutes at 37°C in a 
humidified 5% CO2 atmosphere, then centrifuged and resuspended at a 
concentration of 105cells/ml in fresh culture media. PBMCs, isolated from whole 
blood as described in section 3.4, were suspended in culture media at a 
concentration of 5 million cells/ml. The assay was carried out in duplicate using a 
round bottomed 96 well tissue culture plate. 100μL PBMC solution and 100μL 
K562 cell solution were placed in each well so that the PBMC:K562 cell ratio was 
50:1. Control wells consisting of PBMCs only and K562 cells only were also 
created. Where applicable, 100nM 25-OH Vitamin D3, 100nM 1,25-(OH)2 Vitamin 
D and/or 20ng/ml IL-2, along with appropriate vehicle controls were added to 
the wells. 100nM 25-OH Vitamin D3 is a similar concentration to physiological 
plasma concentrations in patients who are Vitamin D sufficient. 100nM 1,25-
(OH)2 Vitamin D is a supraphysiological dose, but is the dose used in  previous 
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studies which reported finding an effect (73). The tissue culture plate was gently 
centrifuged (50g for 1 minute at room temperature) to ensure contact between 
the cells and then incubated for 3 hours. This ratio was chosen after measuring 
NK cell cytotoxicity at PBMC:K562 cell ratios of 25:1, 50:1 and 100:1 after 2, 3 
and 4 hours(figure 3.5). While %NK cell cytotoxicity was greatest after 4 hours 
and at ratios of 100:1, incubations at ratios of 50:1 and for 3 hours was felt to be 












Figure 3.5 Effects of different PBMC:K562 cell ratios and assay durations on 
%NK Cytotoxicity. 
After incubation, the tissue culture plate was centrifuged to pellet cells at the 
bottom of the wells, supernatant was removed and the cells resuspended in 
200μL PBS and transferred to polypropylene tubes. 22μL SYTOX® Blue dead cell 
stain (pre-diluted 1:800 in PBS) was added to each tube and mixed 1 minute prior 
to analysis on the flow cytometer.  
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The K562 cells, having been stained with CellTracker™ Green, are FitC positive. 
The FitC positive population were selected and cells assessed for SYTOX® Blue 
positivity (Violet-1 Channel). The K562 only control cells were assessed first to 
evaluate spontaneous death, then the PBMC and K562 cell combination assessed 
to evaluate total cell death. The %NK cytotoxicity was calculated as the 
difference between total cell death and spontaneous cell death. Figure 3.6 shows 













Figure 3.6 Natural Killer Cell Cytotoxicity Assay Example 
Cells in R5 are positive for SYTOX® Blue staining A - K562 cells only, B - PBMCs and 
K562 Cells. 
3.7.2 Separation of Natural Killer cells 
Natural Killer cells were purified from PBMCs by negative selection using a 
commercially available isolation kit (Miltenyi Biotec, Gladbach, Germany). The 
specific antibodies used in this kit are not released by Miltenyi as it is 
commercially sensitive information. Following PBMC extraction from whole 
blood using the method described in section 3.4, 10 million cells were 
A B 
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centrifuged to form a pellet, then resuspended in 40μL of autoMACS™ running 
buffer (Miltenyi Biotec, Gladbach, Germany). 10μL of NK cell biotin conjugated 
antibody cocktail (targeted against non-NK cell antigens) was added to the cell 
solution then the mixture was incubated at 4°C for 15 minutes, with gentle 
flicking every 5 minutes to prevent cells settling at the bottom of the tube. Next, 
20μL of magnetic microbead conjugated antibody cocktail, targeted against 
biotin was added to the cell solution and the mixture was incubated at 4°C for 15 
minutes, with gentle flicking every 5 minutes. The cell solution was then washed 
and resuspended in autoMACS™ running buffer. The NK cells were isolated using 
a QuadroMACS™ (midi) magnetic separator and a LS column (Miltenyi Biotec, 
Gladbach, Germany). The column was prewashed with 3 mL autoMACS™ running 
buffer which were discarded and a new collection tube placed under the column. 
Next, the sample was loaded and washed through the column with a further 7 
mL autoMACS™ running buffer. The purified NK cells pass through the column 
while other cells are bound to magnetic microbeads and therefore stick to the 
walls of the column. The elute was pelleted by centrifugation then resuspended 
in culture media (RPMI). Purity of the NK cell population was assessed by flow 
cytometry, using the method for identifying NK cells described in section 3.6. An 
example is shown in figure 3.7. Purity >95% was predetermined to be acceptable 
and was achieved on each occasion. 
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Figure 3.7 Example of cell population obtained using negative isolation kit 
3.7.3 Collection of RNA 
RNA was extracted from purified natural killer cells, type 2 alveolar epithelial 
cells, monocytes and alveolar macrophages using a commercially available kit 
(NucleoSpin® RNA Extraction Kit, Machey Nagel, Duren, Germany). Type 2 
alveolar epithelial cells and alveolar macrophages were extracted from human 
lung resection tissue provided by the Midlands Lung Tissue Collective (MLTC). 
The MLTC is a regional scheme involving The University of Birmingham, Glenfield 
Hospital Leicester and Birmingham Heartlands Hospital that allows the use of 
lung resection specimens obtained from patients undergoing either a lobectomy 
or pneumonectomy for research into lung disease. The surgery is conducted at 
Birmingham Heartlands Hospital Thoracic Unit as part of therapy for lung cancer. 
Patients recruited had provided consent for any tissue removed as a part of their 
surgery not required for diagnostic or clinical purposes to be used for research 
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(North West REC Reference 07/MRE08/42; UKCRN ID 6664). Monocytes were 
extracted from PBMCs and isolated by plastic adhesion.  
In order to extract alveolar macrophages from lung tissue, 2000ml of 0.9% saline 
was flushed through the sample by injection through a 14 gauge hollow needle 
moved through the sample from multiple sites. The washed through fluid that 
was produced during this process was collected, decanted into 50ml centrifuge 
tubes and spun in a pre-chilled centrifuge at 4oC and 500g for 5 minutes.  The 
supernatant was then discarded and the cell pellets pooled and re-suspended in 
15ml of RPMI. The cell solution was over-layered on 10ml of lymphoprepTM 
(Axis-Shield, Dundee, UK) and spun in a centrifuge at ambient temperature for 20 
minutes at 800g with the centrifuge brake turned off. The resultant buffy inter-
phase was aspirated with a Pasteur pipette into a 15ml centrifuge tube.  A cell 
count and viability assay was then performed on this suspension using a 
haemocytometer and the trypan blue exclusion test as described above. The 
original cell suspension was then diluted to give a concentration of 1 million cells 
per ml. Cells were cultured in 24-well cell culture plates at 37oc in a 5% CO2 
atmosphere. Alveolar macrophages were isolated from the cell solution by 
plastic adhesion.   
The lung sample was then further processed to extract type II alveolar epithelial 
cells. Trypsin solution was instilled into the lung tissue in exactly the same way as 
the saline lavage, until it overflowed into the Petri dish(10-15 ml/5cm3 piece). 
The covered Petri dish was placed into a 37oC, 5% CO2 incubator for 15 min. This 
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process was repeated twice to give a total trypsinisation period of 45 min. Next, 
the tissue was chopped finely into 1-2mm3 pieces in the presence of FCS 
(10ml/5cm3 piece) and DNase I (250 –µg/ml HBSS; 7ml/5cm3 piece). FCS inhibits 
trypsin activity and DNase I was added to degrade glutinous DNA released from 
ruptured cells during the mincing process. The minced tissue suspension was 
shaken vigorously by hand for 5 min; this stage enhances type II cell recovery. 
The tissue suspension was filtered through a large gauge mesh (400-500 µm) and 
then a 40 µm cell filter to remove undigested tissues and debris from the 
enzymatically-released epithelial cells, which pass through the filter. The filtrate 
was centrifuged at 300g at 120C for 7 min. The cell pellet was suspended in 50-
100 ml 50% DCCM-1 and 50% HBSS containing 100 –µg/ml DNase I (10 ml of 
HBSS containing  250 –µg/ml DNase I, 15 ml of HBSS and 25 ml of DCCM-1 
without 10% FCS). The resuspended cell suspension were plated into either T-75 
culture flasks and incubated at 370C for ninety minutes to enable any 
contaminating macrophages to adhere. The media containing the nonadherent 
type II cell-enriched cell population was removed and centrifuged at 300g, 120C 
for 7 minutes. The cell pellet was resuspended in 3 ml of red cell lysis buffer and 
incubated for 3 min. 10ml HBSS was added and the solution centrifuged at 300g, 
120C for 7 minutes. The cell pellet was resuspended in 5mL 10% DCCM. Cells 
were counted using a haemocytometer. Cells were plated onto collagen-coated 
plates and put on plate shaker for three minutes to spread cells evenly. Cells 
were incubated in a humidified atmosphere in 5% CO2 at 37
0C for 24 hours. After 
24 hours the media and non-adherent cells were gently removed, leaving  
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remaining loosely attached cells and fresh 10% DCCM-1 medium was applied. 
After another 16-24 h, the media was removed and remaining loose cells washed 
off with HBSS. Fresh DCCM-1 medium was added. The cells formed a confluent 
monolayer within 3 days of plating which was used for RNA extraction. 
Cells were pelleted by centrifugation, then lysed using 3.5μL β-mercaptoethanol 
and 350μL buffer RA1. The lysate was filtered by centrifuging for 1 minute at 
11,000g. 350μL 70% Ethanol was added to the homogenized lysate and mixed by 
pipetting, and then the RNA was captured by being passed through the supplied 
column. After further centrifugation to remove unbound lysate, membrane 
desalting buffer (MDB) was passed through the RNA column and the column was 
once again centrifuged. DNase reaction mixture was added to the column to 
digest deoxyribose nucleic acid (DNA) and left to incubate for 15 minutes at 
room temperature. Then the column was washed and dried using first RAW2 
buffer to inactivate the DNase, then RA3 buffer to remove the digested DNA and 
other residual chemicals. Finally, the purified RNA was removed from the column 
using RNase-free water. Extracted RNA concentration and purity was checked 
using a NanoDrop 2000 Spectrophotometer (NanoDrop Products, Wilmington, 
DE, USA) routinely revealing a 260/280 ratio of  ~2.0-2.1 confirming minimal 
impurity. Mean RNA concentration was 62.8 ng/μl (SD 26.6 ng/μl). 
3.7.4 Real Time Polymerase Chain Reaction 
Real-time polymerase chain reaction or quantitative PCR (qPCR) is used to 
determine the relative quantities of specific sequences of nucleic acids present in 
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biological samples. A fluorescent DNA probe is used to identify the target 
sequences which are repeatedly exposed to optimal replication conditions in 
order to increase their quantity. The signal generated by the fluorescent DNA 
probe increases with every cycle as the quantity of DNA increases and the 
number of cycles before the signal from the probe crosses a pre-set threshold 
can be used to calculate the quantity of DNA in the original sample, compared to 
a control. 
In order to carry out qPCR, the extracted RNA needed to be converted into 
complimentary  DNA (cDNA). This was carried out using a commercially available 
high capacity RNA-to-cDNA™ kit (Applied Biosystems, Carlsbad, CA, USA) 
according to manufacturer instructions. cDNA concentration was assessed by 
spectrophotometry and diluted to 10 ng/mL. qPCR was performed in duplicate 
using the Light Cycler® 480 instrument (Roche Diagnostics GmbH, Manheim, 
Germany). Added to each well was a mixture of 10 μL Master Mix (Roche), 9 μL 
cDNA and 1 μL primer (table3.4). The reaction protocol was 10 minutes pre-
incubation followed by 45 cycles of 95°C for 10 seconds, 60°C for 30 seconds and 
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Table 3.4 Primers used for qPCR 
Target Reference 
Sequence 



























Data was outputted as a Cp value per well. Each sample/gene combination was 
performed in duplicate and a mean Cp value calculated. ΔCp was calculated by 
subtracting the mean Cp of the gene of interest from the mean Cp of the stably 
expressed housekeeping gene GAPDH. This acts as an internal comparison, 
accounting for sample differences. Because the ΔCp value is the inverse of the 
degree of gene transcription, it was multiplied by -1 to aid data presentation. The 
use of GAPDH as a single housekeeping gene is our laboratory’s standard 
protocol which has been used for multiple similar experiments by members of 
our group. The expression of GAPDH by the different cell types is shown in figure 
3.8 – there was no significant difference in GAPDH expression across the 
different cell types. 
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Figure 3.8 Expression of GAPDH by the different cell types examined 
n=6 for NK cells and n=4 for Type 2 cells and Monocytes/AM. Kruskall Wallis test 
overall was not significant (p=0.0587) and Dunn’s multiple comparsions test 
showed no significant differences between individual data sets. 
3.8 Severity Scores 
3.8.1 APACHE-II  
The Acute Physiology and Chronic Health Evaluation II (APACHE-II) score is tool 
which can help to quantify severity of illness and predict mortality on admission 
to ITU. It was developed using records from over 5000 individuals admitted to 
ICUs in 13 different US hospitals. It uses a point score based on admission values 
of 12 physiological measures (core temperature, Glasgow coma score, mean 
arterial pressure, heart rate, respiratory rate, oxygenation, arterial pH, 
haematocrit, white cell count, serum sodium, potassium and creatinine) age and 
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previous health status. Possible scores range from 0 to 71 with more severe 
illness scoring higher.  
3.8.2 SOFA 
The Sequential Organ Failure Assessment (SOFA) was designed to focus on organ 
dysfunction and morbidity following ITU admission. The score is made up of 6 
organ systems, each of which is allocated a score ranging from 0 to 4. The scoring 
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Table 3.5 SOFA scoring system (139) 
Parameter 
Score 
0 1 2 3 4 





















































<20 20-32 33-101 102-204 >204 
Coagulation Platelets 
(x109/L) 
















*Inotrope drug doses are in µg/kg/min. Dop = dopamine, Dob=Dobutamine, 
Epi=Epinephrine, Nor=Norepinephrine 
3.9 Diagnosis of post-operative ARDS 
In order to determine which patients developed ARDS post oesophagectomy, all 
chest radiographs and CT scans performed on study patients as part of their 
routine clinical care were examined by at least 2 doctors with experience in 
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diagnosing ARDS. Imaging from the institutions involved in the study were stored 
in digital form on the hospital Picture Archiving and Communications Systems 
(PACS) and viewed on a single workstation. The clinicians examining the imaging 
decided whether there was radiological evidence of ARDS (ie bilateral opacities 
not fully explained by effusions, lobar/lung collapse or nodules). This was then 
entered into a database alongside oxygenation and ventilation data in order to 
determine whether all criteria for ARDS had been met. Diagnosis of ARDS was 
made according to the Berlin criteria (table 1.1). Chest Radiograph criteria was 
judged to have been met if the clinicians examining the radiographs agreed that 
the radiographs were consistent with ARDS. Oxygenation criteria were judged to 
have been met if the P/F ratio was consistent with ARDS on at least one occasion 
and radiograph criteria had been met. 
3.10 Data Handling and Analysis 
3.10.1 Data Collection, Storage and Validation 
Data for the trials was prospectively collected using a bespoke case report form 
(CRF) (Appendix 1). Baseline data was collected from the medical records or by 
speaking with the patient. PICCO data was collected at the time of measurement 
by writing the obtained measurements directly into the CRF. As there was no 
source data for this important aspect of the investigation, figures obtained were 
checked by 2 people at the time of acquisition and indexed values obtained from 
the machine were checked by manually recalculation. No differences were found 
between the transcribed indexed data and the calculated index data. 
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Patients were allocated a trial ID to ensure patient anonymity. The CRFs were 
securely stored in a locked filing cabinet in a pass-card protected room at the 
Centre for Translational Inflammation Research (CTIR), University of Birmingham. 
Once collected, data was transferred to electronic storage for analysis using 
Microsoft Excel 2010. Results of laboratory analysis were also stored 
electronically in anonymised form. All electronic data was stored in a password 
protected, encrypted format and backed up regularly using the University 
servers. Data integrity was regularly checked against the source data. 
3.10.2 Data Analysis 
Data was analysed using Prism v6.05 (GraphPad, La Jolla, CA, USA) except for 
linear regression which was analysed using SPSS v21 (IBM, Somers, New York, 
USA). Where missing data was required for analysis (for example for paired 
data), the most recent known value was carried forward where less than 20% of 
values were missing. Where more than 20% of data was not available, data was 
analysed using non-paired tests. Continuous data was assessed for normality 
using D’Agostino and Pearson Omnibus test and the appropriate parametric or 
non-parametric test applied.  Statistical significance was pre-defined as p<0.05. 
To assess the significance of differences between two sets of data the unpaired T 
test was used for parametric data, while the Mann Whitney U Test was used for 
non-parametric data, except paired data which was assessed using paired T test 
(parametric) or Wilcoxon signed rank test (non-parametric). For comparison of 
three or more datasets, ANOVA was used for parametric data, Kruskal Wallis test 
Page | 72  
 
was used for non-parametric data, Repeated Measures one way ANOVA was 
used for parametric paired data and Friedman’s test was used for non-
parametric paired data with Holm-Sidak (parametric) or Dunn’s (non-parametric) 
multiple comparison test to assess differences between individual sets. No 
adjustment for multiple comparisons was made when assessing the cytokine 
data as this work was intended to be hypothesis generating and in order to 
power a study where multiplicity could be adjusted for, greater numbers would 
be required. Correlations were tested using Pearson for parametric data and 
Spearman rank correlation for non-parametric data. Nominative data was 
assessed using Fisher’s exact test where the expected frequency of one or more 
cells was less than 5 and Chi squared test for larger samples.   
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CHAPTER 4 





The contents of this chapter have been published: Vitamin D deficiency 
contributes directly to acute lung injury. RCA  Dancer, D Parekh, S Lax, V D’Souza, 
S Zheng, CR Bassford, D Park, D Bartis,  R Mahida , AM Turner, E Sapey, W Wei, B 
Naidu, PM Stewart, WM Fraser, KB Christopher, MS Cooper, F Gao, DM Sansom, 
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4.1 Introduction 
Interest in the immunomodulatory effects of vitamin D has prompted 
investigators to consider whether vitamin D deficiency may be associated with 
the development of critical illness. In 2009 Jeng et al published a study showing 
that critically ill patients have lower plasma concentrations of 25-OH vitamin D 
than healthy controls and that this correlates with plasma concentrations of 
cathelicidin (63).  Multiple subsequent studies have shown high prevalence of 
vitamin D deficiency in ICU populations and that 30 day mortality is increased in 
patients admitted to the ICU with vitamin D deficiency (108, 140). In one study, 
blood culture positivity was higher in patients with vitamin D deficiency (108), 
while a further study showed that patients with vitamin D deficiency in the first 
30 days after admission with severe sepsis or septic shock were more likely to die 
that patients with sufficient plasma concentrations (141). No previous studies 
have investigated the prevalence of Vitamin D deficiency specifically in humans 
with ARDS, but studies in animal models have suggested that vitamin D may 
ameliorate lung injury, reducing systemic IL6 concentrations and neutrophil 
recruitment to the lung (see section 1.2.6).  
Oesophagectomy patients are at high risk of post-operative ARDS with 
preoperative factors such as chronic respiratory disease, smoking pack-years and 
abnormal lung function associated with increased risk (142). Patients awaiting 
oesophagectomy often have difficulty swallowing and are therefore at risk of 
malnutrition. 30% of patients had impaired nutritional status in one study (143). 
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The prevalence of Vitamin D deficiency in patients undergoing oesophagectomy 
is unknown but a study of preoperative 25-OH Vitamin D plasma concentrations 
in patients awaiting cardiac surgery found that 60% of patients were deficient in 
Vitamin D (<50nmol/L) and a further 25.5% had insufficient plasma 
concentrations (50-75nmol/L). The same study found that 29.5% of patients had 
preoperative 1,25-(OH)2 Vitamin D plasma concentrations below 41pmol/L (144).  
4.2 Hypothesis and Research Questions 
4.2.1 Hypothesis 
Patients undergoing oesophagectomy have high prevalence of vitamin D 
deficiency and those patients who are deficient have higher risk of post-
operative ARDS. Patients with vitamin D deficiency have lower survival post-
oesophagectomy then patients with higher plasma concentrations. 
4.2.2 Research Questions 
1. How do plasma concentrations of circulating Vitamin D in patients 
undergoing oesophagectomy compare with patients with ARDS and 
healthy controls? 
2. Is Vitamin D deficiency a risk factor for ARDS post oesophagectomy? 
3. How does Vitamin D deficiency relate to biomarkers of alveolar oedema 
and systemic inflammation? 
4. Do circulating Vitamin D plasma concentrations predict post-operative 
mortality? 
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4.3 Methods 
Initial investigations were carried out on stored samples taken on the day of 
recruitment from 52 patients with ARDS recruited to the BALTI and BALTI2 trials 
(41, 145) and preoperative samples from 55 patients at risk of ARDS due to 
undergoing oesophagectomy who were enrolled in the translational sub-study of 
BALTI-prevention (146). 25-OH Vitamin D3 plasma concentrations were also 
measured in 18 healthy volunteers (10F:8M mean age 46.9, SD 14.5), for 
comparison with the patient groups. 25-OH Vitamin D3 were measured by LC-
MS/MS and 1,25-OH2 Vitamin D plasma concentrations were measured by EIA in 
a DEQAS certified laboratory. Plasma Vitamin D Binding Protein plasma 
concentrations were measured using ELISA. Results from the oesophagectomy 
patients were analysed using a database of clinical, PICCO and biochemical 
parameters. In order to determine whether patients had developed ARDS or not 
post-operative chest radiographs and oxygenation were analysed by 2 
respiratory physicians and 1 radiologist with experience of diagnosing ARDS. 
Statistical significance was defined as p<0.05. Statistical tests used are detailed in 
section 3.10.2. Continuous data in tables is presented as mean (SD) for 
parametric data and median (IQR) for non-parametric data. Nominative data is 
expressed as n (%). Statistical significance in the graphs is denoted using * for 
p≤0.05, ** for p≤0.01, *** for p≤0.001 and **** for p≤0.0001. Non-significance 
is denoted using ns. For comparison of survival curves, significance was 
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calculated using Log Rank (Mantel Cox) test and hazard ratios using Mantel-
Haenszel test using Prism v6.05 (GraphPad, La Jolla, CA, USA). 
4.4 Results 
4.4.1 Comparison of 25-OH Vitamin D3 plasma concentrations in patients with 
and at risk of ARDS 
All patients with ARDS and 52 patients in the at-risk group (95%) were Vitamin D 
deficient (25-OH Vitamin D3 plasma concentrations <50nmol/L). 8 healthy 
volunteers were also Vitamin D deficient (44%). Plasma concentrations of 
circulating 25-OH Vitamin D3 were significantly lower in at-risk patients than in 
healthy controls. Patients with ARDS had greater plasma concentrations of 
Vitamin D deficiency than patients at risk of ARDS due to undergoing 
oesophagectomy (figure 4.1) 
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Figure 4.1 25-OH Vitamin D3 in patients with and at-risk of ARDS  
n=52 for ARDS, n=55 for At-Risk, n=18 for Healthy Controls. Black horizontal lines 
indicate median for each dataset. Dotted reference lines indicate 25-OH Vitamin 
D3 50 and 75nmol/L. Overall Kruskal Wallis p<0.0001, significance shown 
between groups uses Dunns correction for mulitple comparisons. 
Circulating plasma concentrations of Vitamin D Binding Protein (VDBP) were also 
measured in the majority of the patients with and at-risk of ARDS. Again, patients 
with ARDS had significantly lower plasma concentrations of VDBP compared with 
the at-risk cohort (p<0.0001), who had significantly lower plasma concentrations 
than healthy controls (p=0.0018, figure 4.2). 
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* * * *
 
Figure 4.2 Vitamin D Binding Protein in patients with and at risk of ARDS 
n=42 for ARDS, n-47 for at-risk and n=18 for healthy controls. Black horizontal 
lines indicate median for each dataset. Overall Kruskal Wallis p<0.0001 
significance shown between groups uses Dunns correction for mulitple 
comparisons. 
4.4.2 1,25-(OH)2 Vitamin D in patients with and at-risk of ARDS 
Preoperative circulating plasma concentrations of 1,25-(OH)2 Vitamin D were 
normal in the majority of patients undergoing oesophagectomy. Patients with 
ARDS had lower circulating plasma concentrations of 1,25-(OH)2 Vitamin D, and 
17/52 (33%) had undetectable plasma concentrations. No patients in the at-risk 
group had undetectable plasma concentrations of 1,25-(OH)2 Vitamin D (figure 
4.3). 
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Figure 4.3 1,25-(OH)2 Vitamin D in patients with and at-risk ARDS  
n=52 for ARDS and n=55 for At-Risk. Dotted reference lines indicate normal range 
43-144pmol/L. Where plasma concentrations were undetectable (<20pmol/L), a 
value of 19.9 has been assigned for analysis and illustrative purposes. P<0.0001 
(Mann Whitney). 
4.4.3 Correlation between 25-OH Vitamin D3 and 1,25-(OH)2 Vitamin D plasma 
concentrations in patients undergoing oesophagectomy 
Spearman Rank correlation between plasma concentrations of 25-OH Vitamin D3 
and 1,25-(OH)2 Vitamin D was significant, but did not show a strong relationship 
(Spearman ρ=0.2745, p=0.0425, r2=0.0623, figure 4.4). 
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Figure 4.4 Correlation between 25-OH Vitamin D3 and 1,25-(OH)2 Vitamin D 
plasma concentrations in patients undergoing oesophagectomy 
n=55. Dotted reference lines indicate 25-OH Vitamin D 50nmol/L and 1,25-(OH)2 
Vitamin D 43-144pmol/L. 
4.4.4 Preoperative risk factors for development of ARDS post oesophagectomy 
Preoperative median plasma concentrations of vitamin D were significantly lower 
in those patients who developed ARDS post-operatively. Vitamin D status was 
the only preoperative predictive marker of ARDS on univariate analysis (see table 
4.1).  
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Table 4.1 Comparison of patients who did and did not develop ARDS post 
oesophagectomy 






Male – n (%) 13 (93) 34 (83) 0.6639 
Age (years)  
mean (SD) 
61 (12.3) 63 (11.1) 0.5144 
BMI (kg/cm2)  
mean (SD) 
25.7(5.6) 24.7 (4.5) 0.4942 
FEV1 (% pred)  
mean (SD)* 
89.2 (5.8) 94.7 (3.82) 0.4486 
Tumour Type = 
Adenocarcinoma  
n (%) 
11 (79) 29 (71) 0.7342 
Tumour Stage 
n(%) 
1 2 (14) 3 (7) 
0.5596 2 3 (21) 14 (34) 
3 9 (64) 24 (59) 
Smoker  
n(%) 
Current 6 (42) 8 (20) 
0.1568  Former 6 (42) 29 (71) 
Never 2 (14) 4 (10) 
Pack Years   
median (IQR) 
33 (20-40) 30 (15-45) 0.7335 
Plasma 25-OH Vitamin 
D3 (nmol/L) mean (SD) 
17.3 (7.65) 25.4 (11.9) 0.0207 
Plasma 1,25-(OH)2 
Vitamin D (pmol/L) 
median (IQR) 
66 (47-92) 89 (76-107) 0.0098 
*Data for FEV1 was not available for 4 patients 
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Univariate p values were not adjusted for multiple comparisons as the data was 
intended to be hypothesis generating and the n numbers were not sufficient to 
allow for this. Regression analysis of the above factors was also hampered by the 
small sample size. The analysis was carried out with the assistance of our 
statisician, Dr Peter Nightingale. The data was checked for collinearity (defined as 
VIF > 2.0) which, unsurprisingly, showed that smoking status and pack years were 
related. In view of the sample size and collinearity, the data was examined using 
a forward stepwise model. This model required two steps before no further 
significant variables were found and identified 1,25-(OH)2 Vitamin D (p=0.006) 
and tumour stage (p=0.096) as predictors of lung injury in this group. While 
tumour stage was included in the model, it was not significant at the 5% level. 
The two variable model was significant (χ2=12.593 p=0.006, Nagelkerke R square 
= 0.317). As there were 4 missing values for FEV1 and this parameter was not a 
significant predictor of lung injury, the analysis was run again without including 
FEV1. Using this analysis, 1,25-(OH)2 Vitamin D was the only significant predictor 
of lung injury (χ2=6.455, p=0.011, Nagelkerke R square 0.163) with an Odds Ratio 
of 0.970 (95%CI 0.944-0.996).   
4.4.5 Identification of cut off values for 25-OH Vitamin D3 and 1,25-(OH)2 
Vitamin D 
In order to further investigate the relationship between Vitamin D and 
development of ARDS, a receiver operating characteristic (ROC) curve was used 
to identify values for 25-OH Vitamin D3 and 1,25-(OH)2 Vitamin D below which 
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risk of development of ARDS was increased. For 25-OH Vitamin D3 the model was 
significant with an area under the curve (AUC) of 0.71 (95% CI 0.57-0.86 
p=0.0189). A cut off of 17.85nmol/L has specificity 73.2% and sensitivity 64.3% 
with a likelihood ratio of 2.40 for development of ARDS (figure 4.5). 















Figure 4.5 ROC curve to identify a value of 25-OH Vitamin D3 below which 
development of ARDS is more likely 
AUC 0.71 (95% CI 0.57-0.86 p=0.0189). Dotted reference lines indicate specificity 
of 73.2% and sensitivity 64.3% 
For 1,25-(OH)2 Vitamin D the model was also significant with AUC=0.73 (95% CI 
0.56-0.90, p=0.0108). This showed that a cut-off of 1,25-(OH)2 Vitamin D 
<71.50pmol/L has specificity 85.7% and sensitivity 64.3% with a likelihood ratio 
of 4.39 for prediction of development of ARDS (figure 4.6). 
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Figure 4.6 ROC curve to identify a value of  1,25-(OH)2 Vitamin D below which 
development of ARDS is more likely  
AUC 0.73 (95% CI 0.56-0.90, p=0.0108). Dotted reference lines indicate specificity 
of 85.7% and sensitivity 64.3% 
 
4.4.6 Effects of Vitamin D status on cytokine plasma concentrations  
Patients were divided into two groups according to 25-OH Vitamin D3 plasma 
concentrations as suggested by the ROC analysis. Differences in cytokine plasma 
concentrations between the groups were analysed. The full data is shown in 
tables A1-A6 in the appendix. Figure 4.7 shows the change over time in plasma 
concentrations of IL6. Patients with higher plasma concentrations of 25-OH 
Vitamin D had marginally higher levels of IL6 post op, but did not have as great 
increases in IL6 during the perioperative period.  
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Figure 4.7 Comparison of perioperative changes in plasma concentration of IL6 
between 25-OH Vitamin D3 groups 
n=20 (each timepoint) for 25-OH Vitamin D3 < 17.85nmol/L, n=35 (each 
timepoint) for 25-OH Vitamin D3 >17.85nmol/L. Overall Friedman test p<0.0001 
for both groups. Difference between preop samples p=0.040, Post-op samples 
p=0.005 (both Mann Whitney). 
 
Similar preoperative differences in IL8 were seen between the groups, but while 
plasma concentrations in patients who were most deficient in 25-OH Vitamin D3 
tended to fall by Day 1 post op, in the patients with higher plasma 
concentrations IL8 tended to continue to increase (figure 4.8). 
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Figure 4.8 Comparison of perioperative changes in plasma concentration of IL8 
between 25-OH Vitamin D3 groups  
n=20 (each timepoint) for 25-OH Vitamin D3 < 17.85nmol/L, n=35 (each 
timepoint) for 25-OH Vitamin D3 >17.85nmol/L. Overall Friedman test p<0.0001 
for both groups. Difference between preop samples p=0.012, Day 1 samples 
p=0.015 (both Mann Whitney). 
 
Similarly, plasma concentrations of IL17 were higher pre- and post-operatively in 
patients with greater plasma concentrations of 25-OH Vitamin D3 (figure 4.9). 
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Figure 4.9 Comparison of perioperative changes in plasma concentration of 
IL17 between 25-OH Vitamin D3 groups  
n=20 (each timepoint) for 25-OH Vitamin D < 17.85nmol/L, n=35 (each timepoint) 
for 25-OH Vitamin D >17.85nmol/L. Overall Friedman test p=0.0045 for 25-OH 
Vitamin D < 17.85nmol/L and p<0.0001 for 25-OH Vitamin D > 17.85nmol/L. 
Difference between preop samples p=0.001, Post-op samples p=0.016 (both 
Mann Whitney). 
 
When the cohort was divided according to 1,25 Vitamin D the differences 
generally were not replicated (tables A1-A6). 
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4.4.7 Effects of Vitamin D status on perioperative changes in alveolar oedema  
Perioperative changes in alveolar oedema, as measured by PICCO catheter, were 
compared between groups. EVLWI significantly increased perioperatively in both 
25-OH Vitamin D3 groups, but while in patients with 25-OH Vitamin D3 plasma 
concentrations greater than 17.85 EVLWI returned to baseline by D1, in patients 
with more severe deficiency day 1 EVLWI was significantly higher than preop 
plasma concentrations (figure 4.7). As baseline values varied, fold changes were 
analysed. Patients with 25-OH Vitamin D3 less than 17.85 had greater increases 
in extravascular lung water index (EVLWI) perioperatively compared with 
patients with less severe deficiency (p=0.0113) but there was no significant 
difference in fold change between the post op and day 1 measurements 
(p=0.4782, figure 4.8). 
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Figure 4.10 Differences between 25-OH Vitamin D3 groups in perioperative 
EVLWI 
n=20 for <17.85 datasets and n=35 for >17.85 datasets. Black horizontal lines 
indicate median for each dataset. Friedman test for 25-OH Vitamin 
D3<17.85nmol/L p=0.0013, Friedman test for 25-OH Vitamin D3>17.85nmol/L 
p<0.0001.Friedmans test with multiple comparisons used to test for differences 
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Figure 4.11 Differences between 25-OH Vitamin D3 groups in perioperative fold 
change in EVLWI  
n=20 for 25-OH Vitamin D3 <17.85 and n=35 for 25-OH Vitamin D3 >17.85. 
Comparison made using unpaired T test for post-op and Mann Whitney Test for 
day 1. Dotted reference line indicates fold change=1; data points below the line 
decreased post op and data points above the line increased post op 
 
For PVPI, there was a significant rise perioperatively, followed by a significant fall 
between post op and day 1 measurements which resulted in no significant 
difference between preop and day 1 PVPI (figure 4.9). The difference in fold 
change increases in PVPI between the preoperative and post-operative time 
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points was not significant at the 5% level (p=0.0619) and no difference in fold 
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Figure 4.12 Differences between 25-OH Vitamin D3 groups in perioperative 
PVPI 
n=20 for <17.85 datasets and n=35 for >17.85 datasets. Black horizontal lines 
indicate median for each dataset. RM one-way ANOVA for 25-OH Vitamin 
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Figure 4.13 Differences between 25-OH Vitamin D3 groups in perioperative fold 
change in PVPI  
n=20 for 25-OH Vitamin D3 <17.85 and n=35 for 25-OH Vitamin D3 >17.85. 
Comparison between groups made using Mann Whitney test. Dotted reference 
line indicates fold change=1; datapoints below the line decreased post op and 
datapoints above the line increased post op 
 
When changes are considered by 1,25-(OH)2 Vitamin D plasma concentration, 
similar changes in EVLWI and PVPI are seen in both groups (figures 4.11 and 
4.12). 
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Figure 4.14 Differences between 1,25-(OH)2 Vitamin D groups in perioperative 
EVLWI 
n=15 for <71.5 datasets and n=40 for >71.5 datasets. Black horizontal lines 
indicate median for each dataset. Friedman test for 1,25-(OH)2 Vitamin 
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Figure 4.15 Differences between 1,25-(OH)2 Vitamin D groups in perioperative 
PVPI 
n=15 for <71.5 datasets and n=40 for >71.5 datasets. Black horizontal lines 
indicate median for each dataset. Friedman test for 1,25-(OH)2 Vitamin 
D<71.5pmol/L p=0.0037, Friedman test for 1,25-(OH)2 Vitamin D>71.5pmol/L 
p<0.0001. 
 
There were no significant differences in fold change between groups when 1,25-
(OH)2 Vitamin D was used to define groups.  
4.4.8 Association between Vitamin D and survival 
There was no significant difference in survival between oesophagectomy 
patients with 25-OH Vitamin D3 < 17.85nmol/L and patients with higher plasma 
concentrations (p=0.0988, figure 4.16). In ARDS patients recruited to the BALTI 
and BALTI2 studies there was no difference in plasma concentrations of 25-OH 
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Vitamin D between patients who died within 28 days of admission and those 
who survived (p=0.2712, figure 4.17).  
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p = 0.09 88
 
Figure 4.16 Kaplan Meier Survival Curve comparing differences in survival of 
patients post oesophagectomy by 25-OH Vitamin D3 group  
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Figure 4.17 Comparison of 25-OH Vitamin D3 plasma concentrations with 28-
day mortality in patients with ARDS (BALTI and BALTI2 cohorts) 
32 patients died within 28 days and 20 patients survived. Unpaired T test used for 
comparison between groups. Horizontal black lines indicate mean for each 
dataset 
Median circulating 1,25-(OH)2 Vitamin D plasma concentrations in patients from 
the BALTI and BALTI2 studies with ARDS who survive their hospital admission are 
higher than in patients who do not survive (p=0.0083 figure 4.18).   
 
 
Page | 98  
 




























Figure 4.18 Comparison of 1,25-(OH)2 Vitamin D plasma concentrations in ARDS 
patients with 28-day mortality 
32 patients died within 28 days and 20 patients survived. Mann Whitney test 
used to compare groups. Horizontal black lines indicate median for each dataset 
Median post-operative survival in patients with preoperative 1,25-(OH)2 Vitamin 
D plasma concentrations less than 71.5nmol/L was 565days compared with 
1187days in patients with greater plasma concentrations (Mantel-Haenszel 
hazard ratio 3.774, 95%CI 1.622-8.784, p=0.0021, figure 4.19). 
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Figure 4.19 Kaplan Meier Survival Curve comparing differences in survival of 
patients post oesophagectomy by 1,25-(OH)2 Vitamin D group  
n=15 for 1,25-(OH)2 Vitamin D < 71.5pmol/L, n=40 for 1,25-(OH)2 Vitamin D > 
71.5pmol/L  
Data regarding cause of death was not available for all patients. However, 
examination of the notes for 31 of the patients who had died since their 
operation revealed that 19 (61%) had evidence of cancer recurrence at the time 
of their death. 
4.5 Discussion 
We have found that Vitamin D deficiency is common in patients undergoing 
oesophagectomy and that patients who develop ARDS post op have lower 
plasma concentrations of both 25-OH Vitamin D3 and 1,25-(OH)2 Vitamin D. This 
compares with patients on the intensive care unit who have ARDS, in whom we 
found vitamin D deficiency was ubiquitous. Our findings suggest that Vitamin D 
deficiency increases risk of development of ARDS. 
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Plasma concentrations of both 25-OH Vitamin D3 and 1,25-(OH)2 Vitamin D early 
in the course of the disease in patients with established ARDS were lower than 
preoperative plasma concentrations in the patients undergoing oesophagectomy 
who developed ARDS (25-OH Vitamin D3: established ARDS median plasma 
concentrations 13.1nmol/L, oesophagectomy ARDS median plasma 
concentrations 17.3nmol/L, 1,25-(OH)2 Vitamin D: established ARDS median 
plasma concentrations 36pmol/L, oesophagectomy ARDS median plasma 
concentrations 66pmol/L). This suggests Vitamin D plasma concentrations may 
fall early in the course of the illness prior to development of ARDS (i.e. during the 
course of development of pneumonia, sepsis, pancreatitis  etc). Potential 
mechanisms by which vitamin D deficiency could be established during the onset 
of lung injury include malabsorption from the gut, dysregulated hydroxylation of 
precursors in the liver, insufficient VDBP synthesis to bind, store and transport 
25-OH vitamin D, ineffective renal uptake in the proximal tubule cell of VDBP-
bound vitamin D and dysregulated 25-OH vitamin D metabolism in the kidneys. 
High metabolism of Vitamin D during severe illness may leave patients with pre 
existing Vitamin D defiency unable to replenish stores of Vitamin D and at risk of 
dysregulated immunity.  
 VDBP is a member of the albumin family and the regulation of its production is 
poorly understood. Our finding of reduced VDBP in ARDS versus at risk and 
normal individuals supports a role for either reduced production or increased 
losses as an explanation for some of the degree of deficiency seen. Equally the 
low observed plasma concentrations of circulating 1,25-(OH)2 vitamin D in the 
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ARDS patients suggests reduced renal metabolism as this is the major source of 
circulating 1,25-(OH)2 Vitamin D (48). Clearly, Vitamin D deficiency in the context 
of critical illness is likely to be multifactoral. 
The prevalence of Vitamin D deficiency in the oesophagectomy cohort was 
higher than expected. A recent study of patients with colon, lung and breast 
cancer admitted to a general ward for active treatment found that 77% of 
patients had 25-OH Vitamin D plasma concentrations <50nmol/L and that 
median plasma concentrations across these three populations was 38.2nmol/L, 
compared with prevalence of 95% deficiency and median plasma concentrations 
of 21nmol/L in our cohort. The high plasma concentration of deficiency in 
patients undergoing oesophagectomy meant that it was not possible to use the 
lower limit of normal of 25-OH Vitamin D3 (50nmol/L) to compare patients. Using 
the ROC curve analysis we identified a cut off for 25-OH Vitamin D3 which 
represented increased risk of ARDS. A recently published study found that similar 
25-OH Vitamin D plasma concentrations  (17.5nmol/L) carry an increased risk of 
mortality in severe sepsis (147) which supports the significance of this plasma 
concentration of severe deficiency.  
We found that preop inflammatory cytokines were slightly higher in patients 
with 25-OH Vitamin D3 plasma concentrations >17.85nmol/L, but perioperative 
inflammatory response was lower in these patients. The greater absolute plasma 
concentrations and fold change in IL6 in patients with lower plasma 
concentrations of 25-OH Vitamin D3 may be important as IL6 has been 
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highlighted as a cytokine which is associated with fewer ventilator free days and 
increased mortality in patients with ARDS (148, 149). The same studies suggested 
that IL8 may also be a factor in ARDS, but while patients with more severe 
Vitamin D deficiency had greater perioperative fold change in IL8, there was no 
difference in absolute plasma concentrations immediately post op and by day 1 
post op the patients with greather plasma concentrations of 25-OH Vitamin D3 
had higher IL8. In addition, while IL8 plasma concentrations in patients with 
severe 25-OH Vitamin D3 deficiency tended to fall, plasma concentrations in 
patients with higher plasma concentrations tended to rise. This finding was not 
replicated in the 1,25-(OH)2 Vitamin D groups.  
Patients with lower plasma concentrations of 25-OH Vitamin D3 had greater 
perioperative increases in extravascular lung water, a biomarker of alveolar 
oedema which has been shown to be an independent risk factor for outcome in 
ARDS (150). There was also a trend towards greater increases in PVPI at the post 
op timepoint. As PVPI is the ratio between Extravascular Lung Water and 
Pulmonary Blood Volume, higher PVPI indicates that alveolar oedema is likely to 
be inflammatory rather than hydrostatic in nature. This finding, supports an 
inflammatory mechanism behind perioperative increases in EVLWI. Baseline 
EVLWI and PVPI did vary between patients and the reasons for this are likely to 
be multifactoral – while Vitamin D status may play a role, a number of other 
factors including smoking status and tumour stage are also likely to contribute. 
As EVLWI and PVPI tended to have returned to baseline by the day following the 
operation and therefore the perioperative increases seen are unlikely to be 
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clinically meaningful, but the data does provide a quantatitive measure of 
alveolar inflammation.  
Alveolar macrophages are the predominant cell in the resting healthy lung and 
express CYP27B which means they are capable of converting 25-OH Vitamin D to 
1,25-(OH)2 Vitamin D  and are therefore not reliant on circulating plasma 
concentrations of 1,25-(OH)2 Vitamin D (58). 1,25-(OH)2 Vitamin D plasma 
concentrations were not as clearly associated with biomarkers of alveolar 
epithelial dysfunction such as sRAGE and EVLWI, suggesting that 25-OH Vitamin 
D plasma concentrations may be more important in the alveoli.  The action of 25-
OH Vitamin D on monocytes and macrophages may also be responsible for the 
differences in IL8 seen on day 1 post op, as the VDR and IL8 gene binding sites 
are close in proximity and studies have shown that IL8 gene expression in 
monocytes and macrophages is dependent on Vitamin D (151, 152).  
Our data has limitations. In addition, while blood from the patients with ALI was 
collected as soon as possible following admission to ITU, we are unable to be 
sure whether levels of 25(OH) Vitamin D3 are low prior to the development of ALI 
in that cohort or whether levels fall because of the development of ALI. The size 
of the cohort of patients who underwent oesophagectomy is small (although it is 
the largest cohort to date of patients undergoing oesophagectomy in whom 
EVLWI and PVPI have been measured to our knowledge) with 14 patients 
developing lung injury post oesophagectomy. This means that the risk of finding 
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significant correlations by chance is increased and the data should be regarded 
as hypothesis generating, rather than conclusive.  
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CHAPTER 5 
EFFECTS OF HIGH-DOSE, ONE-OFF 
VITAMIN D SUPPLEMENTATION ON 
PLASMA VITAMIN D STATUS  
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5.1 Introduction 
To my knowledge, there are no studies investigating dosing strategies for pre-
operative Vitamin D supplementation in patients awaiting elective surgery. 
Supplementation in surgical patients presents its own challenges – while many 
supplementation regimes aim to achieve sufficient circulating plasma 
concentrations of 25-OH Vitamin D over 8-12 weeks (123), in surgical patients 
such as those undergoing oesophagectomy, a rapid increase in 25-OH Vitamin D 
plasma concentrations over a short period of time is required in order to achieve 
sufficient plasma concentrations without delaying the operation.  
The two isoforms of Vitamin D (ergocalciferol/Vitamin D2 and 
cholecalciferol/Vitamin D3) differ only in structure of one of their side chains, but 
this difference appears to alter their biological potency with supplementation 
with cholecalciferol more likely to increase circulating total 25-OH Vitamin 
plasma concentrations than ergocalciferol (153). As early studies showed that 
supplementation with Vitamin D2 or D3 was effective at preventing rickets in 
children, the two isoforms were traditionally assumed to have biological 
equivalence. However, it has been shown that the 25-OH Vitamin D2 isoform has 
a lower affinity for VDBP and is metabolised differently, resulting in lower 
conversion of 25-OH Vitamin D2 to 1,25-(OH)2 Vitamin D2 than is seen with 
equivalent plasma concentrations of Vitamin D3 (154). The difference in biological 
potency may have clinical effects - a Cochrane review found that 
supplementation with cholecalciferol reduced mortality in elderly women while 
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supplementation with ergocalciferol did not (155). Multiple studies have found 
that 25-OH Vitamin D3 plasma concentrations decrease in response to 
supplementation with ergocalciferol, (156, 157) but similar studies of the impact 
of cholecalciferol have not been published. This is important because studies of 
supplementation frequently report the effect on total Vitamin D plasma 
concentrations, but if 25-OH Vitamin D2 plasma concentrations decrease with an 
increase in 25-OH Vitamin D3, the biological effects of supplementation in 
patients with relatively high plasma concentrations of 25-OH Vitamin D2 may be 
underestimated. 
A number of factors have been shown to influence the response to 
cholecalciferol administration, including baseline plasma concentrations of 25-
OH Vitamin D, demographic factors such as age, sex and BMI, genetic variation in 
genes related to Vitamin D metabolism and environmental factors such as 
season of administration (158). Most studies have examined responses after at 
least 8 weeks of regular treatment and in many cases response has been 
measured at 12 months. The short term effects of a one-off high dose 
supplement on 25-OH Vitamin D and 1,25-(OH)2 Vitamin D plasma 
concentrations in patients awaiting surgery are not clear. However, a placebo 
controlled pilot study of high dose cholecalciferol supplementation in critically ill 
patients found that 25-OH Vitamin D plasma concentrations increased 
significantly in patients who received cholecalciferol within 24 hours and that 
this difference was sustained over 7 days post dose (159).  
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There is limited data concerning the immediate effects of undergoing an 
operation on 25-OH Vitamin D plasma concentrations. Studies in patients 
undergoing arthroscopy have found that 25-OH Vitamin D plasma concentrations 
decrease by day 2 post op and that this is associated with a fall in serum VDBP 
and an increase in urinary VDBP, suggesting increased renal losses (160, 161). 
One study of patients undergoing gastric bypass surgery measured baseline 25-
OH Vitamin D plasma concentrations 2 weeks post op and found that 32% of 
patients were deficient, but no pre-operative plasma concentrations are 
available for comparison (162). Another study in patients undergoing gastric 
bypass found that 64% of patients were deficient preop. All patients in this study 
were advised to commence daily supplementation with 800-1200IU Vitamin D 
preop and continue this post op. There was no significant change in 25-OH 
Vitamin D plasma concentrations at 3 months post op but no plasma 
concentrations were taken in the immediate post-op period (163).  
5.2 Aims and Hypothesis 
5.2.1 Hypothesis 
A one-off high dose cholecalciferol supplement given 3-14 days prior to planned 
oesophagectomy will increase circulating 25-OH Vitamin D plasma 
concentrations above 50nmol/L in all cases. 
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5.2.2 Research Questions 
1. What is the effect of a one-off dose of oral cholecalciferol, given up to 14 
days pre-op, on circulating 25-OH Vitamin D plasma concentrations? 
2. What is the effect of oral cholecalciferol on circulating plasma 
concentrations of 1,25-(OH)2 Vitamin D? 
3. What factors influence short term response to supplementation with 
cholecalciferol? 
4. What is the effect of pre-operative supplementation on post-operative 
circulating Vitamin D plasma concentrations? 
5.3 Methods 
Patients were initially recruited to an open label study to determine the best 
dose of cholecalciferol to administer preop (see section 3.2.1). Patients were 
administered the dose of cholecalciferol after consenting to inclusion in the trial 
at the pre-operative assessment clinic appointment which was 3-14 days prior to 
the planned date of the operation. Plasma concentrations of 25-OH Vitamin D 
peak at 7 days post oral dosing and decrease linearly thereafter, returning to 
baseline around day 84 on average (133). This window was therefore 
pragmatically chosen in order for the operation to coincide with peak plasma 25-
OH Vitamin D concentrations while maximising recruitment of patients. The drug 
used was Vigantol® 812 oil (Merck Darmstadt Germany), an oily solution 
containing 20,000IU/ml cholecalciferol. Patients unable to swallow due to the 
severity of their oesophageal disease are routinely given a nasogastric or 
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percutaneous endoscopic gastrostomy feeding tube and the drug was 
administered via that if required.  
Following the open-label study, patients were recruited to the VINDALOO trial. 
(see section 3.2.2). The primary endpoint for the Vindaloo trial was extravascular 
lung water at the end of the operation and the trial was powered to detect a 
change of 20% in EVLWI with a power of 80% (p=0.05). This study was conceived 
as a phase 2, proof of efficacy study and therefore the endpoint chosen was not 
intended to be clinically meaningful. As a group, patients undergoing 
oesophagectomy have a mean post-operative EVLWI of 10.1ml/kg and standard 
deviation of 3.0ml/kg and the power calculation estimated 34 patients were 
required in each arm to reach the primary endpoint. In order to allow for 
dropouts such as open/close cases, changes to operative plans and other 
difficulties with data collection, it was intended to recruit 40 patients in each arm 
of the study. 
Plasma 25-OH Vitamin D2 25-OH Vitamin D3 and total 1,25-(OH)2 Vitamin D 
plasma concentrations were measured in a DEQAS quality controlled laboratory. 
25-OH Vitamin D plasma concentrations were measured by LC-MS/MS and 1,25-
(OH)2 Vitamin D plasma concentrations were measured by EIA. Plasma Vitamin D 
Binding Protein plasma concentrations were measured using ELISA. Background 
and demographic data were collected from the patient’s notes or by speaking 
directly with the patient. Serum calcium, serum bilirubin and eGFR are a routine 
part of clinical care and were measured by the hospital laboratories. 
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Statistical significance was defined as p<0.05. Statistical tests used are detailed in 
section 3.10.2. Continuous data in tables is presented as mean (SD) for 
parametric data and median (IQR) for non-parametric data. Nominative data is 
expressed as n (%). Statistical significance in the graphs is denoted using * for 
p≤0.05, ** for p≤0.01, *** for p≤0.001 and **** for p≤0.0001. Non-significance 
is denoted using ns.  
5.4 Results 
5.4.1 Dose effects of oral cholecalciferol 
18 patients were recruited to an open label dose response trial. 3 doses of oral 
cholecalciferol were trialled sequentially – the first 6 patients received 100,000 
IU, the second 6 patients received 200,000IU and the final 6 patients received 
300,000 IU. One patient, who received 200,000IU, withdrew from the trial before 
post-dose blood for Vitamin D plasma concentrations could be taken (figure 5.1). 
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Figure 5.1 Consort diagram of recruitment to open label dosing study 
There were no episodes of preoperative hypercalcaemia and the drug was well 
tolerated, as assessed by patient-reported side effects. None of the three doses 
increased circulating 25-OH Vitamin D plasma concentrations in all patients. 
Interpretation of the dose effect was complicated by a significant difference in 
the pre-dose Vitamin D plasma concentrations between groups, possibly as a 
result of high incidence of sunny weather conditions at the time the study was 
undertaken (figure 5.2). All the doses trialled were well tolerated, and the 
patients who received 300,000IU had the highest median pre-dose 25-OH 
Vitamin D indicating that this dose is safe in patients who are not deficient. 
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Therefore, the decision was made to proceed to the randomised controlled trial 
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Figure 5.2 Dose effects of supplementation on circulating 25-OH Vitamin D3 
plasma concentrations  
n=6 for 100,000IU and 300,000IU and n=5 for 200,000IU. Wilcoxon signed rank 
test used for each comparison. Black horizontal lines indicate median value for 
each dataset. Dotted horizontal reference lines indicate 25-OH Vitamin D3 plasma 
concentrations 50nmol/L and 75nmol/L. Months of recruitment is indicated in 
parentheses under each dose. 
5.4.2 VINDALOO Trial Patient Characteristics  
79 patients were recruited to the trial. 39 were randomised to receive placebo 
and 40 received active drug (300,000 IU cholecalciferol). Trial recruitment is 
summarised in the consort diagram (figure 5.3) 
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Figure 5.3 Consort Diagram of recruitment to VINDALOO 
There were no significant differences in patient characteristics which are 
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Table 5.1 Comparison of patient demographics between patients from the 
historical cohort described in Chapter 4 (BALTI-p cohort) and patients recruited 
to the Vindaloo trial  
 
























Male – n (%) 47 (85) 31 (79) 36 (90) 0.193 








35 (64) 24 (63) 20 (51) 
Current  
n (%) 
14 (25) 4 (11) 8 (21) 
Unknown  
n (%) 
0 (0) 1 (2) 1 (3) 
Pack Years – median (IQR) 
30 (15-
45) 
20 (0-40) 15 (0-36) 0.350 
Adenocarcinoma – n (%) 40 (73) 32 (82) 35 (88) 0.500 
Tumour 
Stage 
0/1 – n (%) 5 (9) 4 (11) 7 (18) 
0.335 2 – n (%) 17 (31) 13 (34) 8 (21) 
3 – n (%) 33 (60) 22 (55) 25 (62) 
Pre-randomisation plasma 
25-OH Vitamin D3 (nmol/L) 









Page | 116  
 
5.4.3 Safety and tolerability of high dose preoperative cholecalciferol  
4 patients reported developing diarrhoea and vomiting after administration of 
the trial drug. All episodes were self-limiting and required no medical treatment. 
2 patients received placebo and 2 patients received active drug. Circulating 25-
OH Vitamin D plasma concentrations increased in the two patients in the 
cholecalciferol despite their symptoms; one patient’s 25-OH Vitamin D3 plasma 
concentration increased from 83.8 to 100.8nmol/L and the other patient’s 25-OH 
vitamin D3 plasma concentration increased from 56.4 to 92.1nmol/L. 
No patients reported symptoms of hypercalcaemia following randomisation. Pre-
operative serum calcium plasma concentrations were measured in 70 of the 76 
patients who proceeded to pre-operative follow up. Pre-operative plasma 
concentrations were not available in 6 patients (2 received cholecalciferol, 4 
received placebo), but post-operative plasma concentrations were not elevated. 
There was no significant difference in post-randomisation (pre-operative) serum 
calcium plasma concentrations (p=0.4419) or fold change in serum calcium 
(p=0.5170) between groups (figure 5.4 and 5.5). No patient in the cholecalciferol 
group had hypercalcaemia post randomisation. One patient in the placebo group 
had post randomisation calcium above the upper limit of normal; their post-
randomisation Vitamin D plasma concentration was deficient (37.7nmol/L). 
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Figure 5.4 Effects of cholecalciferol on post randomisation serum calcium 
plasma concentrations 
n=34 for placebo and n=36 for cholecalciferol. Mann Whitney test used for 
comparison. Black horizontal lines indicate median value for each dataset. Dotted 
reference lines indicate the normal range for serum calcium (2.20-2.65mmol/L) 


























Figure 5.5 Effects of cholecalciferol on fold change in serum calcium plasma 
concentrations 
n=34 for placebo and n=36 for cholecalciferol. Mann Whitney test used for 
comparison. Black horizontal lines indicate median value for each dataset. Dotted 
reference line indicates fold change=1; datapoints below the line decreased post 
randomisation and datapoints above the line increased post randomisation 
Due to the nature of the operation, multiple patients developed Serious Adverse 
Events (SAEs) including two patients who died prior to discharge from hospital, 
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but there were no Suspected Unexpected Serious Adverse Reactions (SUSARs) 
reported during the trial.  
5.4.4 Effects of cholecalciferol on circulating 25-OH Vitamin D plasma 
concentrations 
55% of patients were deficient in Vitamin D prior to randomisation (25-OH 
Vitamin D3 <50nmol/L) and 32% of patients had insufficient plasma 
concentrations (25-OH Vitamin D3 50-75nmol/L). Patients recruited to VINDALOO 
had significantly higher circulating 25-OH Vitamin D3 plasma concentrations than 
the BALTI-p cohort described in chapter 4 (p<0.0001, figure 5.6). While 36% 
(20/55) of patients had plasma concentrations lower than 17.85nmol/L in the 
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Figure 5.6 Comparison of baseline 25-OH Vitamin D3 plasma concentrations in 
patients awaiting oesophagectomy  
n=55 for BALTIp dataset and n=76 for VINDALOO dataset. Mann Whitney test 
used for comparison. Black horizontal lines indicate median value for each 
dataset. Dotted horizontal reference lines indicate 25-OH Vitamin D3 plasma 
concentrations 50nmol/L and 75nmol/L 
Patients who received active drug had greater circulating 25-OH Vitamin D3 
plasma concentrations post randomisation than patients who received placebo 
(p<0.0001, figure 5.7). Pre to post randomisation circulating 25-OH Vitamin D3 
plasma concentrations decreased by 11% on average in the placebo group but 
increased by 64% in the active drug group (p<0.0001).  
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Figure 5.7 Effects of cholecalciferol on 25-OH Vitamin D3 plasma concentrations  
n=38 for each dataset. Wilcoxon signed rank test used to compare within groups 
and Mann Whitney test used to compare between groups. Black horizontal lines 
indicate median value for each dataset. Dotted horizontal reference lines indicate 
25-OH Vitamin D3 plasma concentrations 50nmol/L and 75nmol/L 
31 patients (42%) had detectable of plasma concentrations of 25-OH Vitamin D2 
at baseline (>2.5nmol/L). Patients with undetectable plasma concentrations 
were assigned a plasma concentration of 2.49nmol/L for analysis. Post-
randomisation plasma concentrations fell significantly in the group that received 
cholecalciferol (p=0.0005) but not in the placebo group (p=0.0652), with no 
difference in post randomisation plasma concentrations between groups 
(p=0.2998, figure 5.8).  
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Figure 5.8 Effects of cholecalciferol on 25-OH Vitamin D2 plasma concentrations   
n=38 for each dataset. Wilcoxon signed rank test used to compare within groups 
and Mann Whitney test used to compare between groups. Black horizontal line 
indicates median for each dataset. Dotted horizontal reference line indicates 
lower limit of detection, 2.5nmol/L. Where 25-OH Vitamin D2 plasma 
concentrations were undetectable a plasma concentration of 2.49nmol/L has 
been allocated for illustrative and analysis purposes. 
For those patients with detectable Vitamin D2 plasma concentrations the median 
change post-randomisation was -0.9nmol/L in both groups (p=0.9880). 
The low plasma concentrations of 25-OH Vitamin D2 seen in this cohort meant 
that total plasma concentrations of 25-OH Vitamin D followed a similar pattern 
to 25-OH Vitamin D3 with greater post-randomisation plasma concentrations in 
the group that received active drug (figure 5.9). 58% of patients who received 
placebo had total 25-OH Vitamin D plasma concentrations <50nmol/L compared 
with 5% of patients who received active drug and 11% of patients who received 
placebo had plasma concentrations >75nmol/L compared with 55% of patients 
who received active drug (figure 5.10). 
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Figure 5.9 Effects of cholecalciferol on total 25-OH Vitamin D plasma 
concentrations  
n=38 for each dataset. Wilcoxon signed rank test used to compare within groups 
and Mann Whitney test used to compare between groups. Black horizontal lines 
indicate median value for each dataset. Dotted horizontal reference lines indicate 
25-OH Vitamin D plasma concentrations 50nmol/L and 75nmol/L. Where 25-OH 
Vitamin D2 plasma concentrations were undetectable (<2.5nmol/L), 2.49nmol/L 
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Figure 5.10 Differences between groups in proportions of patients with 
deficient (<50nmol/L), insufficient (50-75nmol/L) and sufficient (75nmol/L) 25-
OH Vitamin D plasma concentrations 
 
 
5.4.5 Effects of cholecalciferol on circulating 1,25-(OH)2 Vitamin D plasma 
concentrations 
In contrast with 25-OH Vitamin D, there was no significant difference in 
circulating plasma concentrations of 1,25-(OH)2 Vitamin D between the BALTIp 
and Vindaloo cohorts (figure 5.11). 27.6% (21/76) patients in the Vindaloo cohort 
had baseline 1,25-(OH)2 Vitamin D plasma concentrations less than 71.5 pmol/L 
(as identified by ROC  curve analysis in chapter 4) which was similar to the BALTI-
p cohort (15/55, 27.2%). 
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Figure 5.11 Comparison of baseline 1,25-(OH)2 Vitamin D plasma 
concentrations in patients awaiting oesophagectomy 
n=55 for BALTIp dataset and n=76 for VINDALOO dataset. Mann Whitney test 
used to compare groups. Black horizontal lines indicate median value for each 
dataset. Dotted reference line indicates 1,25-(OH)2 Vitamin D = 71.5pmol/L. 
Cholecalciferol administration did not result in a significant difference in 1,25-
(OH)2 Vitamin D plasma concentrations between groups (Figure 5.12). Paired 
analysis of changes within the two groups showed that while plasma 
concentrations of 1,25-(OH)2 Vitamin D went up significantly in the 
cholecalciferol group (p=0.0003), they did not change significantly in the placebo 
group (p=0.2380). Fold change in 1,25-(OH)2 Vitamin D plasma concentrations 
was significantly higher in the cholecalciferol group than in the placebo group 
(p=0.0009 figure 5.13). Post randomisation, 34.2% (13/38) patients who received 
placebo had 1,25-(OH)2 Vitamin D plasma concentration <71.5pmol/L compared 
with 18.4% (7/38) of patients who received cholecalciferol (X2 p=0.1181). 
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Figure 5.12 Effects of cholecalciferol on 1,25-(OH)2 Vitamin D plasma 
concentrations 
n=38 for each dataset. Paired T test used for comparison within groups and 
unpaired T test used for comparison between groups. Black horizontal lines 
indicate mean for each dataset. Dotted reference line indicates 1,25-(OH)2 
Vitamin D = 71.5pmol/L, dashed lines indicate normal range for 1,25-(OH)2 
Vitamin D (43-144pmol/L). 






























Figure 5.13 Effects of cholecalciferol on change in 1,25-(OH)2 Vitamin D 
n=38 for each dataset. Mann Whitney Test used to compare groups. Black 
horizontal lines indicate median for each dataset. Dotted reference line indicates 
fold change=1; datapoints below the line decreased post randomisation and 
datapoints above the line increased post randomisation 
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5.4.6 Relationship between 25-OH Vitamin D and 1,25-(OH)2 Vitamin D 
There was a significant correlation between post randomisation 25-OH and 1,25-
(OH)2 Vitamin D plasma concentrations (Pearson ρ=0.3715, p=0.0008, r
2=0.1380, 
figure 5.14). 2 (2.6%) patients were deficient in both 25-OH and 1,25-(OH)2 
Vitamin D. 23 (30.2%) patients were deficient in 25-OH Vitamin D but had non-
deficient 1,25-(OH)2 plasma concentrations (>43pmol/L). 1 (1.3%) patient had 
deficient 1-25-(OH)2 Vitamin D with non-deficient 25-OH Vitamin D and 50 
(65.7%) patients had both non-deficient 25-OH and 1,25-(OH)2 plasma 
concentrations. 
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Figure 5.14 Correlation between post randomisation plasma concentrations of 
25-OH and 1,25-(OH)2 Vitamin D. 
n=76. Vertical dotted reference line indicates 25-OH Vitamin D = 50nmol/L. 
Horizontal dotted reference line indicates 1,25-(OH)2 Vitamin D 43pmol/L  
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5.4.7 Effects of cholecalciferol on circulating Vitamin D Binding Protein 
Cholecalciferol had no significant short-term effect on circulating plasma 
concentrations of Vitamin D Binding protein. There was no difference between 
groups in pre- or post-randomisation plasma concentrations of Vitamin D Binding 
Protein (VDBP) and no difference in fold change. Median post randomisation 
plasma concentrations for placebo were 685.1mg/L and for cholecalciferol were 
725.0mg/L (p=0.9764, figure 5.15). 
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Figure 5.15 Effects of Cholecalciferol on plasma Vitamin D Binding Protein 
concentration 
n=38 for each dataset. Wilcoxon signed rank test used for comparison within 
groups and Mann Whitney Test used for comparison between groups. Black 
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5.4.8 Factors associated with variability in 25-OH Vitamin D response to 
cholecalciferol administration 
The effect of cholecalciferol on circulating 25-OH and 1,25-(OH)2 Vitamin D 
plasma concentrations was variable. I looked at the effects of a range of factors 
on response to cholecalciferol administration.  
5.4.8.1 Effect of baseline Vitamin D plasma concentration on response to 
cholecalciferol 
Increases in circulating 25-OH Vitamin D plasma concentrations were greatest in 
patients who had the lowest plasma concentrations pre-randomisation, resulting 
in a negative correlation (Spearman ρ=-0.7573, p<0.0001, r2=0.6083 figure 5.16).  
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Figure 5.16 Correlation between baseline total 25-OH Vitamin D and fold 
change in plasma concentrations 
n=38. Baseline total 25-OH Vitamin D data is log transformed 
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However, there was a positive correlation between baseline and post 
randomisation plasma concentrations of 25-OH Vitamin D with patients with the 
highest baseline plasma concentrations still tending to have the highest post 
randomisation plasma concentrations (Spearman ρ=0.5323, p=0.0006, r2=0.4835 
figure 5.17). 
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Figure 5.17 Correlation between baseline and post randomisation total 25-OH 
Vitamin D plasma concentrations 
n=38. Reference lines indicate total 25-OH Vitamin D plasma concentrations of 
50nmol/L 
 
5.4.8.2 Effect of Demographic Parameters on response to cholecalciferol 
Female patients who received supplementation had lower fold change in total 
25-OH Vitamin D in response to cholecalciferol than male patients, but this did 
not translate into a difference in post randomisation Vitamin D plasma 
concentrations (table 5.2). 
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Table 5.2 Differences between sexes in Vitamin D response to supplementation 
 Male (n=34) Female (n=4) P value 
Baseline total 25-OH 
Vitamin D (nmol/L) 
43.6 (31.8-68.1) 59.0 (42.3-68.5) 0.4759 
Post randomisation total 
25-OH Vitamin D (nmol/L) 
80.4 (67.6-96.5) 64.6 (57.0-78.6) 0.1284 
Fold change in total 25-
OH Vitamin D  
1.67 (1.26-2.34) 1.15 (1.05-1.43) 0.0419 
 
Older patients tended to have lower post randomisation plasma concentrations 
of total 25-OH Vitamin D (Spearman ρ=-0.3706, p=0.0220, r2=0.2717, figure 5.18) 
and lower response to cholecalciferol administration (Spearman ρ=-0.3580, 
p=0.0273, r2=0.0181).  
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Figure 5.18 Correlation between Age and post randomisation total 25-OH 
Vitamin D plasma concentrations 
n=38. Reference line indicates total 25-OH Vitamin D plasma concentrations of 
50nmol/L 
There was no correlation between BMI and post randomisation total 25-OH 
vitamin D plasma concentration (Spearman ρ=-0.2680, p=0.1038, r
2=0.0776) or 
fold change (Spearman ρ=0.1100, p=0.5110, r2=0.0029) in response to 
cholecalciferol. 
5.4.8.3 Effect of time between dose and operation on response to 
cholecalciferol 
Patients were administered cholecalciferol between 3 and 14 days of the 
expected date of their oesophagectomy. On occasion the operation may be 
delayed at short notice, due to factors such as patient illness, or lack of hospital 
beds. On 2 occasions there was a gap between the dose and the operation of 
more than 14 days. Both patients had received active drug, for one the gap was 
15 days and for one 29 days. There was no correlation between either fold 
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change (Spearman ρ=-0.0517 p=0.7577, r2=0.0025, figure 5.19) or post 
randomisation total 25-OH Vitamin D plasma concentration (Spearman ρ=-
0.1528, p=0.3597, r2=0.0306) and the number of days between the dose and the 
operation. 
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Figure 5.19 Correlation between days between dose and operation and 
response to cholecalciferol.  
n=38. One outlier (29 days) is not shown for illustrative purposes but was 
included in the analysis. 
5.4.8.4 Effect of Season of recruitment on response to cholecalciferol 
The season of year when the patient was administered cholecalciferol did not 
affect the fold change in total 25-OH Vitamin D plasma concentrations 
(p=0.1505) or post-operative total 25-OH Vitamin D plasma concentrations 
(p=0.6644). As Vitamin D production in the skin is greatest in the summer, the 
data was divided into two groups – May-Sept and Oct-April, with no difference in 
fold change (p=0.6618) or post cholecalciferol total 25-OH Vitamin D (p=0.8190, 
figure 5.20).  
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Figure 5.20 Effects of time of year of cholecalciferol administration on total 25-
OH Vitamin D plasma concentrations 
May-Sept n=14, Oct-April n=24. Wilcoxon signed rank tesst used for comparison 
within groups and Mann Whitney Test used for comparison between groups. 
Black horizontal line indicates median for each dataset.  
5.4.8.5 Effect of baseline liver function on response to cholecalciferol 
As hydroxylation of Vitamin D to form 25-OH Vitamin D takes place in the liver, 
liver function may impact on post cholecalciferol plasma concentrations of 25-
OH Vitamin D. Bilirubin plasma concentrations reflect the liver’s ability to take 
up, process and secrete bilirubin into the bile and is therefore generally useful as 
a test of liver function. It is the measure of liver function used in the SOFA score 
(see section 3.8.2) and is generally easily obtainable as part of standard post-
operative blood monitoring. There was no significant relationship between 
baseline bilirubin and fold change in total 25-OH Vitamin D plasma 
concentrations (Spearman ρ=0.0833, p=0.6289, r2=0.0243) or post cholecalciferol 
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total 25-OH Vitamin D plasma concentrations (Spearman ρ=0.0985, p=0.5676, 
r2=0.0008). 
5.4.8.6 Effect of baseline renal function on response to cholecalciferol 
As hydroxylation of 25-OH Vitamin D to form 1,25-(OH)2 Vitamin D occurs 
predominantly in the kidney and Vitamin D is renally excreted I investigated 
whether baseline renal function (eGFR) correlates with response to 
cholecalciferol. There was no correlation between eGFR and fold change in total 
25-OH Vitamin D plasma concentrations (Spearman ρ=-0.1571, p=0.3461, 
r2=0.0617) or post cholecalciferol total 25-OH Vitamin D (Spearman ρ=-0.1883, 
p=0.2575, r2=0.0274). 
5.4.8.7 Effect of baseline Vitamin D Binding protein plasma concentrations on 
response to cholecalciferol 
As total 25-OH Vitamin D circulates bound to VDBP I considered the effect of 
baseline VDBP on response to cholecalciferol. There was no correlation between 
baseline VDBP and fold change (Spearman ρ=0.1124, p=0.5018, r2=0.0145) or 
post cholecalciferol total 25-OH Vitamin D (Spearman ρ=-0.0620, p=0.7114, 
r2=0.0262). 
5.4.8.8 Linear regression analysis of post cholecalciferol 25-OH Vitamin D3 
plasma concentrations  
To further investigate causes in the variance in preoperative total 25-OH Vitamin 
D plasma concentrations in patients who received cholecalciferol, I performed a 
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multiple regression. There was no evidence of collinearity between the factors 
examined (VIF was less than 2.0 for all factors). In view of the small sample size, a 
forward stepwise regression was used to examine the data. A significant three 
variable model (F(3,34) = 21.096, p<0.001) which explained 65% of the variability 
seen emerged (R square = 0.65). This demonstrated that baseline total 25-OH 
Vitamin D level (p<0.001), age (p=0.001) and renal function (p=0.024) were 
significant predictors of post randomisation total 25-OH Vitamin D level in 
patients who received cholecalciferol (table 5.3). Residuals were checked for 
normality by visual inspection of the Q/Q plot and found to be acceptable. 
Table 5.3 Forward Stepwise linear regression analysis of predictors of post 
cholecalciferol 25-OH Vitamin D 












0.0006 0.605 0.112 0.574 <0.001 
Age 0.0220 -1.137 0.306 -0.404 0.001 
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5.4.9 Factors associated with variability in 1,25-(OH)2 Vitamin D response to 
cholecalciferol administration 
The same factors were examined to investigate whether they influenced post 
randomisation 1,25-(OH)2 Vitamin D following supplementation with 
cholecalciferol.  
5.4.9.1 Effects of Baseline 1,25-(OH)2 Vitamin D on response to cholecalciferol 
On univariate analysis, baseline 1,25-(OH)2 Vitamin D plasma concentrations 
significantly correlated with fold change in 1,25-(OH)2 Vitamin D (figure 5.21) and 
post cholecalciferol 1,25-(OH)2 Vitamin D (figure 5.22). 1 patient (2.6%) with 
baseline 1,25-(OH)2 Vitamin D plasma concentrations greater than 71.5pmol/L 
had post cholecalciferol plasma concentrations less than 71.5pmol/L. 6 patients 
(15.8%) had baseline plasma concentrations less than 71.5pmol/L at both 
baseline and post cholecalciferol administration. 8 patients (21.1%) had baseline 
plasma concentrations less than 71.5pmol/L and post cholecalciferol plasma 
concentrations greater than 71.5pmol/L. 23 patients (60.5%) had plasma 
concentrations greater than 71.5pmol/L at both time points.  
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Figure 5.21 Correlation between baseline 1,25-(OH)2 Vitamin D plasma 
concentration and fold change in 1,25-(OH)2 Vitamin D 
n=38. Vertical dotted reference line indicates baseline 1,25-(OH)2 Vitamin D = 
71.5pmol/L. Horizontal dotted reference line indicates fold change = 1 – data 
points below this line decreased post cholecalciferol and data points above the 
line increased post cholecalciferol 
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Figure 5.22 Correlation between baseline 1,25-(OH)2 Vitamin D and post 
cholecalciferol 1,25-(OH)2 Vitamin D 
n=38. Dotted reference lines indicate 1,25-(OH)2 Vitamin D = 71.5pmol/L 
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5.4.9.2 Effects of demographics on 1,25-(OH)2 Vitamin D response to 
cholecalciferol 
There was no significant difference between sexes in fold change (p=0.2791) or 
post cholecalciferol 1,25-(OH)2 Vitamin D (p=0.9816). There was no significant 
correlation between age and fold change in 1,25-(OH)2 Vitamin D (figure 5.23) 
with no significant correlation between age and post cholecalciferol 1,25-(OH)2 
Vitamin D plasma concentration (Pearson ρ=-0.1508, p=0.3662, r2=0.0227).  
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Figure 5.23 Correlation between age and fold change in 1,25-(OH)2 Vitamin D 
plasma concentrations 
n=38.  Dotted reference line indicates fold change = 1 – data points below this 
line decreased post randomisation and data points above the line increased post 
randomisation 
There was no correlation between BMI and fold change (Spearman ρ=-0.0008, 
p=0.9964, r2=0.0396) or post cholecalciferol plasma concentrations (Pearson ρ=-
0.0725, p=0.6652, r2=0.0053). 
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5.4.9.3 Effect of time between dose and operation on 1,25-(OH)2 Vitamin D 
response to cholecalciferol 
There was no significant correlation between the number of days between blood 
sampling and fold change (Spearman ρ=-0.1547, p=0.3538, r2=0.0089) or post 
cholecalciferol 1,25-(OH)2 Vitamin D plasma concentrations (Pearson ρ=-0.0299, 
p=0.8584, r2=0.0009, figure 5.24). 
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Figure 5.24 Correlation between days between dose and operation and 1,25-
(OH)2 Vitamin D response to cholecalciferol.  
n=38. One outlier (29 days) is not shown for illustrative purposes but was 
included in the analysis. Dotted reference line indicates 1,25-OH2 Vitamin D = 
71.5pmol/L 
5.4.9.4 Effect of Season on 1,25-(OH)2 Vitamin D response to cholecalciferol 
The season of year when the patient was administered cholecalciferol did not 
affect the fold change in 1,25-(OH)2 Vitamin D plasma concentrations (p=0.4654) 
or post cholecalciferol 1,25-(OH)2 Vitamin D plasma concentration (p=0.2285). 
There was also no significant difference in fold change (p=0.4925) or post 
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cholecalciferol 1,25-(OH)2 Vitamin D plasma concentrations (p=0.9820) for 
patients recruited between May and September compared with October to April. 
5.4.9.5 Effect of liver function on 1,25-(OH)2 Vitamin D response to 
cholecalciferol 
There was no correlation between baseline bilirubin and fold change in 1,25-
(OH)2 Vitamin D (Spearman ρ=0.0450, p=0.7945, r
2=0.0101) or post 
cholecalciferol 1,25-(OH)2 Vitamin D (Pearson ρ=0.0443, p=0.7974, r
2=0.0020). 
5.4.9.6 Effect of renal function on 1,25-(OH)2 Vitamin D response to 
cholecalciferol 
There was no correlation between eGFR and fold change in 1,25-(OH)2 Vitamin D 
plasma concentrations (Spearman ρ=-0.0824, p=0.6229, r2=0.0572) but baseline 
and post cholecalciferol 1,25-(OH)2 Vitamin D  did correlate with renal function 
(baseline Pearson ρ=0.3530, p=0.0297, r2=0.1246, post cholecalciferol Pearson 
ρ=0.3340, p=0.0404, r2=0.1116, figure 5.25). 
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Figure 5.25 Correlation between renal function and post cholecalciferol 1,25-
(OH)2 Vitamin D Plasma concentrations 
n=38. Dotted reference line indicates 1,25-(OH)2 Vitamin D = 71.5pmol/L 
 
5.4.9.7 Effect of baseline Vitamin D Binding protein plasma concentrations on 
1,25-(OH)2 Vitamin D response to cholecalciferol 
There was no correlation between baseline Vitamin D Binding Protein and fold 
change (Spearman ρ=0.1896, p=0.2542, r2=0.0773) or post cholecalciferol 1,25-
(OH)2 Vitamin D (Pearson ρ=-0.0568, p=0.7349, r
2=0.0032). 
5.4.9.8 Linear regression analysis of post cholecalciferol 1,25-(OH)2 Vitamin D 
plasma concentrations in supplemented patients 
 The above variables were examined using a multiple regression model. There 
was no evidence of collinearity between the factors examined. In view of the 
small sample size, a forward stepwise regression was used to examine the data. 
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This produced a significant model (F(1,36) = 22.720 p<0.001, R square = 0.37) 
which demonstrated that, of the examined variables, baseline total 1,25-(OH)2 
Vitamin D level was the only significant predictor of post randomisation total 
1,25-(OH)2 Vitamin D level in patients who received cholecalciferol (p<0.001). 
Residuals were checked for normality by visual inspection of the Q/Q plot and 
found to be acceptable. 
Table 5.4 Forward Stepwise Linear regression analysis of predictors of post 








B Std. Error 
Baseline 1,25-
OH2 Vitamin D 
<0.0001 0.680 0.143 0.622 <0.001 
 
5.4.10 Effects of cholecalciferol on post-operative plasma 25-OH Vitamin D 
plasma concentrations 
In order to examine perioperative changes in Vitamin D plasma concentrations I 
measured Vitamin D plasma concentrations in plasma from 52 of the patients on 
day 3 or 4 post op. This timepoint was chosen for practical reasons as the 
majority, if not all, patients would be expected to still be receiving inpatient post-
operative care at this point. Postop 25-OH Vitamin D2 was only detectable in 6 of 
the 52 patients investigated (2 received placebo, 4 received cholecalciferol). 
Average fold change in 25-OH Vitamin D2 plasma concentrations in these 6 
patients was 0.66. 17 of the 52 patients had had detectable plasma 
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concentrations of 25-OH Vitamin D2 preop, therefore it had fallen to 
undetectable plasma concentrations in 11 patients (64.7%).  
The very low plasma concentrations of 25-OH vitamin D2 meant that results for 
Vitamin D3 and total vitamin D were very similar. There was a significant 
perioperative fall in total 25-OH Vitamin D plasma concentrations in both groups. 
Patients who received placebo had significantly lower circulating plasma 
concentrations of total 25-OH Vitamin D post op than at baseline but patients 
who received cholecalciferol had no significant difference between post op 
plasma concentrations than at baseline, although the trend was towards higher 
post op plasma concentrations (p=0.0918). Patients who received cholecalciferol 
had higher plasma concentrations of total 25-OH Vitamin D on day 3/4 post op 


































B a s e l in e
P o s t  R a n d o m is a t io n / P r e o p
D a y  3 / 4  P o st o p
* * * * *
* * * * n s
* * * *
 
Figure 5.26 Perioperative Changes in total 25-OH Vitamin D plasma 
concentrations in patients randomised to placebo or cholecalciferol 
n=38 for both preop datasets, n=29 for post op placebo dataset and n=23 for post 
op cholecalciferol dataset. Black horizontal lines indicate median value for each 
dataset. Dotted horizontal reference lines indicate 25-OH Vitamin D plasma 
concentrations 50nmol/L and 75nmol/L. Friedman test for both placebo and 
cholecalciferol groups p<0.0001, with mulitple comparisons within the groups as 
indicated. Mann Whitney test was used to compare data between groups.   
3 (10%) of patients in the placebo group had 25-OH Vitamin D plasma 
concentrations >50nmol/L on day 3/4 post op compared with 13 (57%) in the 
cholecalciferol group (p=0.0006). 
5.4.11 Effects of cholecalciferol on post-operative plasma 1,25-(OH)2 Vitamin D 
plasma concentrations 
While there was a significant perioperative fall in plasma concentrations of 1,25-
(OH)2 Vitamin D in the group that received placebo (p=0.0055), there was no 
significant change in patients who received active drug (p=0.7210). Plasma 
concentrations of 1,25-(OH)2 Vitamin D fell significantly between baseline and 
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day 3/4 postop in the placebo group but there was no significant change 
compared to baseline in the group that received cholecalciferol (p=0.0921), with 
a trend towards plasma concentrations being higher. There was a significant 
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Figure 5.27 Perioperative changes in 1,25-(OH)2 Vitamin D plasma 
concentrations in patients randomised to placebo or cholecalciferol 
n=38 for both preop datasets, n=29 for post op placebo dataset and n=23 for post 
op cholecalciferol dataset. Black horizontal lines indicate median value for each 
dataset. Dotted reference line indicates 1,25-(OH)2 Vitamin D = 71.5pmol/L. RM 
one way ANOVA for placebo p= 0.0010, RM one way ANOVA for cholecalciferol 
p=0.0018 with multiple comparisons within groups as indicated. Unpaired t test 
was used to compare data between groups.  
5.5 Discussion 
Supplementation with a one off dose of 300,000IU oral cholecalciferol 3-14 days 
before planned oesophagectomy was a safe and effective method of increasing 
pre-operative plasma concentrations of circulating 25-OH Vitamin D in our 
Page | 146  
 
patients. There were no clinically significant increases in serum calcium in the 
patients who received cholecalciferol and no SUSARs during the trial. The low 
circulating plasma concentrations of 25-OH Vitamin D2 in this cohort of patients 
makes the effects of cholecalciferol on Vitamin D2 plasma concentrations hard to 
assess but we did not find any evidence of a significant effect. Total 25-OH 
Vitamin D plasma concentrations were significantly higher in patients who 
received cholecalciferol with 95% of patients having plasma concentrations 
greater than 75nmol/L compared with 42% of patients who received placebo. 
Cholecalciferol administration also resulted in significant increases in 1,25-(OH)2 
Vitamin D plasma concentrations, although post randomisation absolute plasma 
concentrations were not significantly different between groups. Post 
randomisation plasma concentrations of 1,25-(OH)2 Vitamin D were similar in the 
VINDALOO cohort were similar to preoperative plasma concentrations seen in 
the BALTI-prevention cohort described in chapter 4. This is in contrast to 25-OH 
Vitamin D plasma concentrations where VINDALOO patients had significantly 
higher plasma concentrations than BALTIp patients. 
The majority of 25-OH Vitamin D circulates bound to Vitamin D Binding Protein, 
but unbound (or “free”) and albumin bound fractions also circulate in the 
plasma. The plasma concentration of circulating free 25-OH Vitamin D can be 
calculated using the following formula: 
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Free 25OHD =     total 25OHD         (164) 
1 + (6 x 103 x ALB) + (7 x 108 x DBP) 
25OHD = 25-OH Vitamin D 
DBP = Vitamin D Binding Protein 
ALB = Serum Albumin 
As free 25-OH Vitamin D is inversely proportional to circulating concentrations of 
Vitamin D binding protein and cholecalciferol administration did not have any 
significant short term effect on circulating plasma concentrations of Vitamin D 
Binding Protein, patients who received Vitamin D are likely to have had 
substantial increases in free 25-OH Vitamin D. This may be an important finding 
as while renal cells express the endocyclic receptor megalin and are able to 
process 25-OH Vitamin D whilst bound to Vitamin D binding protein (165), most 
extra-renal tissues do not express megalin (166). Indeed, monocytes cultured in 
serum from Vitamin D binding protein knockout mice generate greater quantities 
of cathelicidin than controls and cathelicidin production under these conditions 
can be suppressed by addition of increasing quantities of Vitamin D Binding 
Protein (167). If high dose cholecalciferol administration results in substantial 
increases in the free component of circulating 25-OH Vitamin D, this may 
significantly enhance its immune effects, without this necessarily being reflected 
by circulating 1,25-(OH)2 Vitamin D plasma concentrations. 
Increases in Vitamin D plasma concentrations were greatest in patients with 
lower initial Vitamin D plasma concentrations although patients with higher 
baseline plasma concentrations of vitamin D also had the highest post 
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randomisation plasma concentrations. In addition to baseline Vitamin D plasma 
concentrations, the linear regression analysis suggested that age and renal 
function significantly impacted on total 25-OH Vitamin D plasma concentrations 
post cholecalciferol. However, we did not find any factors that had a significant 
impact on 1,25-(OH)2 Vitamin D other than baseline plasma concentrations. It is 
interesting that renal function negatively correlated with 25-OH Vitamin D 
plasma concentrations but not 1,25-(OH)2 Vitamin D plasma concentrations as 
classically the kidney produces the majority of circulating 1,25-(OH)2 Vitamin D 
(48). One possible explanation for this is if increased production of 1,25-(OH)2 
Vitamin D in the kidney leads to increased onward metabolism and excretion, 
but in patients with lower glomerular filtration rates less 25-OH Vitamin D is 
hydroxylated to form 1,25-(OH)2 Vitamin D, resulting in a negative correlation. 
None of the patients recruited to the trial had a history of renal failure, and this 
finding would suggest that use of high doses of cholecalciferol in patients with 
renal failure could have a greater impact on 25-OH Vitamin D plasma 
concentrations than in patients with normal renal function, which may have 
implications for future studies.  
It is likely that genetic variations also impact response to cholecalciferol and one 
weakness of this data is that patient numbers were not high enough to 
adequately investigate that variable. In particular, for 1,25-(OH)2 Vitamin D the 
variables examined did not explain a lot of the variance seen, suggesting that 
other factors are likely to be significantly contributing. A number of studies have 
reported links between single nucleotide polymorphisms (SNPs) in Vitamin D 
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pathway genes and vitamin D metabolite concentrations. The majority of these 
relate to DBP, the gene encoding Vitamin D binding protein, although 
polymorhisms in CYP2R1 which is involved in hydroxylation of Vitamin D to 25-
OH Vitamin D have also been reported to affect plasma concentrations. A recent 
review article found reports linking a total of 35 SNPs in 7 different genes to 
Vitamin D concentrations (168). However, a recent study in 220 older adults in 
the UK which investigated the impact of 15 SNPs in six genes did not find that 
they made any impact after adjusting for multiple comparisons (169). 
Post-op, 25-OH Vitamin D plasma concentrations significantly fell in both groups 
compared to preoperative plasma concentrations. While plasma concentrations 
returned to baseline in patients who received cholecalciferol, in the placebo 
group plasma concentrations were significantly below baseline with only 10% of 
patients having 25-OH Vitamin D plasma concentrations greater than 50nmol/L. 
Perioperative fold change in 25-OH Vitamin D plasma concentrations was similar 
in both groups suggesting that the fall relates to the operation rather than the 
cholecalciferol administration. Intake of Vitamin D (via the skin or gut) will 
naturally be low during the perioperative period as patients typically have no 
nutritional intake on the day of the operation and feeding only slowly increases 
over the course of the first post-operative week as the gut heals. 
Oesophagectomy elicits a catabolic metabolic response characterised by lipolysis 
and protein breakdown (170) which theorectically could lead to increased 
release of Vitamin D stored in fat cells, but I have not found any evidence that 
this occurs. Patients often receive large volumes of intravenous fluids over the 
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perioperative period leading to plasma dilution. Serum total protein and albumin 
concentrations also fall during the perioperative period, supporting dilution as a 
potential factor. A further potential cause of perioperative falls in 25-OH Vitamin 
D is increased metabolism during the perioperative period. Patients in the 
placebo group also saw similar falls in circulating 1,25-(OH)2 Vitamin D, but 
plasma concentrations did not change perioperatively in patients who had 
received cholecalciferol. This could indicate that patients in the placebo group 
have insufficient circulating 25-OH Vitamin D to maintain plasma concentrations 
of 1,25-(OH)2 vitamin D in the perioperative period, whereas patients who 
received cholecalciferol supplementation are better able to maintain circulating 
1,25-(OH)2 Vitamin D plasma concentrations post op.  
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CHAPTER 6 
EFFECTS OF VITAMIN D 
SUPPLEMENTATION ON ALVEOLAR 
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6.1 Introduction 
In chapter 4 I demonstrated that preoperative vitamin D deficiency is common in 
patients undergoing oesophagectomy and associated with increased risk of post-
operative ARDS. I also demonstrated that 25-OH Vitamin D plasma 
concentrations relate to biomarkers of systemic and alveolar inflammation in the 
post-operative period. In chapter 5 I demonstrated that patients recruited to the 
Vindaloo trial who received cholecalciferol had significantly higher preoperative 
circulating 25-OH vitamin D plasma concentrations than patients who received 
placebo. 
This chapter will consider the effects of high dose cholecalciferol on post-
operative markers of systemic and alveolar inflammation. Patients undergoing 
oesophagectomy experience a marked inflammatory response with cytokines 
such as IL-1β, IL6, IL-10 and thrombin increasing during the operation while other 
markers of inflammation such as C reactive protein (CRP) and complement 
factors such as C3a increase shortly after the operation (171, 172). Marked 
perioperative neutrophilia and lymphopenia have also been noted in patients 
undergoing oesophagectomy (172). 
Pre and post-operative scoring systems to help predict patients who will suffer 
increase morbidity and mortality post-op have been developed. A number of 
preoperative scoring systems consider the ratio between inflammatory cells – 
the neutrophil lymphocyte ratio, lymphocyte to monocyte ratio and platelet to 
lymphocyte ratio have all been suggested by various groups (173-177). Other 
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scores which aim to quantify the level of preoperative inflammation using serum 
albumin and CRP such as the modified Glasgow prediction score (mGPS) have 
also been suggested (178-180). However, none of these scoring systems are 
currently routinely used in clinical practice.  
APACHE-II is a commonly used severity scoring system and mortality prediction 
derived from a large sample of ICU patients in the United States. It is uses 12 
physiological measurements, age and previous health status to generate a 
severity score between 0 and 71 which can be converted to predicted mortality 
when reason for ICU admission is taken into account (181). The full scoring 
system is detailed in chapter 3. SOFA scoring aims to quantify the degree of 
organ dysfunction and morbidity in ICU patients and is based on 6 organ systems. 
It can be used serially to help track patient’s progress during their ICU admission 
(139). 
6.2 Hypothesis and Research Questions 
6.2.1 Hypothesis 
Supplementation with cholecalciferol reduces perioperative inflammation, 
resulting in lower perioperative increases in alveolar oedema and circulating 
cytokines 
6.2.2 Research Questions 
1. What is the effect of supplementation with cholecalciferol on PICCO 
biomarkers of alveolar oedema and inflammation? 
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2. What is the effect of supplementation with cholecalciferol on 
perioperative changes in circulating cytokines? 
3. What is the clinical effect of supplementation with cholecalciferol in 
patients undergoing oesophagectomy? 
6.3 Methods 
Patients were recruited to the VINDALOO trial (see section 5.4.2 for consort 
diagram). Clinical data including development of complications were collected 
prospectively using a custom designed case report form. Full blood count and 
CRP were measured by the hospital laboratories as a routine part of clinical care. 
PICCO measurements were collected perioperatively according to the method 
detailed in chapter 3. Inflammatory cytokines were measured by Luminex except 
LL37 which was measured by ELISA. APACHE-II and SOFA score were calculated 
using data gathered from the clinical notes according to the scoring systems 
detailed in chapter 3. 
Statistical significance was defined as p<0.05. Statistical tests used are detailed in 
section 3.10.2. Continuous data in tables is presented as mean (SD) for 
parametric data and median (IQR) for non-parametric data. Nominative data is 
expressed as n (%). Statistical significance in the graphs is denoted using * for 
p≤0.05, ** for p≤0.01, *** for p≤0.001 and **** for p≤0.0001. Non-significance 
is denoted using ns. 
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6.4 Results 
6.4.1 Perioperative inflammatory response in patients undergoing 
oesophagectomy and effects of cholecalciferol 
To demonstrate the level of inflammatory response in our cohort, I compared 
plasma concentrations of circulating white cells pre and post op. The white cell 
count fell marginally between the preoperative assessment clinic and 
immediately prior to the operation and then rose post op and remained elevated 
more than 7 days. There was no difference in WCC between placebo and 
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Figure 6.1 Perioperative changes in white cell count in patients undergoing 
oesophagectomy 
Placebo: n=34 (baseline), n=31 (preop), n=32 (post op), n=35 (day 1), n=31 (day 3) 
and n=29 (day 7). Cholecalciferol: n=33 (baseline), n=29 (preop), n=31 (post op), 
n=31 (day 1), n=31 (day 3) and n=24 (day 7). Symbol represents median for each 
group, error bars represent inter quartile range. Dotted reference lines indicate 
the normal range for white cell count (4.0-11.0x109/L). There was no significant 
difference between groups at any timepoint. Friedman test for combined data 
p<0.0001 with multiple comparisons using Dunn’s test used to compare individual 
timepoints as shown on graph. P values shown on graph indicate differences 
between combined data.   
In the immediate preoperative period, the number of circulating neutrophils and 
eosinophils did not significantly change while the number of circulating 
lymphocytes and monocytes significantly decreased. Perioperatively, the number 
of circulating neutrophils and monocytes significantly increased while the 
number of lymphocytes and eosinophils significantly decreased, with eosinophils 
being undetectable in all bar 7 cases at the post op time point. Numbers of 
circulating neutrophils and monocytes remained elevated 1 week post op and 
numbers of circulating lymphocytes remained depressed 1 week post op, but 
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numbers of circulating eosinophils were significantly higher on day 7 post op 
than they were preop. There were no differences between the placebo and 
cholecalciferol groups in the differential white cell count (figure 6.2). 
 
Placebo: n=34 (baseline), n=31 (preop), n=32 (post op), n=35 (day 1), n=31 (day 3) and n=29 (day 7). Cholecalciferol: n=33 (baseline), n=29 
(preop), n=31 (post op), n=31 (day 1), n=31 (day 3) and n=24 (day 7). Symbols represent median for each group with interquartile range 
represented by error bars. Dotted reference lines represent normal range for each parameter. There was no significant difference between 
groups at any timepoint for any of the 4 cell types. Friedman test for combined data p<0.0001 for each cell type with multiple comparisons 
using Dunn’s test used to compare individual timepoints as shown on graph between combined data. 
 
Figure 6.2 Effects of cholecalciferol on perioperative neutrophil, lymphocyte, monocyte and eosinophil counts  
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In comparison, circulating levels of CRP, a generalised marker of inflammation 
showed a delayed response to oesophagectomy, with levels frequently 
undetectable immediately post op (27%), but then increasing rapidly in the 
immediate post-operative period and peaking on day 3 post op. Again, there was 
no difference in CRP between placebo and cholecalciferol groups at any 
timepoint (figure 6.3). 
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Figure 6.3 Post-operative changes in post-operative CRP in patients undergoing 
oesophagectomy 
Placebo: n=28 (post op), n=26 (day 1), n=33 (day 3), n=19 (day 7). Cholecalciferol: 
n=20 (post op), n=19 (day 1), n=24 (day 3), n=14 (day 7). Symbol represents 
median for each group, error bars represent inter quartile range. Where plasma 
concentrations were undetectable (<3mg/L) a value of 2.9mg/L has been used for 
analysis. Kruskal Wallis p<0.0001 for combined data. 
 
6.4.2 Effects of Cholecalciferol on pre-operative blood cell ratios  
There were no significant differences between the cholecalciferol and placebo 
groups in preoperative neutrophil:lymphocyte ratio (placebo median = 2.7 IQR 
1.9-3.4, cholecalciferol median = 2.3 IQR = 1.7-3.6, p=0.4380), 
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lymphocyte:monocyte ratio (placebo median = 2.4 IQR = 1.7-3.4, cholecalciferol 
median = 2.8 IQR = 2.0-3.7, p=0.5012) or platelet:lymphocyte ratio (placebo 
median = 153 IQR = 108-184, cholecalciferol median = 130 IQR = 95-187, 
p=0.4920). 
6.4.3 Effects of cholecalciferol on perioperative changes in cytokine plasma 
concentrations 
To investigate the effect of cholecalciferol on levels of systemic inflammation 
prior to oesophagectomy, I measured levels of cytokines at baseline and preop. 
The analytes were chosen because they were identified during analysis of the 
BALTI-prevention trial as significantly changing over the course of 
oesophagectomy, or because they have previously been shown to be affected by 
Vitamin D. There was a significant difference in levels of IL-1β at baseline, but no 
significant difference in levels of other cytokines (table 6.1).   
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Table 6.1 Comparison of Cytokine Plasma concentrations at Baseline 
*For LL37 placebo n=34 and cholecalciferol n=32 due to no EDTA plasma being 
available for the missing cases 
Plasma concentrations of the majority of cytokines fell slightly between baseline 
and preoperative measurements but there was no difference between groups in 
fold change of any of the cytokines measured. A significant difference in plasma 
concentrations of IL-1β remained, but there was still no difference in plasma 
concentrations of other cytokines (table 6.2). 
Cytokine 
Baseline plasma concentration (pg/ml) 
p-value 
Placebo (n=38) Cholecalciferol (n=38) 
IL6 11.00 (9.00-13.13) 11.50 (9.50-15.06) 0.4510 
IL8 55.88 (45.81-83.63) 57.50 (46.38-69.13) 0.7942 
IL10 15.50 (14.00-16.50) 15.50 (14.50-17.00) 0.6165 
TNF-α 13.25 (10.94-14.50) 12.50 (10.50-14.06) 0.5958 
s-RAGE 48.50 (36.88-58.00) 44.50 (37.88-66.94) 0.9239 
s-TNF-R1 468.5 (269.8-617.6) 447.4 (309.0-970.0) 0.4518 
s-TNF-R2 2758 (2287-4521) 3316 (2245-4965) 0.4965 
LL37* 5.06 (1.81-12.32) 4.96 (1.46-10.05) 0.4572 
IL2 13.3 (11.8-15.1) 13.5 (12.0-15.1) 0.990 
IL1ra 479.0 (401.8-621.5) 483.1 (375.3-623.7) 0.944 
IL1β 8.0 (6.5-9.5) 7.1 (5.9-8.5) 0.046 
IL17 13.9 (12.4-15.3) 13.5 (13.0-15.3) 0.961 
 
 
Table 6.2 Preoperative differences in absolute cytokine plasma concentrations and fold change (preop/baseline) 
*For LL37 placebo n=35 and cholecalciferol n=32 due to no EDTA plasma being available for the missing cases 
Cytokine 








IL6 10.25 (8.50-11.88) 9.88 (8.50-12.50) 0.7739 0.94 (0.80-1.06) 0.87 (0.69-0.98) 0.2451 
IL8 48.63 (35.88-58.63) 46.00 (38.06-53.50) 0.3217 0.81 (0.65-0.98) 0.76 (0.69-0.90) 0.5572 
IL10 14.88 (14.00-16.50) 14.88 (14.00-17.25) 0.4286 0.97 0.90-1.04) 0.97 (0.92-1.03) 0.8748 
TNF-α 12.50 (11.00-14.13) 12.50 (11.00-13.50) 0.4988 0.97 (0.92-1.08) 0.96 (0.89-1.04) 0.5853 
s-RAGE 43.25 (36.38-61.44) 42.00 (33.50-52.63) 0.5892 0.97 (0.83-1.06) 0.90 (0.77-1.02) 0.2580 
s-TNF-R1 396.1 (260.1-596.6) 414.4 (315.0-612.8) 0.4273 0.84 (0.77-1.06) 0.82 (0.67-1.10) 0.7896 
s-TNF-R2 2365 (2003-3677) 2865 (2211-4340) 0.2559 0.85 (0.80-1.00) 0.93 (0.79-1.09) 0.2737 
LL37 3.91 (1.80-13.50) 5.58 (2.11-11.08) 0.9156 1.12 (0.66-1.31) 1.02 (0.68-1.43) 0.9797 
IL2 12.63 (11.38-14.75) 13.00 (11.94-14.06) 0.6103 0.92 (0.88-1.00) 0.97 (0.90-1.04) 0.1979 
IL-1ra 462.3 (321.4-666.1) 432.8 (332.9-617.9) 0.7626 0.98 (0.76-1.26) 0.90 (0.78-1.10) 0.4153 
IL-1β 7.75 (7.00-10.00) 7.13 (6.00-8.00) 0.0073 1.00 (0.93-1.10) 1.00 (0.92-1.05) 0.1800 
IL-17 13.50 (12.69-14.63) 13.50 (12.50-14.63) 0.9938 0.96 (0.93-1.04) 0.97 (0.95-1.00) 0.7977 
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Perioperatively, plasma concentrations of most cytokines increased, although 
little change in IL-2, IL-17 and LL37 was seen. Fold change in plasma 
concentrations of IL-8, TNF-α and IL-1β was greater in the cholecalciferol group 






Table 6.3 Perioperative differences in absolute cytokine plasma concentrations and fold change (postop/preop) 
*For LL37 placebo n=31 and cholecalciferol n=26 due to no EDTA plasma being available for the missing cases
Cytokine 








IL6 296.4 (188.5-488.5) 546.3 (202.8-920.0) 0.0527 27.62 (21.85-43.45) 45.52 (21.73-87.16) 0.0537 
IL8 82.8 (59.9-134.7) 102.0 (75.3-156.0) 0.1659 1.88 (1.38-2.58) 2.30 (1.76-3.76) 0.0331 
IL10 60.13 (31.3-107.1) 43.0 (31.0-76.0) 0.3690 3.81 (1.94-6.83) 2.59 (1.90-5.22) 0.2940 
TNF-α 10.5 (9.5-11.5) 11.0 (10.0 12.5) 0.0959 0.85 (0.80-0.95) 0.92 (0.85-1.05) 0.0140 
s-RAGE 51.8 (38.1-86.8) 51.0 (37.8-67.4) 0.8409 1.15 (0.92-1.45) 1.26 (1.08-1.57) 0.1682 
s-TNF-R1 806.6 (520.4-1302) 1146 (653.1-1440) 0.1565 2.14 (1.42-3.16) 2.40 (1.41-3.25) 0.7422 
s-TNF-R2 3112 (2429-4697) 4140 (3122-5510) 0.0964 1.24 (1.00-1.52) 1.29 (1.03-1.43) 0.5767 
LL37* 5.71 (2.45-7.98) 4.61 (2.30-11.58) 0.9336 0.99 (0.62-1.67) 1.02 (0.75-1.48) 0.9029 
IL2 13.0 (11.4-13.8) 13.5 (12.0-15.0) 0.1547 1.01 (0.96-1.05) 1.06 (0.97-1.08) 0.1591 
IL-1ra 2812 (1573-4766) 4256 (2404-5431) 0.1662 6.49 (2.97-13.39) 10.35 (4.03-12.17) 0.3622 
IL-1β 9.3 (8.0-10.5) 9.0 (7.5-10.5) 0.7812 1.12 (0.99-1.34) 1.28 (1.17-1.62) 0.0066 
IL-17 13.0 (12.0-14.0) 13.5 (13.0-14.0) 0.2703 0.96 (0.93-1.01) 0.96 (0.93-1.03) 0.6689 
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By day 1 post op plasma concentrations of inflammatory cytokines were 
generally falling again, with no difference seen in plasma concentrations of most 
of the inflammatory cytokines. However, patients who received cholecalciferol 
had significantly higher plasma concentrations of TNFR1 and TNFR2 on day 1 
post op. There was a trend towards greater fold change in LL37 in the patients 
who received placebo, but no difference in absolute plasma concentrations 
(table 6.4).  
 
 
Table 6.4 Post-operative differences in absolute cytokine plasma concentrations and fold change (day 1/post-op) 
*For LL37 placebo n=28 and cholecalciferol n=24 due to no EDTA plasma being available for the missing cases 
Cytokine 











IL6 240.5 (133.8-444.4) 249.0 (153.4-451.4) 0.8860 0.90 (0.46-1.32) 0.53 (0.29-1.00) 0.1010 
IL8 81.5 (68.0-121.0) 85.0 (68.5-151.6) 0.9568 1.04 (0.78-1.31) 1.01 (0.52-1.30) 0.2954 
IL10 27.0 (21.0-36.8) 26.5 (23.5-37.0) 0.7188 0.59 (0.33) 0.71 (0.42) 0.2267 
TNF-α 11.5 (10.5-13.4) 12.0 (10.5-13.0) 0.4145 1.06 (0.99-1.20) 1.09 (1.00-1.15) 0.6190 
s-RAGE 35.3 (28.8-44.3) 40.0 (30.8-72.1) 0.0774 0.71 (0.22) 0.78 (0.22) 0.1779 
s-TNF-R1 716.1 (447.6-1157) 886.0 (606.8-1844) 0.0279 0.93 (0.62-1.19) 1.07 (0.62-1.46) 0.2956 
s-TNF-R2 3666 (2402-4828) 5130 (3607-6865) 0.0112 1.07 (0.89-1.27) 1.18 (0.96-1.52) 0.2715 
LL37* 14.63 (5.17-23.03) 9.30 (3.56-15.83) 0.4487 2.12 (1.51-4.21) 1.50 (0.96-2.55) 0.0576 
IL2 13.0 (12.0-14.4) 13.3 (12.0-14.5) 0.7962 1.03 (0.96-1.11) 1.00 (0.92-1.04) 0.0687 
IL-1ra 1266 (854-1651) 1255 (1023-22.16) 0.4889 0.49 (0.31-0.67) 0.35 (0.23-0.58) 0.2541 
IL-1β 8.5 (7.8-10.0) 8.0 (7.0-10.0) 0.2319 1.00 (0.87-1.05) 0.85 (0.73-1.07) 0.1109 
IL-17 13.0 (12.3-14.5) 13.5 (12.7-15.0) 0.3932 1.00 (0.98-1.06) 1.03 (0.96-1.08) 0.9867 
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Between D1 and D3 post op, there was little change in plasma concentrations of 
many cytokines. Plasma concentrations of LL37 increased significantly in both 
groups and fold change was greater in the group who received cholecalciferol 
although absolute plasma concentrations on day 3 were not significantly 
different. For IL2, there was a significant difference in fold change between the 




Table 6.5 Post-operative differences in absolute cytokine plasma concentrations and fold change (day 3/day 1) 
*n=27 for placebo and n=24 for cholecalciferol as there was insufficient plasma to carry out these tests for 2 patients 
**n=23 for placebo and n=18 for cholecalciferol as EDTA plasma was not available for all patients 
Cytokine 











IL6 124.5 (68.1-329.3) 162.0 (127.5-360.4) 0.2473 0.54 (0.30-1.06) 0.69 (0.28-1.20) 0.8487 
IL8 92.6 (64.7-135.8) 88.0 (71.5-172.8) 0.3881 0.91 (0.68-1.39) 1.06 (0.90-1.47) 0.1972 
IL10 17.8 (16.0-22.3) 20.0(16.3-24.5) 0.3496 0.72 (0.55-0.87) 0.65 (0.55-0.87) 0.6353 
TNFa 12.0 (10.6-13.5) 13.0 (11.3-17.4) 0.1638 1.05 (0.96-1.18) 1.13 (0.98-1.36) 0.4178 
s-RAGE* 36.5 (33.0-52.0) 35.8 (28.1-45.5) 0.3270 1.10 (0.85-1.19) 0.87 (0.70-1.04) 0.0705 
s-TNF-R1* 1044 (518.3-1689) 958.3 (617.1-1531) 0.8546 1.12 (0.87-1.34) 0.99 (0.72-1.54) 0.3224 
s-TNF-R2* 5043 (3391-7505) 5000 (4134-7627) 0.3418 1.20 (0.95-1.64) 1.13 (0.91-1.49) 0.6156 
LL37** 12.54 (5.37-41.99) 24.08 (9.91-43.88) 0.4472 1.76 (0.98-2.41) 2.11 (1.73-4.59) 0.0269 
IL2 13.3 (12.3-14.9) 13.5 (12.4-17.3) 0.2971 0.98 (0.90-1.05) 1.04 (0.99-1.12) 0.0391 
IL-1ra 1038 (746-1402) 1486 (890-2171) 0.0633 0.81 (0.67-1.13) 1.12 (0.61-1.56) 0.3237 
IL-1B 9.3 (8.0-11.5) 8.8 (7.6-12.5) 0.6395 1.06 (0.96-1.20) 1.09 (0.91-1.32) 0.8390 
IL-17 13.8 (12.5-14.5) 14.5 (13.3-16.0) 0.2954 1.04 (0.99-1.08) 1.05 (0.98-1.16) 0.3103 
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6.4.4 Effects of cholecalciferol on PICCO biomarkers of alveolar oedema and 
inflammation 
While post-operative EVLWI was significantly higher than preoperative values in 
patients who received placebo, there was no significant perioperative difference 
in EVLWI in patients who received cholecalciferol. However this did not translate 
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Figure 6.4 Effects of cholecalciferol on perioperative EVLWI  
n=35 for placebo preop and postop and 32 for placebo day 1, n=33 for 
cholecalciferol preop and postop and 31 for day 1. Black horizontal lines indicate 
median for each dataset. Overall Friedman test p<0.0001 for placebo and 
p=0.0057 for cholecalciferol. Dunn's multiple comparisons test used to look for 
differences within the groups, Mann Whitney test used to compare between groups. 
 
Patients who received cholecalciferol smaller post-operative fold change in 
EVLWI, but this was not significant at the 5% level (p=0.0528, figure 6.5). 
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Figure 6.5 Effect of cholecalciferol on post-operative fold change EVLWI 
n=35 for placebo and n=33 for cholecalciferol. Unpaired T test used to compare 
groups. Black horizontal lines indicate mean for each dataset. Dotted reference 
line indicates fold change=1; datapoints below the line decreased post op and 
datapoints above the line increased post op 
Comparison of patients who were Vitamin D deficient preop compared with 
those who had insufficient or sufficient plasma concentrations showed a 
significant difference in fold change (p=0.0076, figure 6.6). 
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Figure 6.6 Differences in post-operative fold change in EVLWI according to 25-
OH Vitamin D status 
n=21 for 25-OH Vitamin D <50nmol/L and n=47 for 25-OH Vitamin D >50nmol/L. 
Mann Whitney test used to compare groups. Black horizontal lines indicate 
median for each dataset. Dotted reference line indicates fold change=1; 
datapoints below the line decreased post op and datapoints above the line 
increased post op 
By day 1 post-op, changes in EVLWI had largely resolved with median day 
1/preop fold change = 0.96. There were no significant differences between 
groups at this point (p=0.6954, figure 6.7) 
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Figure 6.7 Effect of cholecalciferol on day 1 post-op fold change EVLWI 
n=32 for placebo and n=31 for cholecalciferol. Unpaired T test used to compare 
groups. Black horizontal lines indicate mean for each dataset. Dotted reference 
line indicates fold change=1; datapoints below the line decreased post op and 
datapoints above the line increased post op 
There was no correlation between preoperative 25-OH Vitamin D or 1,25-(OH)2 
Vitamin D and post op or day 1 EVLWI or PVPI. Analysis of PVPI showed that 
while in the placebo group post-operative levels were significantly higher than 
preoperative levels, in the cholecalciferol group there was no significant 
difference. On day 1 post op, levels in the placebo group were not significantly 
different to pre-operative levels, but in the cholecalciferol group day 1 levels 
were significantly lower than preoperative levels (figure 6.8). 
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Figure 6.8 Effects of cholecalciferol on perioperative PVPI  
n=35 for placebo preop and postop and 32 for placebo day 1, n=33 for 
cholecalciferol preop and postop and 31 for day 1. Day 1 measurements could not 
be taken for 2 patients because the PICCO line had been removed by the clinical 
team overnight and for 1 patient because the central line was not working. Black 
horizontal lines indicate median for each dataset. Friedman test p<0.0001 for 
placebo, p=0.0015 for cholecalciferol.Dunn's multiple comparisons test used to look 
for differences within the groups, Mann Whitney test used to compare between groups. 
There was a significant difference in post-operative fold change between the 
groups (p=0.0274, figure 6.9). 
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Figure 6.9 Effect of cholecalciferol on post-operative fold change PVPI 
n=35 for placebo and n=33 for cholecalciferol. Mann Whitney test used to 
compare groups. Black horizontal lines indicate median for each dataset. Dotted 
reference line indicates fold change=1; datapoints below the line decreased post 
op and datapoints above the line increased post op 
This difference persisted when Vitamin D deficient patients were compared with 
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Figure 6.10 Differences in post-operative fold change in PVPI according to 25-
OH Vitamin D status 
n=22 for 25-OH Vitamin D <50nmol/L and n=46 for 25-OH Vitamin D >50nmol/L. 
Mann Whitney test used to compare groups. Black horizontal lines indicate 
median for each dataset. Dotted reference line indicates fold change=1; 
datapoints below the line decreased post op and datapoints above the line 
increased post op 
Comparison of changes on day 1 showed that the previously seen increases in 
PVPI had largely resolved and there was no longer a significant difference 
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Figure 6.11 Effect of cholecalciferol on day 1 post-op fold change PVPI 
n=32 for placebo and n=31 for cholecalciferol. Unpaired T test used to compare 
groups. Black horizontal lines indicate mean for each dataset. Dotted reference 
line indicates fold change=1; datapoints below the line decreased post op and 
datapoints above the line increased post op  
Analysis of other PICCO parameters showed no significant difference in fold 
change (table 6.6). 
Table 6.6 Effects of cholecalciferol on perioperative fold change in Cardiac 
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6.4.5 Effects of cholecalciferol on post-operative oxygenation 
There was no difference P/F ratio between the groups post-op (figure 6.12). In 
addition, there was no significant correlation between preop total 25-OH Vitamin 
D levels and post op P/F ratio (Pearson r =0.0913, p=0.4588, r2=0.0083), but 
there was a weak correlation between preop 1,25-(OH)2 Vitamin D plasma 
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Figure 6.12 Comparison of Post op and Day 1 P/F ratio between groups 
n=35 for placebo post op and n=34 for day 1, n=33 for cholecalciferol post op and 
n=32 for day 1. Paired T tests were used for comparison within groups and 
unpaired T tests were used for comparison between groups.  Black horizontal 
lines indicate median for each dataset. Dotted horizontal reference lines indicate 
P/F ratios of 40kPa, 26.6kPa and 13.3kPa 
As PaO2 was not measured routinely in patients after discharge from the 
Intensive Care Unit, I used the ratio of oxygen saturations to inspired oxygen 
concentration (S/F ratio) to compare oxygenation between groups over the first 
7 days post op. An S/F ratio of 315 is equivalent to a P/F ratio of 40kPa while an 
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S/F ratio of 235 is equivalent to a P/F ratio of 26.6kPa (182). There was no 
significant difference in S/F ratios between groups in the first 7 days post op 
(figure 6.13) 
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Figure 6.13 Comparison of S/F ratios between groups for 7 days post op 
n=35 for placebo (all timepoints), n=33 for cholecalciferol Preop - day 1 and n=32 
for cholecalciferol day 2 - day 7. Symbols represent median for each group with 
interquartile range represented by error bars. Dotted horizontal reference lines 
represent S/F ratio 315 and 235. Friedman test for combined data p<0.0001 for 
each cell type with multiple comparisons using Dunn’s test used to compare 
individual timepoints as shown on graph. 
 
There was a significant correlation between preop total 25-OH Vitamin D and S/F 
ratio on day 1 (Pearson r=0.2513, p=0.0387, r2=0.0632) but not at any other 
timepoint up to day 7 post op. There was also a significant correlation between 
preop 1,25-(OH)2 Vitamin D plasma concentrations and S/F ratio post op 
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(Spearman r=0.3838, p=0.0012, r2=0.1146), on day 1 (Spearman r=0.2871, 
p=0.0176, r2=0.0749), on day 2 (Pearson r=0.3192, p=0.0085, r2=0.1166) and on 
day 4 (Spearman r=0.2574, p=0.0379, r2=0.0463). On day 3 the relationship was 
not significant (Spearman r=0.2084, p=0.0906, r2=0.0436). There was no 
correlation between either day 3 total 25-OH Vitamin D or day 3 1,25-(OH)2 
Vitamin D and S/F ratio on days 3-7. 
6.4.6 Effects of cholecalciferol on clinical diagnoses of ARDS 
7 of the patients developed ARDS as defined by the Berlin criteria. A further 2 
patients met AECC criteria, but were not ventilated with PEEP/CPAP at least 
5cmH2O. 4 of the patients received placebo and 3 received cholecalciferol 
(p=1.000). The prevalence of ARDS in the Vindaloo cohort was lower than in the 
BALTI cohort (10% vs 25% p=0.0263). There was no difference in plasma 
concentrations of total 25-OH Vitamin D (ARDS median = 61.9nmol/L IQR=60.2-
73.7nmol/L, No ARDS median=60.99nmol/L IQR=41.1-79.7nmol/L, p=0.9969) or 
1,25-(OH)2 Vitamin D (ARDS median = 104.2pmol/L IQR = 75.7-111.1pmol/L, No 
ARDS median=100.7pmol/L, IQR=69.9-119.3pmol/L, p=0.8761) between patients 
who developed ARDS and those who did not. 
6.4.7 Effects of cholecalciferol on post op adverse events 
There were no differences in rates of adverse events between the groups, as 
summarised in table 6.7. 
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Table 6.7 Adverse Events in patients recruited to the Vindaloo Trial 
 Placebo (n=35) Cholecalciferol (n=33) P value 
Hospital/Ventilator 
acquired Pneumonia 
12 (34%) 13 (39%) 0.6624 
Reintubation 7 (20%) 8 (24%) 0.6733 
Mechanically 
Ventilated on day 1 
post op 
4 (11%) 7 (21%) 0.2735 
Any respiratory 
complication 
17 (49%) 17 (52%) 0.8083 
Any infection 15 (49%) 18 (55%) 0.3351 
Any cardiac 
complication 
12 (34%) 6 (18%) 0.1325 
Required inotropes in 
first 7 days post op 
18 (51%) 16 (48%) 0.8083 
Renal replacement 
therapy 
0 (0%) 1 (3%) 0.4853 
Returned to theatre 1 (3%) 1(3%) 1.0000 
Any surgical 
complication 
8 (23%) 12 (36%) 0.2218 
 
Patients in the cholecalciferol group tended to develop pneumonia later in the 
postoperative course (median day of pneumonia development in the placebo 
group was 3.5 whereas in the cholecalciferol group it was 5.0). This difference 
did not meet significance (p=0.0891). 1/12 patients in the placebo group and 
5/13 patients in the cholecalciferol group developed pneumonia after day 7 post 
op (p=0.1602). The majority of patients were not ventilated on any of the first 7 
days post op and there was no significant difference between groups in 
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ventilator free days in the first 7 days post op (median for both groups 7 days 
ventilator free, p=0.2799). 10 (29%) patients in the placebo group and 12 (36%) 
patients in the cholecalciferol group required ventilation at some point in the 
first 7 days after the operation (p=0.4924). 
6.4.8 Effects of cholecalciferol on post-operative morbidity and mortality 
prediction scores  
APACHE-II score was calculated on admission to the intensive care unit. There 
was no significant difference in APACHE-II scores between groups (placebo 
mean=8.8 SD=3.15, cholecalciferol mean = 8.7 SD=4.51, p=0.8636). The median 
mortality predicted by the APACHE-II scores was 4.7% for placebo and 4.1% for 
cholecalciferol (p=0.4201). There was no significant correlation between preop 
total 25-OH Vitamin D and APACHE-II score (Pearson ρ=-0.2225, p=0.0683, 
r2=0.0495), and no correlation between 1,25-(OH)2 Vitamin D and APACHE-II 
score (Pearson ρ=-0.101, p=0.3773, r2=0.0118). 
There was no significant difference in SOFA score on day 1 post op (placebo 
median=3 IQR = 2-5, cholecalciferol median=4.0 IQR = 2-6, p=0.4071) and no 
correlation between preop vitamin D plasma concentration and day 1 SOFA 
score (25-OH Vitamin D: Spearman ρ=-0.0954, p=0.4392, r2=0.0116, 1,25(OH)2 
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6.4.9 Effect of cholecalciferol on length of ITU and Hospital Stay 
On average, patients who received cholecalciferol spent 5 days on ITU post op 
while patients who received placebo spent 4 days on ITU (p=0.0469, figure 6.14). 































Figure 6.14 Effects of cholecalciferol on length of ITU admission post 
oesophagectomy 
n=35 for placebo and n=33 for cholecalciferol. Mann Whitney test used to 
compare between groups. Black horizontal lines indicate median for each dataset 
However, there was no significant difference between groups in length of 
hospital admission with median length of stay 13 days for both groups 












Figure 6.15 Effects of cholecalciferol on length of hospital admission post 
oesophagectomy 
n=35 for placebo and n=33 for cholecalciferol. Mann Whitney test used to 
compare between groups. Black horizontal lines indicate median for each dataset 
 
6.4.10 Effects of cholecalciferol on post op mortality 
2 patients died prior to hospital discharge. Both had received placebo. One 
patient died 24 days post randomisation (preop total 25-OH Vitamin D= 
13.2nmol/L and 1,25-(OH)2 Vitamin D=58.0pmol/L) and the other 73 days post 
randomisation (preop total 25-OH Vitamin D = 73.7nmol/L and 1,25-(OH)2 
Vitamin D=111.1pmol/L).  
The only patient who died within 30 days of randomisation was the patient 
detailed above. 2 further patients (4 in total) died within 90 days of 
randomisation. Both received cholecalciferol. One patient died 75 days post 
randomisation (preop total 25-OH Vitamin D= 74.9nmol/L and 1,25-(OH)2 
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Vitamin D=186.3pmol/L) and the other died 82 days post randomisation  (preop 
total 25-OH Vitamin D= 83.4nmol/L and 1,25-(OH)2 Vitamin D=77.1pmol/L). 
So far, overall, there is no difference in post randomisation survival between the 
two groups (p=0.9952, figure 6.16). 
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Figure 6.16 Kaplan Meier Survival Curve demonstrating survival post 
randomisation.  
n=35 for placebo and n=33 for cholecalciferol. Vertical symbols on survival curves 
represent censored values (patients who were alive at last known time point). 
 
6.5 Discussion 
The results in this chapter demonstrate that patients undergoing 
oesophagectomy have a marked inflammatory response with changes in 
circulating white cells, inflammatory cytokines and alveolar oedema. This is in 
line with findings in the BALTI-prevention trial (42), from which the cohort 
examined in chapter 4 were drawn as well as other published literature (171, 
172). The results suggest there are two main peaks of inflammation in the 
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perioperative period – changes in white cells and inflammatory cytokines 
including IL-6 and IL-8 occur during the operation whilst plasma concentrations 
of C-reactive protein and LL-37, an antimicrobial peptide, appear to peak around 
day 3 post op. This demonstrates that the inflammatory response to surgical 
stress evolves over several post-operative days.  
There was little difference in absolute plasma concentrations of inflammatory 
cytokines during the perioperative period, with the exception of s-TNF-RI and s-
TNF-RII on day 1 post op when patients who received cholecalciferol had 
significantly higher plasma concentrations. In addition, patients who received 
cholecalciferol had significantly greater perioperative fold change in plasma 
concentrations of inflammatory cytokines, although this did not translate into a 
difference in overall plasma concentrations and had resolved by day 1 post op. 
Other studies have found little evidence Vitamin D supplementation leads to 
changes in circulating cytokines (183, 184) although a study of Vitamin D 
supplementation in patients with multiple sclerosis did show upregulation of 
gene expression of IL-6 in peripheral blood mononuclear cells (PBMCs) (185). 
By day 3 plasma concentrations of LL37, an antimicrobial peptide, had increased 
significantly more in the cholecalciferol group than in the placebo group, 
although, again there was no difference in absolute plasma concentrations. This 
coincides with peak plasma concentrations of CRP for the cohort as a whole, 
which were not different between groups and also the peak period for 
development of post op pneumonia (over 70% of patients who developed post 
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op pneumonia did so between days 2 and 5 post op). While there was no 
difference in numbers of infections between groups, there was a trend towards 
patients in the cholecalciferol group developing pneumonia at a later time point 
than patients in the placebo group. This result suggests that patients who 
received cholecalciferol may have an enhanced response to the presence of 
microbes, resulting in post-operative pneumonia developing later in the post-
operative course.  
Cholecalciferol administration significantly reduced perioperative increases in 
inflammatory alveolar oedema, as shown by reductions in extra vascular lung 
water and pulmonary vascular permeability index. The differences seen were 
more apparent when the cohort was divided according to preoperative 25-OH 
Vitamin D plasma concentration. Interestingly, in a significant proportion of 
patients who received cholecalciferol levels of EVLWI decreased during the 
operation. The mechanism behind this is not clear but could be related to a 
direct effect of vitamin D on the alveolar capillary barrier. Activated alveolar 
macrophages and respiratory epithelial cells are capable of converting 25-OH 
Vitamin D to 1,25-(OH)2 Vitamin D (60, 186) . My group has shown in-vitro that 
physiologically relevant doses of 25-OH Vitamin D stimulates wound repair and 
cellular proliferation and reduces sFasL induced cell death of human type 2 
alveolar epithelial cells  (187).  In addition to its antimicrobial actions, LL37 has 
been shown to stimulate wound vascularization and re-epithelialization of 
healing skin (188) 1,25-(OH)2 Vitamin D has been shown to reduce expression of 
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ICAM-1 on pulmonary endothelial cells and reduce platelet activating factor 
induced neutrophil adherence to endothelial cells (189). While there was no 
significance difference between groups in post op oxygenation, there was a 
correlation between 1,25-(OH)2 Vitamin D plasma concentrations and S/F ratio 
on a number of post-operative days.  
The trial was not powered to detect differences in clinical diagnoses of ARDS or 
respiratory complications and there was no difference between groups in 
incidence of these clinical outcomes. While patients who received cholecalciferol 
spent 1 day longer on ITU on average, there was no significant difference in 
ventilator free days, numbers of patients requiring reintubation or total length of 
hospital stay. The increased length of ITU stay may reflect the later development 
of pneumonia in the cholecalciferol group, as both average around 5 days and it 
is common to delay discharge from ITU is there is a suspicion that patients are 
starting to develop a chest infection so treatment can be commenced before 
transfer to a new clinical team. 
  
 



























We’ve shown that patients with and at risk of ARDS are highly likely to be 
Vitamin D deficient and that a one-off administration of 300,000IU 
cholecalciferol is a safe and effective way of increasing Vitamin D plasma 
concentrations in a short period of time preop. We have also demonstrated an 
association between circulating 1,25-(OH)2 Vitamin D plasma concentrations and 
post-operative mortality in patients undergoing oesophagectomy. The majority 
of patients who undergo oesophagectomy die following recurrence of the 
disease (section 4.4.10). 
Natural Killer (NK) Cells are lymphocytes that form part of the innate immune 
system. They are part of the first line of defence against both infection and 
cancer and are widely distributed in blood, spleen, liver, lung and bone marrow 
(190). They act in two ways; they are able to directly kill cells by forming 
synapses with target cells and releasing perforin and granzyme and they are able 
to co-ordinate immune responses via cytokine release (191). 
NK Cells are defined by a lack of CD3 expression and by the presence of CD56 
(192). There are two major subsets of natural killer cells which are distinguished 
by their levels of CD56 expression. CD56dim cells make up approximately 90% of 
NK cells in the peripheral blood and mediate cytotoxicity responses. CD56bright 
cells are primarily cytokine producers and are better able to leave the 
vasculature. They constitute the majority of natural killer cells found in lymph 
nodes (191). 
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NK cells originate in the bone marrow from CD34+ haematopoietic cells. They 
mature in secondary lymphoid tissue which contains a highly enriched 
population of CD34+CD45RA+ pre-NK cells (193). Antigen presenting cells such as 
dendritic cells in secondary lymphoid tissue express membrane bound IL-15 
which is required for NK cell maturation. All NK cells are initially CD56bright. 
Some CD56bright cells remain within the lymph nodes and interact with 
dendritic cells while others undergo a further maturation step forming CD56dim 
cells which return to the circulation via the efferent lymphatic system (194)  
(figure 7.1). 
 
Figure 7.1 NK cell development (194)  
(1) Bone marrow derived CD34+CD45RA+ cells circulate in the blood and (2) 
extravasate across lymph node high endothelial venules to enter the 
parafollicular space. There, (3) pro-NK cells are activated by dendritic cells to 
progress through distinct stages of maturation to create both CD56bright and 
CD56dim NK cells, as detailed on the right. Mature CD56dim NK cells return to the 
circulation via the efferent lymph (4), whereas some CD56bright NK cells remain 
within the secondary lymphoid tissue to interact with dendritic cells (5) 
Production of cytokines and chemokines by NK cells in early innate immune 
responses is a key step in recruitment and function of other haematopoietic cells 
(195). While CD56bright cells produce greater amounts of cytokine per cell, 
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CD56dim cells produce a greater proportion of the total level of cytokine 
secreted into peripheral blood due to their greater numbers (194). 
NK cells make up around 10% of resident lymphocytes in the lung (190). Survival 
of NK cells in the lung may be promoted by bronchial epithelial cells which 
spontaneously produce IL15 (196). In the resting state, cytotoxicity of pulmonary 
NK cells is suppressed – the cells form synapses with target cells but killing is 
suppressed (197, 198). Lung NK cells regain their activity after 24 hours in culture 
or after stimulation with IL-2 (198). Within hours of infection or other 
inflammatory stimulus large numbers of NK cells are recruited to the lungs from 
the blood (199-201). Peripheral blood NK cells can be suppressed by culture with 
BAL fluid or alveolar macrophages (but not macrophages from other tissues) 
(202, 203). 
Numbers of circulating cytotoxic NK cells are reported to fall by day 1 post 
oesophagectomy and remain low on day 3 post-op (172) and low pre- and post-
operative NK cell activity is associated with poor outcomes following cancer 
surgery (204, 205). NK cells are reportedly more severely affected by surgical 
stress than other lymphocytes. Low NK cell activity has been reported to be 
related to high concentrations of plasma catecholamines in the perioperative 
period and is exacerbated by use of norepinephrine as a result of interactions 
with beta-2 adrenoceptors (206, 207). Some groups have suggested that Natural 
Killer cell transfer (208), or administration of an influenza vaccination to boost 
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Natural Killer Cell activity (209) could be used in the perioperative period to 
improve long term outcomes  
Studies have suggested that Vitamin D affects NK cell function, but findings have 
not been consistent. While some groups have found that adding 1,25-(OH)2 
Vitamin D to culture media enhances the ability of NK cells to kill K562 cells (a 
cancer cell line) (73), other groups have suggested that 1,25-(OH)2 Vitamin D 
reduces NK cell cytotoxicity by reducing IL2 release from PBMCs (210). A study in 
healthy Italian nonagenarians found a positive correlation between serum 1,25-
(OH)2 Vitamin D plasma concentrations and circulating NK cell numbers and 
cytotoxicity (211), while a group investigating the effect of 1,25-(OH)2 Vitamin D 
on in vitro NK cell development from haematopoetic stem cells found that NK 
cell development was impaired and those cells that did develop had significant 
reductions in function. This group found no effect of Vitamin D on mature NK cell 
function (212). Finally, a study of NK cell function in women with recurrent 
pregnancy losses found that 1,25-(OH)2 Vitamin D reduced NK cell cytotoxicity in 
cells from women with this condition, but had no effect on cells from healthy 
controls, suggesting that different disease states may alter the association seen 
(213). 
In view of the suggested link between Vitamin D and Natural Killer Cell function, 
and the importance of this cell in defence against cancer and infection (both of 
which are highly relevant in patients undergoing oesophagectomy), we examined 
changes in NK cell numbers in our cohort. 
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7.2 Research Hypothesis and Questions 
7.2.1 Hypothesis 
Vitamin D supplementation results in alteration in the perioperative number and 
function of circulating NK cells making development of recurrence post-op less 
likely. 
7.2.2 Research Questions 
1. How do NK cell numbers change perioperatively? 
2. Is there a relationship between development of adverse event post-op and NK 
cell numbers? 
3. What is the effect of supplementation with cholecalciferol on circulating NK 
cell numbers? 
4. What is the effect in-vitro of culture in the presence of Vitamin D on NK cell 
cytotoxicity? 
5. How does expression of the Vitamin D receptor in NK cells compare with other 
cell types? 
7.3 Methods 
PBMCs were isolated from heparinised whole blood, stained for surface markers 
of NK cells, then analysed by flow cytometry. Comparison of NK cell numbers was 
made between patients who survived two years and those who died within two 
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years. This timepoint was chosen as it was the maximum possible prior to 
submission of this thesis. In vitro, NK cell function was assessed using cells from 
healthy volunteers for a cytotoxicity assay as outlined in chapter 3. Cell 
expression of the Vitamin D receptor was assessed in three cell types – natural 
killer cells, monocytes/alveolar macrophages and alveolar type 2 cells using 
qPCR. The method of purification of all three cell types in described in the 
methods chapter (chapter 3). 
Continuous data was assessed for normality and data was assessed repeated 
measures ANOVA for parametric data and Friedman test for non-parametric 
data. For comparison between groups across multiple timepoints 2 way ANOVA 
was used with multiple T tests to examine difference s between individual 
timepoints. Where data was missing, the last known figure was brought forward 
for the purposes of statistical analysis. 
7.4 Results 
7.4.1 Perioperative changes in total circulating NK cells 
Numbers of circulating NK cells were expressed as both absolute number and as 
a percentage of the total lymphoid pool. The absolute number of circulating NK 
cells increased preop, in contrast with the absolute number of lymphocytes 
which did not significantly change preop, but trended towards a fall in numbers 
(figure 6.2). Perioperatively, absolute numbers of NK cells fell (in line with the 
overall fall in total lymphocyte numbers), and by day 3 post-op numbers of 
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circulating NK cells were significantly lower than at either preoperative timepoint 
(figure 7.2). 
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Figure 7.2 Perioperative changes in circulating NK cell numbers 
Baseline n=28, Preop n=29, Day 1 n=24, Day 3 n=21. Friedman test p<0.0001 with 
Dunn’s multiple comparison test used to compare individual timepoints as shown 
on graph.  Black horizontal line indicates median for each dataset 
When expressed as a percentage of the total lymphoid pool, the proportion of 
NK cells increased preop, did not change perioperatively and then decreased 
back to baseline levels by day 3 post op (figure 7.3). 
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Figure 7.3 Perioperative changes in circulating NK cells expressed as % of total 
lymphoid pool 
Baseline n=28, preop n=29, day 1 n=24, day 3 n=21. Friedman test p<0.0001 with 
Dunn’s multiple comparison test used to compare individual timepoints as shown 
on graph. Black horizontal line indicates median for each dataset 
7.4.2 Perioperative changes in the ratio between cytotoxic and cytokine 
secreting NK cells 
The preop increase in total circulating NK cells occurred as a result of increases in 
circulating numbers of CD56dimCD16+ (cytotoxic) cells; Numbers of 
CD56brightCD16- (cytokine secreting) cells did not significantly change preop. 
Absolute numbers of both types of cell significantly decreased perioperatively 
(figure 7.4). 
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Figure 7.4 Perioperative changes in cytotoxic and cytokine secreting NK cells 
Baseline n=28, Preop n=29, Day 1 n=24, Day 3 n=21 for both cell types. Friedman 
test p<0.0001 for both cell types with Dunn’s multiple comparison test used to 
compare individual timepoints as shown on graph. Median and IQR for each 
timepoint shown 
When expressed as a percentage of the total lymphoid pool, CD56dimCD16+ cells 
show a similar pattern to total cell numbers increasing preop, remaining 
unchanged perioperatively and falling back to baseline proportions by day 3 post 
op. CD56brightCD16- cells however do not change preop but significantly increase 
in proportion perioperatively and significantly decrease between day 1 and day 3 
post op (figure 7.5) 
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Figure 7.5 Perioperative changes in cytotoxic and cytokine secreting NK cells 
expressed as % of total lymphoid pool 
Baseline n=28, preop n=29, day 1 n=24, day 3 n=21. Friedman test p<0.0001 for 
both cell types with Dunn’s multiple comparison test used to compare individual 
timepoints as shown on graph. Median and IQR for each timepoint shown 
7.4.3 Comparison of circulating NK cells and development of post-operative 
adverse events 
There was no difference in total numbers of NK cells at any timepoint in patients 
who developed post-operative pneumonia, any infection or any respiratory 
complication. Patients who developed a surgical complication had significantly 
higher circulating absolute and proportionate NK cells on day 3 post op but there 





Page | 199  
 
 














Yes 10.2 (4.3) 13.9 (5.0) 15.7 (6.8) 10.8 (6.0) 
No 11.0 (5.0) 16.2 (8.2) 17.9 (8.0) 9.1 (4.5) 
P value 0.677 0.402 0.502 0.472 
n (Yes) 11 11 9 8 
Any Infection 
Yes 10.4 (4.0) 15.0 (6.7) 17.1 (7.3) 9.9 (5.3) 
No 10.9 (5.6) 15.7 (8.0) 17.0 (8.1) 9.6 (4.9) 
P value 0.806 0.793 0.973 0.895 
n (Yes) 15 16 13 13 
Respiratory 
Complication 
Yes 10.2 (4.2) 14.6 (5.2) 15.7 (6.1) 9.0 (5.7) 
No 11.2 (5.4) 16.2 (9.1) 18.4 (8.7) 10.8 (4.1) 
P value 0.598 0.575 0.377 0.416 
n (Yes) 15 15 12 12 
Surgical 
Complication 
Yes 11.2 (3.8) 16.4 (7.7) 17.6 (6.5) 14.4 (3.7) 
No 10.4 (5.1) 14.7 (6.9) 16.8 (8.2) 7.4 (3.9) 
P value 0.669 0.556 0.7378 0.0008 
n (Yes) 8 9 8 7 
Mean (SD) of absolute NK cell numbers (x106) shown for each parameter. 
7.4.4 Differences between total NK cell numbers in patients who die within two 
years of their operation 
The timepoint of 2 years was chosen as this was the maximum time we could 
follow up for prior to the submission of this thesis. Data was available for 16 
patients who were thought to have had curative surgery. 7 had died within 2 
years of their operation and 9 had not. There was a significant difference in 
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preoperative total numbers of circulating NK cells between the groups and a 
trend towards patients who died within 2 years having lower numbers of NK cells 
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Figure 7.6 Comparison of circulating absolute numbers of NK cells in patients 
who survived at least 2 years post op and those who did not 
Survived: n=9 at baseline and preop,n=8 on  day 1, n=6 on day 3, Died: n=7 at 
baseline and preop, n=6 on day 1 and n=4 on day 3.  Black horizontal lines 
indicate median for each dataset. Friedman test p=0.0014 for survived, p=0.0508 
for died. Mann Whitney test used to compare between groups. 
Preoperative data was also available for 3 patients who were found to have 
incurable cancer during their operation; average preop NK cells in these patients 
was also low – 113.7x106/L compared with 150.97x106/L in patients who died 
and 288.27x106/L in patients who survived.  
There was no difference in smoking status, number of patients undergoing 
preoperative chemotherapy, TNM staging or rate of post-operative respiratory 
or surgical complications between the patients who died within 2 years and the 
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patients who survived. 43% of patients who died received cholecalciferol 
compared with 67% of patients who survived. This difference was not statistically 
significant and there was no significant difference at any timepoint between 
1,25-(OH)2 Vitamin D plasma concentrations between patients who died within 2 
years and those who survived. 
The changes seen were replicated in both cell types with cytotoxic and cytokine 
secreting cells being higher on average in patients who survived than patients 
who died and the greater difference being seen at the preoperative timepoint. 
7.4.5 Effects of cholecalciferol on NK cells 
There was no significant difference between patients who received placebo and 
patients who received cholecalciferol in the number of circulating NK cells at any 
timepoint (figure 7.7). When changes between the timepoints for the individual 
groups were considered, there was greater variability in the patients who 
received cholecalciferol. Patients who received placebo only had significantly 
different levels between the preop and day 3 timepoint, while there were 
significant differences between preop and both post-operative timepoints for 
the cholecalciferol groups. 
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Figure 7.7 Effects of cholecalciferol on circulating NK cell numbers 
Placebo: Baseline n=12, Preop n=13, Day 1 n=11, Day 3 n=10. Cholecalciferol: 
Baseline n=16, Preop n=16, Day 1 n=13, Day 3 n-11. Mean and SD for each 
timepoint shown. Friedman test p=0.0020 for placebo, p=0.0004 for 
cholecalciferol. No significant difference between groups at any timepoint 
(Unpaired T  test). 
When NK cells were divided into cytotoxic (CD56dimCD16+) and cytokine secreting 
(CD56brightCD16-) subtypes, there was no difference in numbers of circulating 
cells at any of the 4 timepoints but greater variability in cytotoxic cell numbers in 
the patients who received cholecalciferol. Changes in cytokine secreting cell 
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Figure 7.8 Effects of cholecalciferol on circulating cytotoxic NK cell numbers 
Placebo: Baseline n=12, Preop n=13, Day 1 n=11, Day 3 n=10. Cholecalciferol: 
Baseline n=16, Preop n=16, Day 1 n=13, Day 3 n-11. Mean and SD for each 
timepoint shown. Friedman test p=0.0027 for placebo, p=0.0015 for 
cholecalciferol. No significant difference between groups at any timepoint 
(unpaired T test). 
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Figure 7.9 Effects of cholecalciferol on circulating cytokine secreting NK cell 
numbers 
Placebo: Baseline n=12, Preop n=13, Day 1 n=11, Day 3 n=10. Cholecalciferol: 
Baseline n=16, Preop n=16, Day 1 n=13, Day 3 n-11. Mean and SD for each 
timepoint shown. 1way ANOVA p=0.0089 for placebo, p=0.0010 for 
cholecalciferol. No significant difference between groups at any timepoint 
(unpaired T test). 
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7.4.7 Correlations between vitamin D plasma concentrations and numbers of 
circulating NK cells 
At baseline, there was a positive correlation between 1,25-(OH)2 Vitamin D 
plasma concentrations and absolute numbers of total NK cells. On the day of the 
operation (preop), there was no significant correlation between Vitamin D 
plasma concentrations and numbers of NK cells. Post-op (day 3) there was a 
positive correlation between 25-OH Vitamin D plasma concentrations and total 
NK cells, but no relationship with 1,25-(OH)2 Vitamin D plasma concentrations 
was found (table 7.2). There were no significant correlations between change in 
vitamin D plasma concentrations and change in NK cell numbers (data not 
shown). 
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7.4.8 In-vitro effects of Vitamin D on NK cells function 
To investigate the effects of Vitamin D on NK cell function, I carried out 
cytotoxicity experiments in the presence of 100nM 25-OH Vitamin D. I used both 
unstimulated cells and cells stimulated with IL2. As baseline %K562 cell death 
varied the results from the experiments were compared with results from a 
control well which did not contain vehicle or Vitamin D and reported as fold 
difference. No significant difference in cytotoxicity was seen in cells exposed to 
25-OH Vitamin D compared to vehicle control (Wilcoxon paired test unstimulated 
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Figure 7.10 Effects of 25-OH Vitamin D on NK cell Cytotoxicity 
n=8 for unstimulated cells and n=7 for stimulated cells. Wilcoxon signed rank test 
used to compare within groups.  Black horizontal line indicates median for each 
dataset. Dotted reference line indicates fold difference=1; datapoints below the 
line were lower than control and datapoints above the line were higher than 
control 
I also carried out the same experiments using 100nM 1,25-(OH)2 Vitamin D. 1,25-
(OH)2 Vitamin D did not significantly affect cytotoxicity compared to vehicle 
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Figure 7.11 Effects of 1,25-(OH)2 Vitamin D on NK cell Cytotoxicity 
n=8 for unstimulated cells and n=7 for stimulated cells. Wilcoxon signed rank test 
used to compare within groups. Black horizontal line indicates median for each 
dataset. Dotted reference line indicates fold difference=1; datapoints below the 
line were lower than control and datapoints above the line were higher than 
control 
7.4.9 Expression of VDR in NK cells 
To further investigate the above results we measured expression of the Vitamin 
D receptor (VDR) in purified NK cells. Expression of VDR was significantly lower in 
unstimulated NK cells than in type 2 alveolar epithelial cells or monocytes and 
macrophages (figure 7.12).  
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Figure 7.12 Expression of VDR in NK cells, Type II alveolar epithelial cells and 
monocytes/macrophages 
n=6 for NK cells, n=4 for Type II Alveolar Epithelial Cells, n=4 for 
monocytes/macrophages. Black horizontal line indicates median for each 
dataset. Kruskal Wallis p<0.0001 
Stimulation of the purified NK cells with IL2 did not result in a significant change 
in VDR expression (figure 7.13). 
































Figure 7.13 VDR expression in NK cells stimulated with IL2 compared with 
vehicle control 
Datasets are paired. n=3. Mann Whitney Test used to compare groups. Black 
horizontal line indicates median for each dataset. 
 




We’ve demonstrated that NK cells increase prior to oesophagectomy, but that 
this was not as a result of Vitamin D supplementation. Previous studies have 
demonstrated that acute psychological stress has marked effects on NK cell 
numbers and that NK cell numbers correlate with plasma concentrations of 
noradrenaline (214). In vitro and ex-vivo work has also suggests that adrenaline 
(epinephrine) has a marked effect on NK cell cytotoxicity, although there is 
controversy as to whether the effect is suppressive or enhancing (215-217). One 
group have suggested that in-vitro and ex-vivo experiments may overestimate 
effect of stress hormones in vivo (218). Interestingly, patients who survived at 
least 2 years following their operation had greater preoperative circulating NK 
cells than patients who died within two years, suggesting that the effect of stress 
on NK cells offers a survival advantage.  
Overall, there was a trend towards lower circulating NK cells in patients who died 
at all timepoints. All of 8 of the patients analysed died following diagnosis of 
recurrence or metastasis of their tumour suggesting that reduced NK cells during 
the perioperative period may have played a role in their reduced survival. This 
finding means that NK cell count immediately prior to cancer surgery may 
highlight patients who would benefit from increased post-op surveillance. 
Contrary to some previous reports, I found little evidence that Vitamin D affects 
NK cell numbers or function. While there was a correlation between 1,25(OH)2 
Vitamin D and NK cell numbers at baseline, this did not continue after 
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randomisation. The baseline findings replicate the findings in Italian 
nonagenarians (211) but suggest that changes in 1,25-(OH)2 Vitamin D do not 
directly result in a linear change in NK cell numbers over the short term. Our 
finding that preoperative NK cell numbers increase in both the cholecalciferol 
and placebo groups seems at odds with Weeres et al’s finding that NK cell 
development is reduced in the presence of 1,25(OH)2 Vitamin D (212) and might 
reflect in-vivo interplay between different stress hormones, including adrenaline 
which cannot be fully replicated in ex-vivo and in-vitro settings. 
Our finding that Vitamin D does not affect in vitro NK cell functions in cells from 
healthy controls and that relative VDR expression is lower in NK cells compared 
with epithelial cells and monocyte/macrophages support the in vivo findings. 
While the reduced expression of VDR in NK cells does not rule out a paracrine 
effect of Vitamin D on NK cells (for example by increasing IL2 release by other 
cells), the in-vitro NK cell killing experiment was carried out in the presence of 
other PBMCs and also did not find any effect.  
Our data has weaknesses. The n numbers for some of the analysis are small and 
there is a risk that the significant relationships seen are due to chance and that 
more extensive analysis may not confirm the findings. It would have been 
informative to examine NK cell function in the ex-vivo samples, but we were 
limited by the amount of material available for analysis. For our q-PCR 
experiments we used GAPDH as a single housekeeping gene, as per our standard 
laboratory method. However, expression of GAPDH has been shown to differ 
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across different cell types (219), and while we found no difference in levels of 
expression across the three cell types examined (figure 3.8), use of more than 
one reference gene may have strengthened our findings. Our PCR findings 
showing that type 2 alveolar epithelial cells and monocytes/macrophages have 
relatively higher expression of VDR suggests that future work focussing on these 
cell types may yield more positive results. 
In conclusion, Natural Killer cell numbers change markedly over the 
perioperative period and patients who survive 2 years post op have greater 
circulating NK cells than patients who die within 2 years. This correlates with the 
association I found between long term survival and 1,25-(OH)2 Vitamin D plasma 
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8.1 Overview of investigations into Vitamin D supplementation in patients at 
risk of ARDS 
8.1.1 Vitamin D deficiency is common in patients with and at risk of ARDS 
ARDS is a severe form of respiratory failure which results in significant morbidity 
and mortality. We have demonstrated that Vitamin D deficiency is highly 
prevalent in patients with ARDS and severe Vitamin D deficiency in patients who 
undergo oesophagectomy is associated with increased risk of developing ARDS 
post op.  
8.1.2 Preoperative supplementation with 300,000IU cholecalciferol is a safe 
and effective method of rapidly increasing preoperative Vitamin D plasma 
concentrations 
We recruited patients to a placebo controlled trial of Vitamin D replacement 
prior to oesophagectomy and demonstrated that high dose cholecalciferol 
administration up to 2 weeks pre-op is a safe and effective method of increasing 
preoperative Vitamin D plasma concentrations, despite patients in the 
VINDALOO cohort having higher pre-supplementation Vitamin D plasma 
concentrations than expected. Patients who received cholecalciferol had 
significantly greater increases in 25-OH Vitamin D and 1,25-(OH)2 Vitamin D 
between baseline and the day of their operation.  
Perioperatively, Vitamin D plasma concentrations decreased markedly in both 
the placebo and cholecalciferol groups post-op, so that patients who achieved 
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Vitamin D sufficiency preop were still at risk of developing Vitamin D deficiency 
in the post op period.  
8.1.3 Patients with lower 25-OH Vitamin D plasma concentrations have 
evidence of greater perioperative inflammatory alveolar oedema and systemic 
inflammation 
Patients with the lowest Vitamin D plasma concentrations had greater 
perioperative increases in EVLWI, and patients who received cholecalciferol had 
lower increases in EVLWI and PVPI than patients who received placebo.  
Comparison of the two cohorts is complicated by the general difference in 25-OH 
Vitamin D plasma concentrations between the two groups; patients who 
received placebo in the Vindaloo trial had similar preoperative plasma 
concentrations of 25-OH Vitamin D3 to patients with the highest 25-OH Vitamin 
D3 plasma concentrations in the BALTI-p cohort. Perioperative fold change in IL-6 
was similar between the BALTI-p cohort with 25-OH Vitamin D3 plasma 
concentrations >17.85nmol/L and the Vindaloo patients who received placebo, 
while patients with 25-OH Vitamin D3 plasma concentrations <17.85 in the 
BALTIp cohort had much greater fold change than any of the other patients. This 
suggests that patients with very severe vitamin D deficiency have a hyper-
inflammatory response to surgical stress. In both cohorts IL-6 differences 
between groups resolved by day 1 post op but by this timepoint in the Vindaloo 
cohort patients, the cholecalciferol group had elevated circulating plasma 
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concentrations of soluble TNF receptors suggesting enhanced resolution of 
inflammation. 
While there was no difference in incidence of diagnoses of pneumonia between 
patients who received placebo and those who received cholecalciferol, there was 
a trend towards pneumonia developing later in patients who received 
cholecalciferol. Patients who received cholecalciferol also had greater increases 
in LL37 between day 1 and day 3. This, combined with the significant falls in 
circulating Vitamin D plasma concentrations seen perioperatively suggests that 
cholecalciferol administration may support mechanisms that prevent the 
development of infection, but as post-operative plasma concentrations fall this 
ability is lost. Other studies of cholecalciferol supplementation in the acute 
setting have started to consider whether initial high doses should be followed up 
with smaller regular doses to help maintain Vitamin D plasma concentrations. As 
nutrition during the immediate post-operative course in patients undergoing 
oesophagectomy can be difficult (due to the nature of the operation), 
consideration should possibly be given as to whether the recommended daily 
intake of Vitamin D provided in enteral and parenteral feeds is sufficient to 
maintain plasma concentrations and future studies should consider dosing 
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8.1.4 Patients with lower 1,25-(OH)2 Vitamin D plasma concentrations have 
reduced long term post-operative survival 
I found that patients recruited to the BALTI cohort with low plasma 
concentrations of 1,25-(OH)2 Vitamin D have lower post op survival than patients 
with higher plasma concentrations. As the majority of patients who died did so 
following recurrence of their oesophageal tumour I investigated whether this 
finding was due to an effect of Vitamin D on NK cells. While I found that patients 
who survived at least two years have greater numbers of preoperative NK cells 
than patients who died, and there was a trend towards patients who survived 
being more likely to have received cholecalciferol, I found no evidence of an 
effect of Vitamin D on NK cell numbers or function. One limitation of this part of 
my study is that I was unable to test NK cell function in cells from patients 
undergoing oesophagectomy, due to restrictions in the amount of blood we 
could collect from the patients (around 20ml blood would be required in order to 
isolate sufficient cells to carry out the functional experiment, especially in the 
post-operative samples where total numbers of lymphocytes are low). It is 
possible that cells from patients with oesophageal cancer react differently in the 
presence of Vitamin D to cells from healthy controls as Ota et al have 
demonstrated in women with recurrent pregnancy loss (213). 
8.1.5 Incidence of ARDS post oesophagectomy has decreased over past 5 years 
Whilst we found no difference in clinical diagnoses of ARDS between groups in 
patients recruited to VINDALOO, the incidence of ARDS in patients undergoing 
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oesophagectomy was markedly lower in patients recruited to VINDALOO 
compared with patients recruited to BALTIp. This may reflect the differences in 
Vitamin D plasma concentration between the two groups, but is also likely to be 
due to improvements in perioperative care with greater awareness among 
anaesthetists around the importance of protective lung ventilation and the 
dangers of liberal IV fluid administration. This change in the incidence of ARDS 
post oesophagectomy is important for the design of trials using this model and 
may mean that larger cohorts need to be recruited in future, particularly where 
the primary endpoint is development of ARDS. 
8.2 Future Work 
There are many possibilities for development of my findings. As patients with 
ARDS have significantly lower plasma concentrations of both 25-OH Vitamin D 
and 1,25-(OH)2 Vitamin D than patients undergoing oesophagectomy and I have 
demonstrated that high dose Vitamin D is capable of rapidly increasing 
circulating Vitamin D plasma concentrations, trials of cholecalciferol 
supplementation in patients with ARDS should be considered. Trials of oral 
supplementation in general ITU populations have already been undertaken using 
high dose cholecalciferol (220) but found that any effect on circulating Vitamin D 
plasma concentrations was limited, suggesting that in this population 
intramuscular or intravenous dosing should be considered, along with regular 
“top-up” dosing throughout the ITU admission. However, another group 
investigating cholecalciferol supplementation in patients with severe sepsis and 
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septic shock (who are at high risk of ARDS) found that a one-off dose bolus of 
200,000IU or 400,000IU rapidly increased circulating Vitamin D plasma 
concentrations (221). Another group has investigated intravenous 1,25-(OH)2 
Vitamin D administration in critically ill patients and found an effect on 
cathelicidin and IL10 mRNA expression by leucocytes but did not measure 
circulating 1,25-(OH)2 plasma concentrations in order to directly observe the 
effect of the dose administered on Vitamin D plasma concentrations (222). These 
studies highlight the importance of undertaking small scale dosing studies prior 
to undertaking large scale clinical trials in relevant patient groups. 
My findings support the literature showing that NK cell number and function are 
important determining factors in survival post cancer surgery. Whilst I found no 
evidence that Vitamin D affects this parameter, my finding that preoperative NK 
cell numbers were higher in patients who survived at least 2 years post op 
highlights the potential of NK cells as a therapeutic target in patients undergoing 
cancer surgery. In addition, future work investigating other therapies in patients 
undergoing cancer surgery should consider measuring impact on NK cells. 
8.3 Conclusions 
In conclusion, a one off high dose preoperative cholecalciferol supplement is a 
safe and effective way of increasing preoperative Vitamin D plasma 
concentrations and is associated with lower perioperative increases in 
inflammatory alveolar oedema. Preoperative Vitamin D supplementation should 
be considered in patients with and at risk of Vitamin D deficiency. Trials of the 
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effect of cholecalciferol in other patients with conditions placing them at risk of 
ARDS (such as sepsis or pneumonia) should be considered, but will require 
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